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Abstract 
 
Docosahexaenoic acid (DHA) is an omega-3 highly unsaturated fatty acid that plays an 
important role in fetal brain development.  The fetal demand for DHA appears to be met 
by placental transport and various maternal physiological adaptations.  Estrogen, which is 
elevated during pregnancy, is associated with increased DHA biosynthesis, but estrogen 
is also implicated in the synthesis of phospholipids, specifically the regulation of 
phosphatidyl ethanolamine methyltransferase (PEMT) that methylates phosphatidyl 
ethanolamine (PE) to form phosphatidyl choline (PC).  PE in various tissues is typically 
enriched in DHA relative to PC, but PC is the dominant phospholipid in plasma.  The 
conversion of PE to PC by PEMT as a potential mechanism to mobilize maternal DHA to 
plasma for placental transport was examined in diets that mimic human fatty acid intakes 
with and without DHA as well as in a standard rat chow diet low in DHA.  Rats were 
examined at baseline, day 15 and day 20 of pregnancy, and 7 days post partum. The 
accumulation of fatty acids into lipid fractions in maternal plasma and liver were 
determined with DHA in PC increasing dramatically at day 20, particularly in plasma. 
PEMT mRNA expression was increased at day 15 and PEMT liver protein tended to be 
increased at day 20 of pregnancy.  In addition, increased dietary DHA appeared to be 
associated with increased expression of PEMT suggesting DHA hepatic concentrations 
may be upregulating PEMT by a substrate feed forward mechanism.  Given the 
supporting role of PEMT in mobilizing DHA, and the extent of the increase of DHA in 
plasma PC during the last stages of pregnancy, other mechanisms are likely involved that 
remain to be elucidated.  
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 Docosahexaenoic acid (DHA) is a polyunsaturated fatty acid (PUFA) known to 
have an important role in fetal neuronal development, and the fetus is dependent on 
maternal supply (Larque et al., 2006). Evidence indicates that pregnant women in Canada 
do not meet the dietary recommendations for DHA intake (Denomme et al. 2005). Sex is 
associated with different fatty acid profiles, including, DHA in various tissues in both 
humans (Geppert et al., 2009; Metherel et al., 2009) and rat models (Kitson et al., 2012). 
More specifically, estrogen has been hypothesized to regulate the function of various 
proteins involved in lipid metabolism, such as elongases and desaturases that are 
responsible for the de novo synthesis of PUFA (Kitson et.al. 2012).  Estrogen levels rise 
during pregnancy (Yoshinaga et al. 1969) and DHA has also been shown to increase in 
maternal plasma, especially during the third trimester of pregnancy when estrogen levels 
are at their peak (Stark et.al. 2005). Additionally, evidence suggests that there is 
preferential deposition of PUFA, especially Arachidonic acid (ARA) and DHA, in fetal 
tissues during pregnancy (Larque et al. 2006). 
Plasma PUFA are generally found in triacylglycerols (TAG) and phospholipids; 
however, long chain PUFA, such as DHA and ARA, tend to concentrate in the 
phospholipids (Stark, 2008).  Plasma phospholipids are predominantly composed of 
phosphatidylcholine found in lipoproteins (Christie, 1989). Phosphatidylcholine (PC) is 
synthesized through the Kennedy pathway, or by phosphatidylethanolamine (PE) 
methylation through phosphatidylethanolamine methyltransferase (PEMT). Estrogen has 
been shown to up-regulate the PE methylation pathway (Resseguie et al. 2007).  PE 
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typically has higher DHA content than PC (Kitson et al., 2013), Therefore methylation of 
PE to form PC could be a mechanism to increase the DHA content of PC. Up-regulating 
the PE methylation pathway during pregnancy through estrogen action could be a mean 
to increase maternal plasma DHA levels to make DHA more readily available for uptake 
by the fetus.  Additionally, PEMT activity is affected by the intake of specific fatty acids 
(Clandinin et al. 1994); therefore, understanding the effect of dietary intake of DHA 
during pregnancy using a diet with a fatty acid profile that resembles the fat intake of 
humans on PEMT activity is essential to fully characterize the mechanisms involved in 
mobilizing maternal DHA stores to plasma during pregnancy. 
The aim of this thesis is to understand the role of PEMT during pregnancy on 
maternal DHA in various lipid pools during different dietary fatty acid intakes. A 
pregnant rat model was used to determine the effect of pregnancy on PEMT expression 
and activity. Rats were bred, and upon confirmation of pregnancy, they were placed 
either on a diet that mimics the typical western diet, with or without additional DHA, or 
remained on a chow control diet. The expression of PEMT was measured in maternal 
liver at various stages of pregnancy, and in post partum by determining mRNA and 
protein levels, as well as enzyme activity. Additionally, plasma and liver phospholipid 
fatty acid composition was determined to characterize the shift in PC and PE fatty acid 
composition during pregnancy. Understanding the mechanisms of DHA delivery to the 
fetus, the role of maternal diet, and maternal adaptations to increase the bioavailability of 
DHA for fetus delivery, form an important base to determine maternal DHA 
requirements in order to establish evidence based recommendations to support pregnancy 
and fetal development.  




2.1 DHA Role in Fetal Development 
Several randomized controlled clinical trials have indicated a positive effect of 
DHA supplementation on brain development as reviewed previously (Innis, 2007), while 
the effect of low DHA intake on retinal electrophysiology and visual acuity is established 
in non-human primates (Neuringer et al. 1988). In particular, the third trimester of human 
pregnancy appears to be a critical phase of DHA incorporation into neural tissues 
(Martinez 1992). The vulnerability of nervous system to DHA deficiency relates to the 
physiological structure of the brain; 60% of brain matter is composed of fat (Kurlak et al. 
1999), and DHA is one of the most abundant fatty acids in neurons, especially in 
neuronal membranes and vesicles of the synapse (Breckenridge et al. 1972). 
Incorporation of DHA into the phospholipids in the bilayer membranes is thought to 
increase their viscosity, allowing for more efficient signal transduction (Breckenridge 
1972). Other physiological effects are produced by metabolites synthesized from DHA. 
N-docosahexaenoylethanolamide (DEA) is a synaptogenic DHA metabolite that acts as a 
mediator of DHA induced synaptogenesis and hippocampal neuronal growth (Kim et al. 
2011). The effect of DHA and DHA derived synaptogenic mediators has only been 
demonstrated in neuron cell cultures from 18-day-old mice embryos (Cao et al., 2009) 
Pregnancy is generally associated with hyperlipidemia: the significant increase in 
plasma fatty acids, hypothesized to be an adaptation to facilitate the availability of 
essential fatty acids for the growing fetus (Hachey, 1994; Warth et.al. 1975). 
	  	   4 
Additionally, the relative amount of DHA in maternal bloodstream is also shown to 
increase during pregnancy, especially in the plasma phospholipids fraction (Otto et al. 
2001).  DHA is shown to increase by almost 50% in plasma phospholipids, while other n-
3 fatty acids increase by only 20% (Postle, et al. 1995). DHA is also selectively 
transported through the placenta, and deposited in fetal tissue through specific placental 
fatty acid delivery mechanisms (Larque et al. 2011). Increased DHA biosynthesis from 
18:3n-3 (Burdge and Calder. 2006) is a possible mechanism to meet fetal DHA demand; 
however, the mobilization of DHA to the maternal circulation from other tissues is 
another possibility that is relatively understudied.   The effect of dietary intake of DHA 
and other essential fatty acids during pregnancy has been shown to affect maternal fatty 
acid metabolism, as well as tissue composition of the fetus (Childs et.al. 2010). 
Examining maternal intake of essential fatty acids during pregnancy is important, 
especially since the majority of Canadian women eat low levels of DHA during 
pregnancy (Denomme et.al. 2005). 
2.2 Overview of Phospholipids 
Phospholipids are differentiated based on the characteristic polar head group 
attached to the glycerol molecule. The major phospholipid classes include phosphatidyl-
ethanolamine (PE), phosphatidylcholine (PC), phosphatidylinositol (PI), 
phosphatidylserine (PS), and sphingomyelin. PC followed by PE constitutes the majority 
of phospholipids in the lipid bilayer in cellular membranes of eukaryotes. PC is 
predominantly found on the outer layer, while PE is concentrated in the inner layer 
(Christie 1989). In plasma, phospholipids are mainly located in the monolayer membrane 
of lipoproteins, and constitute of almost 99% PC and lyso-phosphatidylcholine (lysoPC) 
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(Christie, 1989). In contrast, erythrocytes in blood have lipid bilayers and therefore 
contain significant amounts of both PE and PC. PI and PS occur in lower concentrations 
in lipid membranes. However, PI is a metabolically important phospholipid, which is 
highly abundant in brain tissue (almost 10% of total phospholipids in the brain) (Holub 
et.al. 1970)  
2.3 De novo synthesis of Phospholipids (Kennedy Pathway; Figure 2.1) 
Phospholipids are synthesized in various locations within the cell, including the 
cytosol, endoplasmic reticulum, and the mitochondrial inner membrane (Vance and 
Vance, 2004). The first step is the addition of an acyl group from acyl-CoA to sn-
glycerol-3-phosphate by sn-glycerol-3-phosphate acyltransferase (GPAT) to form 1-acyl-
sn-glycerol-3-phosphate, also known as lyso-phosphatidic acid (lysoPA). Two main 
isoforms of GPAT have been characterized, which are encoded by different genes, and 
are localized in different locations within the cell. One GPAT isoform is limited to the 
mitochondrial outer membrane, while the second isoform is located in the endoplasmic 
reticulum (Vance and Vance, 2004). The mitochondrial isoform of GPAT is known 
utilize saturated acyl CoAs, while the endoplasmic reticulum isoform does not have such 
specificity. Consequently, the mitochondrial GPAT is thought to be responsible for the 
high proportion of saturated fatty acids in the sn-1 position of the glycerol-3-phosphate 
backbone. Phosphatidic acid (PA) is then formed through the acylation of the sn-2 
position of lysoPA by the action of acyl-CoA:1-acyl-sn-glycerol-3-phsophate 
acyltransferase (AGPAT), which preferentially utilizes unsaturated fatty acyl CoAs. The 
resultant PA can then be used as a substrate for the synthesis of phosphatidylglycerol and 
phosphatidylinositol, but PA can also be dephosphorylated by phosphatidic acid 
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phosphatase to form diacylglycerol (DAG). DAG can then be used to synthesize PE and 
PC, in addition to triacylglycerol (TAG). 
 
2.4 PE Synthesis 
PE comprises 20-40% of the phospholipids in the membranes of mammalian 
cells.  It is biosynthesized through two main pathways: the CDP-ethanolamine pathway, 
and the PS decarboxylation pathway, originally described by Kanfer and Kennedy in 
1964 (Kanfer and Kennedy, 1964). In the latter pathway, PS is transferred from the ER, 
where it is synthesized, to the mitochondrial inner membrane, where it is converted to PE 
by the action of PS decarboxylase (Shiao et al., 1995) However, evidence suggests that 
the route of PE synthesis is tissue dependent with the CDP-ethanolamine pathway being 
the main pathway in mammalian hepatocytes (Sundler and Akesson 1975; Tijburg et al. 
1989) and heart (Zelinski and Choy 1982).  The first step in the CDP-ethanolamine 
pathway is the phosphorylation of ethanolamine by ethanolamine-kinase in the cytoplasm 
forming P-ethanolamine. This step is followed by the conversion of P-ethanolamine to 
CDP-ethanolamine, in a reaction catalyzed by CTP: phosphoethanolamine 
cytidylyltransferase or ethanolamine phosphate cytidylyltransferase (ET). This is 
believed to be the rate-limiting step of the CDP-ethanolamine pathway, and is therefore 
subject to cellular regulation. In the final step, the CDP-ethanolamine is converted to PE 
by the action of CDP-Ethanolamine phosphotransferase, which is a membrane-bound 
protein in the endoplasmic reticulum that attaches the phosphoethanolamine to a DAG. 
CDP-Ethanolamine phosphotransferase appears to prefer DAG containing DHA in the 
sn-2 position as a substrate (Yamashita et al. 1997). In fact, DHA may have a potential 
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effect on phospholipids synthesis, since it was shown to elevate PE synthesis in 
hepatocytes (Sundler et. al. 1974). 
2.5 PC Synthesis 
PC is biosynthesized through two pathways: the CDP-choline pathway that is 
parallel to the CDP-ethanolamine pathway for PE synthesis, and the PE methylation 
pathway 
2.5.1 PC synthesis through Kennedy Pathway 
The CDP-Choline pathway utilizes choline that is acquired from diet (Best and 
Huntsman 1932). The first step in the CDP-choline pathway is the rapid phosphorylation 
of choline upon its entry to the cell by choline kinase in the cytoplasm to form P-choline. 
The P-choline is then converted to CDP-choline in a reaction catalyzed by 
CTP:phosphocholine cytidylyltransferase (CT). As in the PE synthesis pathway, the 
formation of the CDP intermediate is believed to be the rate-limiting step of the CDP-
choline pathway, and subject to cellular regulation. For example, the inter-conversion of 
CT between its soluble, inactive form and its active, membrane-bound form influences 
PC biosynthesis (Vance and Pelech 1984). CDP-choline is converted to PC by the action 
of CDP-Choline phosphotransferase: an important membrane-bound protein in the 
endoplasmic reticulum, which attaches the phosphocholine head group to a DAG 
molecule. 
2.5.2 PC synthesis through PEMT Pathway 
While the former pathway tends to dominate, the latter PE methylation pathway 
has been demonstrated to be responsible for the synthesis of 30%-40% of PC in 
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hepatocytes (Sundler and Akesson 1975; DeLong et al. 1999: Reo et al. 2002). Choline is 
essentially a tri-methylated ethanolamine where the three methyl groups are attached to 
the amine group (Figure 2.1). Consequently, the conversion of PE to PC requires three 
methylation reactions that are catalyzed by one enzyme, phosphatidylethanolamine-N-
methyltransferase (PEMT) (Ridgway and Vance 1988).  Evidence shows that phospho-
methyl-ethanolamine (PME) and phospho-dimethyl-ethanolamine (PDE), the products of 
the first and second methylation steps, respectively, have an inhibitory effect on their 
own formation indicating a negative feedback mechanism.  PEMT is found to be active in 
microsomal membranes and mitochondria-associated membranes (MAM).  MAM are a 
part of the endoplasmic reticulum that is highly rich in enzymes involved in lipid 
biosynthesis (Cui et al.1993). Each step in the methylation pathway utilizes methyl 
groups from methionine, and produces S-adenosylhomocysteine as a byproduct that 
ultimately gets converted to homocysteine. In fact, the activity of PEMT has been 
hypothesized as a mechanism to regulate homocysteine concentrations in the plasma 
(Robinson 2001). Since PC synthesized from the PEMT pathway utilizes PE as a 
substrate, the fatty acyl distribution of PE derived PC species should reflect PE 
synthesized by the Kennedy pathway rather than PC synthesized by the CDP-choline 
pathway. Indeed, evidence shows that PC synthesized by the PEMT pathway was 
predominantly enriched with 16:0 and 18:0 at the sn-1 position, and DHA at the sn-2 
position (Pynn et al. 2011).  
2.6 Phospholipid Fatty Acid Remodeling (Lands’ Cycle) 
Eukaryotes maintain specific fatty acid distributions in the phospholipids of cell 
membranes. Saturated and monounsaturated fatty acids are more likely to be esterified at 
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the sn-1 position, while polyunsaturated fatty acids are predominantly esterified at the sn-
2 position. Glycerophospholipids that are formed through the Kennedy pathway 
(described above) undergo remodeling by subsequent rounds of de-acylation/acylation 
reactions, also known as the Lands’ cycle (Lands, 1958; reviewed in Shindou et.al. 2009). 
The composition of fatty acyls at the sn-2 position is altered through the specific and 
regulated actions of A2 phospholipases (PLA2s) and lyso-phospholipidstransferases 
(LPLATs). There are numerous forms of LPLATs that are thought to be responsible for 
the variety in phospholipids species that differ in the polar phosphate head group as well 
as the fatty acyl attached to their glycerol backbone. The form of active LPLAT is largely 
tissue dependent.  For instance, lyso-phosphatidylcholine-acyl transferase 1 (LPCAT1) is 
highly expressed in lungs and shows preference for utilizing 18:2-CoA or 18:3-CoA 
when remodeling PC, while LPLAT3 is ubiquitous in tissues, and shows higher activity 
towards 20:4-CoA and 18:2-CoA.  The same applies for lyso-phosphatidylethanolamine- 
acyl-transferases (LPEAT), where different forms of LPEAT have different specificities 
for the fatty acyls utilized during PE remodeling (Reviewed in Kitson et.al. 2012). The 
end result is that PC synthesized by the Kennedy pathway is enriched in mono (PC 
16:0/18:1) and di-unsaturated (PC 16:0/18:2) fatty acids. At the same time, PE 
synthesized through the same pathway is specifically enriched in 16:0 and 18:0 at the sn-
1 position, and 20:4n-6 and 22:6n-3 at the sn-2 position (Pynn et al. 2011). The reason 
these fatty acids are not incorporated directly in the Kennedy pathway could be related to 
the essential nature of 18:2 and DHA. If the pathway of phospholipid de novo synthesis 
required DHA or arachidonic acid, the process could be compromised if these fatty acids 
were not available in the diet.  
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2.7 DHA, PEMT and Methyl Nutrients 
The PEMT pathway and the CDP-choline pathway are the main two pathways 
known to produce phosphatidylcholine. The majority of the choline the supplies the 
CDP-choline pathway for PC synthesis is acquired through the diet; however, choline 
requirements in humans can be partially met through the PEMT pathway for PC 
biosynthesis (da Costa et al, 2011). Consequently, PEMT activity can be influenced by 
choline intake, as well as various other methyl nutrients, such as methionine, vitamin B12, 
and folic acid (Hoffman et al. 1981). 
PEMT knockout mice put on choline deficient diet rapidly develop significant 
liver damage (Walkey et al. 1998). Even when supplied a choline sufficient diet, PEMT 
knockout mice showed diminished concentrations of DHA and arachidonic acid in 
plasma PC. In humans, plasma PC content of DHA is directly correlated with PEMT 
activity, especially when choline dietary intake is low (da Costa et al. 2011). This further 
supports the physiological importance of PEMT in modulating plasma phospholipid fatty 
acid composition. Dietary choline intake, however, has no effect on DHA content of PC- 
in pregnant women during the third trimester of pregnancy (West et al., 2013). While 
various dietary factors can regulate PEMT, it appears that hormones are also involved in 
PEMT regulation. In particular, estrogen may influence PEMT activity through direct and 
indirect mechanisms (Hartz et al. 2006).  The effect of different dietary levels of DHA on 
PEMT activity has not been examined previously. 
2.8 Hormonal and Pregnancy Effects on PEMT Activity 
Estrogen has been shown to have significant effects on PEMT activity in both 
human and mouse hepatocytes (Young 1971).  Potential estrogen response element 
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motifs have been identified on the PEMT gene promoter region and treating hepatic cell 
cultures with estrogen at doses mimicking concentrations in humans (0-100nmol/L) 
significantly up-regulates mRNA expression and enzyme activity of PEMT (Resseguie et 
al. 2007). Treatment of rat anterior pituitary membranes with estrogen for 4 days resulted 
in an increase in Vmax of PEMT for each methylation step, while the Km remained 
consistent, indicating an increased concentration of PEMT protein (Drouva et al. 1986).  
With elevated estrogen levels during pregnancy, there is increased activity of PEMT and 
an increase in the rate of methylation of PE to PC (Gwee and Sim, 1979). It is 
hypothesized that the increased PEMT activity during pregnancy is an evolutionary 
mechanism developed to protect choline stores and decrease the risk of choline 
deficiency during pregnancy.  However, the conversion of PE (which tends to be higher 
in DHA) to PC (a principal component of lipoproteins) may also be a mechanism to 
mobilize maternal DHA for placental transport to the fetus. 
In addition to elevations in estrogen, pregnancy is also associated with increased 
insulin production. Insulin sensitivity remains unchanged during early pregnancy 
(Catalano et al., 1993) but decreases during the third trimester. While insulin is known to 
be lipogenic, the direct effect of insulin and insulin resistance on PEMT activity remain 
unclear, and may be tissue dependent (Hoffman et al.1981; Cabrero et al., 1986; Hartz et 
al. 2006; Tashiro et al., 1983; Panagia et al., 1990). 
 
2.9 Placental Fatty Acid Transport (figure 2.2) 
The placenta plays a major role in delivery fatty acids to the fetus, especially 
those that are essential for fetal development, such as arachidonic acid (20:4n-6) and 
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docosahexaenoic acid (DHA). The placental tissue takes up free fatty acids circulating in 
the maternal plasma by specific fatty acid carriers, as well as passive diffusion (Haggarty, 
2002). However, the majority of fatty acids in the plasma are in the form of TAG and 
phospholipids. To accommodate that, the placenta expresses lipoprotein lipase, which 
hydrolyzes triacylglycerols into free fatty acids. Phospholipids can be broken down and 
taken up by placental tissue through the action of extracellular phospholipase A2 type II, 
which is responsible for 80% of placental phospholipase activity (Rice et al., 1998). In 
addition, plasma phospholipids can deliver fatty acids to the placenta through the action 
of endothelial lipase, which has high phospholipase activity (Larque et al., 2010). 
Endothelial lipases mainly hydrolyze phospholipids in the monolayer of lipoproteins, but 
they have been also shown to utilize TAG (Lidegaard et al., 2005). The role of these 
proteins in placental transfer and uptake of fatty acid remains unclear. The free fatty acids 
released in the maternal plasma are then transported via fatty acid translocase fatty acid 
transport protein (FATP), and plasma membrane fatty acid binding protein (FABPpm) 
through the placenta and into the fetal circulation (Hanebutt etl al. 2008). Six FATP 
genes have been identified in human and mouse genomes, and the placenta is shown to 
express two forms of this protein: FATP-1 and FATP-4. (Hanebutt et al., 2008). The 
existence of multiple forms of FATP in placental tissue remain unexplained, but the 
expression of FATP-1 appears to be affected by DHA intake in maternal diet (Larque et 
al. 2006). 
	  	   13 
 
 
Figure 2.1: The Kennedy pathway for PE and PC synthesis (adapted from by Gibellini 
and Smith, 2010) 
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Figure 2.2: Placental lipid fractions breakdown and fatty acids transfer (adapted from 
Larque et al. 2011). FATP, Fatty acid transport protein; FAT, fatty acid translocase; 
FABPpm, fatty acid binding protein on plasma membrane; LPL, placental lipoprotein lipase; 
EL, endothelial lipase; R, lipoprotein receptor; PLA2, phospholipase A2; FFA, free fatty acids; 
TAG, triacylglycerols; PL, phospholipids. 
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Chapter 3 
	  
Pilot study to examine the fatty acid composition of phospholipids in blood of 
women during pregnancy and postpartum 
 
3.1 Methods 
 As a pilot study, three pregnant women were recruited and blood samples were taken 
during the third trimester of pregnancy and at 4 months post partum. Diet was neither 
assessed, nor controlled. Tissue lipids of plasma and erythrocytes were extracted 
according to Folch et al., using 2:1 chloroform:MeOH (v/v) (Folch et al. 1957).  Prior to 
extraction, 10ug of 17:0 standard was added to each sample in the form of 
diheptadecanoyl-sn-glyercol-3-phosphocholine and diheptadecanoyl-sn-glyercol-3-
phosphoethanolamine (Sigma Aldrich).  Individual phospholipids in the lipid extracts 
were isolated using thin layer chromatography (TLC).  In TLC, a silica coated glass plate 
serves as the stationary phase. The sample is applied to the bottom of the plate, the origin, 
and placed in a glass tank that contains a liquid mobile phase at a level below the origin.  
A mixture of liquid solvents is used as the mobile phase, with varying composition 
depending on the nature of the sample and the separation desired. As the mobile phase is 
drawn upwards by capillary action, components of the sample move upwards at different 
rates. The separation of the components is based on polarity, interaction with the 
stationary phase particles, and their solubility in the mobile phase (Christie, 1989).  
Samples can be separated into major lipid classes including phospholipids, 
triacylglycerols, cholesterol esters, and free fatty acids. In addition, the major classes can 
be separated into subclasses; for example, the phospholipids fraction can be separated 
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into PC, PE, PI, PS, lyso-phosphatidylcholine, and sphingomyelin fractions. Internal 
standards, such as 1,2-diheptadecanoyl-sn-glyercol-3-phosphocholine (850360P, Avanti 
Polar Lipids Inc, Alabaster, AL) and diheptadecanoyl-sn-glyercol-3-
phosphoethanolamine are used to allow for quantification. Analysis of the fatty acid 
composition of isolated lipid classes is then determined by GC as described above.  
 For this experiment, TLC H-plates (Fisher Scientific) were activated for an hour 
prior to use. Each plate was scored into 6 equal width lanes, where one of the lanes were 
reserved for a running standard, containing the phospholipids of interest. Total lipid 
extract from each sample was dissolved in 50 µl of chloroform and applied to the base of 
each lane with the use of a syringe. The plate was developed in a solvent mixture 
containing chloroform:MeOH:propanol:KCl (0.25% w/v):triethylamine 
(37.5:11.25:31.25:7.5:22.5, vol/vol) in a TLC tank with a filter paper. Once developed 
and dried, the plate was sprayed with 2,7- dichlorofluorescein in methanol to visualize 
the bands. Individual phospholipids bands were scraped off the plate, and lipids were 
extracted using a modified Folch procedure (Folch et al. 1957). TLC extracts were 
transesterified using 14% BF3-Methanol for one hour at 95°C to generate fatty acid 
methyl esters. Finally, the methyl esters were separated and analyzed using GC/FID, 
where the internal standards were used to quantify individual fatty acids of interest. Data 
from 10 non-pregnant female controls with low DHA status generated from a previous 
study were also examined (Patterson, 2012). 
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3.2 Statistical analysis 
A paired samples t-test was used to analyze all fatty acid differences in maternal 
plasma phospholipids in pregnancy and at 4 months post partum. An independent t test 
was used to analyze the differences in phospholipid fatty acids profiles when comparing 
to non-pregnant controls.  
 
3.3 Results 
Maternal Plasma Composition 
In general, there was a decrease in the relative amount of DHA in PC, but it did 
not reach statistical significance (3.77 ± 0.85	  % during pregnancy compared with 2.65 ± 
0.24	  % at 4 months post partum and 2.81 ± 0.68	  % in non-pregnant controls, Table 3.1).  
In addition, 18:0 in plasma PC decreased in relative concentration during pregnancy 
compared with 4 months post partum and non-pregnant controls (11.01 ± 0.64% in 
pregnancy compared with 14.65 ± 1.51% and 15.85 ± 3.91% for 4 months post partum 
and non-pregnant controls, respectively). Palmitic acid relative concentration appeared to 
increase during pregnancy (31.99 ± 0.44 %) compared with 4 months post partum (26.51 
± 2.31 %) and non-pregnant controls (25.07 ± 1.17%).	  
As for plasma PE, 16:0, 18:0, and 20:4n-6 all appeared to be higher in pregnancy 
and post-partum as compared with non-pregnant controls (Table 3.2). DHA relative 
concentration in PE appeared to be elevated in pregnancy compared with 4 months post 
partum and non-pregnant controls, but the difference was only statistically significant 
compared to non-pregnant controls (3.8 ± 0.57% in pregnancy compared to 2.65 ± 0.24% 
and 1.57 ± 0.66 at 4 months post partum and non-pregnant controls, respectively).  Based 
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on these pilot results, assuming the standard deviation is constant, with 80% power, and 
α=0.5, the number of participants required to achieve statistical significance for DHA 
content in PC and PE between pregnancy and 4 months postpartum is 10. 
The results of this pilot study show a strong trend of increased plasma PC DHA 
levels during pregnancy. The levels of saturated fatty acids, such as 16:0 and 18:0 also 
changed during pregnancy, which may indicate a change in phospholipid metabolism 
during pregnancy. Evidence suggests an increase in overall plasma PC levels, which may 
be caused by up-regulating the PEMT pathway. The effects of dietary intake of DHA 
were not accounted for in this study, and need to be considered in follow-up studies. 
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Table 3.1: Relative percent fatty acid composition of plasma PC during pregnancy 
and in non-pregnant controls 
Name Control Pregnant Post partum 
C 14:0 0.52 ± 0.12 0.71 ± 0.09 0.64 ± 0.31 
C 16:0 25.07 ± 1.17 31.99 ± 0.44 26.51 ± 2.31 
C 18:0 15.85 ± 3.91 11.01 ± 0.64 14.65 ± 1.51 
C 20:0 0.18 ± 0.09 0.18 ± 0.05 0.18 ± 0.09 
C 22:0 0.20 ± 0.09 0.43 ± 0.16 0.22 ± 0.13 
C 23:0 0.32 ± 0.12* 0.15 ± 0.07 0.41 ± 0.15 
C 24:0 0.23 ± 0.09 0.36 ± 0.15 0.30 ± 0.13 
SFA 43.74 ± 5.45 46.71 ± 1.22 43.69 ± 3.6 
    C 14:1 0.04 ± 0.04 0.08 ± 0.04 0.05 ± 0.03 
C 16:1 0.38 ± 0.16 0.86 ± 0.42 0.40 ± 0.04 
C 18:1n-7 1.64 ± 0.41 1.22 ± 0.10 1.73 ± 0.15 
C 18:1n-9 12.33 ± 3.8 9.87 ± 0.80 12.74 ± 3.67 
C 20:1n-9 0.23 ± 0.08 0.21 ± 0.04 0.22 ± 0.08 
C 22:1n-9 0.24 ± 0.17 0.42 ± 0.19 0.29 ± 0.15 
C 24:1n-9 0.21 ± 0.1* 0.54 ± 0.19 0.41 ± 0.21 
MUFA 15.09 ± 3.84 13.23 ± 1.42 15.85 ± 3.46 
    C 18:2n-6 19.90 ± 4.10 18.31 ± 1.18 22.54 ± 3.28 
C 18:3n-6 0.11 ± 0.05 0.11 ± 0.07 0.09 ± 0.05 
C 20:2n-6 0.30 ± 0.08 0.32 ± 0.03 0.58 ± 0.17 
C 20:3n-6 2.54 ± 0.82 2.97 ± 0.43 3.36 ± 0.28 
C 20:4n-6 9.65 ± 1.82 6.65 ± 1.73 7.50 ± 1.20 
C 22:2n-6 0.20 ± 0.15 0.09 ± 0.09 0.20 ± 0.12 
C 22:4n-6 0.62 ± 1.31 0.24 ± 0.07 0.25 ± 0.13 
C 22:5n-6 0.31 ± 0.13 0.40 ± 0.14 0.38 ± 0.14 
N-6 33.57 ± 4.54 29.09 ± 1.8 34.92 ± 2.86 
    C 18:3n-3 0.25 ± 0.07* 0.46 ± 0.01 0.39 ± 0.14 
C 20:3n-3 0.11 ± 0.06 0.15 ± 0.11 0.26 ± 0.18 
C 20:5n-3 0.87 ± 0.51 0.80 ± 0.29 0.51 ± 0.07 
C 22:5n-3 0.80 ± 0.17* 0.56 ± 0.04 0.57 ± 0.12 
C 22:6n-3 2.81 ± 0.68 3.77 ± 0.85 2.65 ± 0.24 
N-3 4.84 ± 1.07 5.74 ± 0.90 4.38 ± 0.54 
    HUFA 17.66 ± 2.00 15.54 ± 2.13 15.49 ± 0.91 
PUFA 38.41 ± 4.81 34.83 ± 2.25 39.29 ± 3.32 
Total 137.07 ± 20.14 212.22 ± 45.65 168.09 ± 43.55 
Mean +/- SD,. *Significantly different compared to pregnancy by paired samples t-test or independent t-
test: p<0.05.  
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Table 3.2: Relative percent fatty acid composition of plasma PE during pregnancy 
and in non-pregnant controls 
Name Control Pregnant Post partum 
C 14:0 1.90 ± 0.36* 2.66 ± 0.26 1.66 ± 0.42 
C 16:0 15.35 ± 4.23* 23.92 ± 1.17 8.22 ± 1.20 
C 18:0 19.71 ± 7.20* 24.64 ± 2.11 10.75 ± 2.58 
C 20:0 0.62 ± 0.22 0.53 ± 0.09 0.56 ± 0.09 
C 22:0 0.94 ± 0.40 1.85 ± 0.62 0.58 ± 0.16 
C 23:0 0.87 ± 0.41 1.25 ± 0.50 0.84 ± 0.38 
C 24:0 0.99 ± 0.28* 1.60 ± 0.31 0.92 ± 0.49 
SFA 42.61 ± 11.54* 62.63 ± 1.52 24.05 ± 3.89 
    C 14:1 0.12 ± 0.04* 0.37 ± 0.11 0.06 ± 0.01 
C 16:1 0.21 ± 0.20 0.42 ± 0.12 0.15 ± 0.05 
C 18:1n-7 0.75 ± 0.43 0.61 ± 0.17 0.64 ± 0.06 
C 18:1n-9 22.98 ± 23.10 7.73 ± 0.88 58.22 ± 5.02 
C 20:1n-9 0.38 ± 0.19 0.37 ± 0.11 0.43 ± 0.08 
C 22:1n-9 1.45 ± 0.91 1.81 ± 0.32 0.89 ± 0.65 
C 24:1n-9 0.88 ± 0.48 0.80 ± 0.24 0.69 ± 0.12 
MUFA 26.86 ± 22.22* 12.36 ± 1.23 61.14 ± 4.31 
    C 18:2n-6 5.00 ± 2.99 5.02 ± 1.07 6.64 ± 1.58 
C 18:3n-6 0.23 ± 0.22 0.21 ± 0.13 0.09 ± 0.01 
C 20:2n-6 0.35 ± 0.15 0.41 ± 0.26 0.30 ± 0.14 
C 20:3n-6 0.69 ± 0.42* 1.04 ± 0.16 0.53 ± 0.43 
C 20:4n-6 4.26 ± 2.72 6.15 ± 2.11 1.77 ± 0.50 
C 22:2n-6 0.62 ± 0.25 0.45 ± 0.15 0.76 ± 0.44 
C 22:4n-6 1.02 ± 0.89* 0.51 ± 0.05 0.81 ± 0.42 
C 22:5n-6 0.72 ± 0.46 0.75 ± 0.12 0.48 ± 0.19 
N-6 12.89 ± 6.26 14.54 ± 1.94 11.38 ± 0.07 
    C 18:3n-3 0.52 ± 0.36 0.44 ± 0.11 0.28 ± 0.12 
C 20:3n-3 0.47 ± 0.30 0.56 ± 0.20 0.32 ± 0.25 
C 20:5n-3 0.63 ± 0.27 0.65 ± 0.16 0.55 ± 0.19 
C 22:5n-3 1.24 ± 0.94 1.06 ± 0.51 1.01 ± 0.16 
C 22:6n-3 1.57 ± 0.66* 3.80 ± 0.57 1.00 ± 0.13 
N-3 4.43 ± 1.75* 6.50 ± 0.78 3.17 ± 0.63 
    HUFA 10.60 ± 5.75* 14.51 ± 1.32 6.47 ± 1.54 
PUFA 17.32 ± 7.60* 21.04 ± 1.30 14.54 ± 0.70 
Total 68.42 ± 18.94 50.16 ± 1.34 42.36 ± 17.83 
Mean +/- SD,. *Significantly different compared to pregnancy by paired samples t-test or independent t-
test: p<0.05 
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Chapter 4 
Rationale	  hypotheses	  and	  objectives 
 
4.1 Rationale  
Docosahexaenoic acid (DHA), an omega-3 fatty acid, plays an important role in 
fetal brain development. Evidence suggests multiple maternal physiological adaptations 
in order to deliver DHA to the fetus (De Vriese et al 2003).  Hormones such as estrogen, 
which is elevated during pregnancy, can increase DHA biosynthesis, but may also 
increase lipids that contain DHA, such as phospholipids in maternal plasma.  
Estrogen increases PEMT expression and activity in isolated hepatocytes 
(Resseguie et al. 2007), and in maternal liver in pregnant rats (Gwee and Sim 1979), 
where activity of PEMT was shown to increase at day 6 of pregnancy.  PEMT catalyzes 
the methylation of PE to form PC in the liver. The PEMT pathway of PC biosynthesis is 
thought to be a mechanism to regulate choline levels, especially when choline demands 
are high, such as during pregnancy. However, PEMT may have a potential role in 
regulating plasma PC fatty acid composition, as PE and the resulting PC synthesized by 
the PEMT pathway are predominantly enriched with 18:0 and DHA. The dominant 
phospholipid in plasma is PC located in circulating lipoproteins that can supply fatty 
acids for fetal transport.  Therefore, PEMT may be involved in mobilizing DHA stores to 
maternal plasma in order to increase its availability to the developing fetus. 
The effects of DHA intake on PEMT expression and activity during pregnancy 
were examined. To our knowledge, the research in this area has focused on the effect of 
choline intake on the PEMT pathway, whereas the role of DHA intake is not well 
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understood. Understanding the dynamics and the mechanisms involved in this pathway 
would provide the basis for dietary recommendations for essential fatty acids such as 
DHA, and advance our understanding of hormonal regulation of fat metabolism. The use 
of a dietary manipulation in rat models in combination with the DHA treatment is 
important considering that 20% of pregnant women in Canada do not consume DHA 
(Denomme et al. 2005). Given that fatty acids can influence PEMT expression, we used a 
rodent diet with a fatty acid profile that mimics the intakes of North Americans, known as 
the Typical Western Diet (TWD). The new TWD was recently developed by Harlan 
based on the 2007-2008 National Health and Nutrition Examination (Hintze et al., 2012) 
and the use of the total Western diet (TWD) in a rat pregnancy study is a novel approach 
in nutritional research.  
 
4.2 Objectives 
The objects of this thesis are to elucidate the role of PEMT and associate it with 
changes in DHA and phospholipid levels in pregnant rats. Rats were bred, and upon 
confirmation of pregnancy, were placed on either a DHA supplemented, or DHA 
deficient Total Western Diet. An additional group of dams were fed with a regular chow 
diet, to serve as a control group. The genetic expression of PEMT in maternal liver was 
examined at the mRNA level, and liver protein levels of PEMT were measured by 
immunoblotting. Additionally, we examined the effects of DHA intake on plasma and 
liver phospholipid fatty acid composition in pregnant rats. Total fatty acids profile of 
plasma and liver tissue, in addition to the fatty acid composition of PC and PE in 
maternal plasma and liver, were determined using gas chromatography.  
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4.3 Hypotheses 
1- PEMT mRNA expression, protein levels, and activity will be increased during 
pregnancy. 
2- Feeding total Western diet (TWD) supplemented with DHA will decrease PEMT 
mRNA expression, protein levels, and enzymatic activity in maternal liver. 
3- Concentrations of 18:0 and DHA in plasma and liver PC will be increased during 
pregnancy relative to baseline and post partum indicating increased PC formed 
from PE. 
4- Providing DHA to pregnant rats will increase DHA and 16:0 in plasma and liver 
PC indicating a decreased role of PEMT in producing DHA enriched PC.   
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Chapter 5 
  
Pregnant Rats model study- PEMT analysis 
 
5.1 Study Design 
All animal procedures were approved by the University of Waterloo Animal Care 
Committee and are in accordance with the guidelines of the Canadian Council on Animal 
Care. A total of 82 Sprague Dawley rats were purchased (72 female rats at 7 weeks of 
age, and 10 male rats at 6 months of age). The 10 male rats were only used for breeding 
purposes, and were not involved in the study. Rats were bred on campus, and upon 
confirmation of pregnancy, pregnant female rats were assigned to either 1) a high DHA 
Total Western Diet (TWD-DHA+) which consists of 1.3% DHA in total fatty acids  2) a 
Total Western Diet with no DHA but omega-3 sufficient (TWD-DHA-) or 3) a typical 
chow rodent diet, throughout 21 days of pregnancy. Diets were purchased from Harlan 
Laboratories (TD.110424 New Total Western Diet; 8640 Teklad 22/5 Rodent Diet) 
(Table 6.1). Pregnant rats (n=6 from each of the three diet groups at each time point of 
pregnancy) were sacrificed at day baseline (non-pregnant rats after 7 days of dietary 
intervention) 15 and 20 of pregnancy, and 7 days postnatal. Pregnant rats were sacrificed 
by exsanguination following anesthesia, using isoflurane, after an overnight fast. 
Maternal blood, liver, heart, brain, and placenta were collected.  Fetuses obtained from all 
time points were also sacrificed immediately after separation from the mother by 
decapitation using sharp scissors, while pups from 7 days postnatal were sacrificed by 
exsanguination following anesthesia using isoflurane. Fetal tissues were collected and 
stored for analyses for fatty acid analysis.  The collected brains, livers, and placentas 
were flash frozen in liquid nitrogen and stored at -80°C for fatty acid composition 
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analyses, mRNA expression, and Western blots and activity assays for 
phosphatidylethanolamine-N-methyltransferase (PEMT).  
5.1.1 Assessing PEMT Gene Expression 
The mRNA expression was determined by quantitative real-time PCR (qRT-
PCR).  Reverse-transcriptase real-time PCR is a technique used to amplify a specific 
sequence of RNA. The first step is to isolate RNA from samples, which is then reverse-
transcribed to cDNA for more stability. Trizol reagent, containing RNAse inhibitor, was 
used to isolate RNA from cells. Chloroform was then added in order to separate RNA 
from other cellular components. Spinning the Trizol layer using a micro-centrifuge 
pelleted RNA. The RNA pellet was then washed with ethanol and dissolved in deionized 
water. Following that, agarose gel electrophoresis with ethidium bromide was performed, 
which insured the integrity of isolated RNA prior to cDNA synthesis. The concentration 
of the samples was then confirmed using absorbance at 260 nm, while the 260/280 ratios 
were used to determine sample purity, as determined by a NanoDrop spectrophotometer. 
Only RNA samples with high purity (260/280 ratio above 1.90) were used for subsequent 
cDNA synthesis by reverse transcriptase. Primers were designed for PEMT through 
Primer-BLAST program on the NCBI website and ordered from Sigma-Aldrich (5’-
CCCAGCTTTGTGGCGGCTGT-3’). A mix containing the PEMT primer and SYBR 
green, a special fluorescent dye that binds to double-stranded DNA used to visualize the 
amplification of a sequence in real time, was added to the cDNA templates. qRT-PCR 
was performed using the following set of conditions: initial incubation at 95°C for 10 
min, followed by 40 cycles of 95°C and 60°C, which resulted in the amplification of the 
target sequence. The qRT-PCR data was expressed relative to glyceraldehyde-3-
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phosphate dehydrogenase gene (GAPDH) (used as a house keeping reference gene during 
pregnancy) (Rekawiecki, et al. 2012).  
PEMT protein levels were determined by immunoblotting as described previously 
(Kitson et al., 2012). Tissue samples were homogenized in a buffer containing complete 
protease inhibitor tablets (0.25mol/L sucrose, 0.01mol/L tris-HCl, 0.01mol/L MgCl2, 
2.5mmol/L DTT). Protein quantification was completed using a bicinchoninic acid 
procedure.  Twenty µg of the protein was then resolved on a 12.5% SDS-PAGE gel and 
transferred to a polyvinylidene fluoride membrane.  Next, 5% milk was used to block the 
membranes in TBS with 0.5% (v/v) Tween (TBST) over night at 4°C. The membranes 
were then incubated with primary antibodies for PEMT (Donated by Professor Dennis 
Vance, University of Alberta) (1:1000 dilution) for 2h at room temperature.  Following 
incubation, the membranes were washed with TBST, incubated again for 1hr at room 
temp with horseradish peroxidase-conjugated secondary antibody (rabbit anti-goat, Santa 
Cruz Biotechnology, 1:8000 dilution), and washed again. The proteins were treated with 
Enhanced Chemiluminescence Western Blotting Detection Reagents and visualized on a 
Chemigenius 2 Bioimaging System using Genesnap software v 7.07.  Finally, the 
molecular weights of proteins, equal protein loading, and adequate transfer of protein to 
membrane were confirmed using ponceau staining and blotting for ß actin. 
5.1.2 Determining the Enzyme Activity of PEMT  
A liver PEMT activity assay was performed as described by Ridgway and Vance 
(Ridgway and Vance, 1998). To assess activity, we used 50 µg of protein homogenized in 
Tris-HCl/L (pH 9.2) and 5 mm DTT buffer/L (Sigma). Samples were incubated with 200 
µmol S-adenosyl-L-methionine/L containing 0.5µCi S-adenosyl-L-[methyl-3H] 
methionine (55.70 Ci/mmol) and 0.4 nmol exogenous phosphatidyl di-methyl-
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ethanolamine /L (P2; Avanti Polar Lipids).  The reaction was carried out for 60 minutes 
at 37°C, when it is stopped by adding ice cold CHCL3:MeOH:1 N HCL (100:50:1, 
vol/vol). Samples vials were vortexed, followed by the addition of 1 ml of 0.1M KCL in 
50% MeOH wash solution. Samples were centrifuged, and the top layer was discarded. 
Finally, samples were dried under nitrogen flow, and resuspended in 60 µl of chloroform. 
A portion of the chloroform phase (20µl) was applied to a silica gel TLC/ G plate 
(ANALTECH, cat. 01011), and the plate was developed in CHCL3:MeOH:Acetic acid: 
H2O (50:30:5:2,vol:vol).  Liquid Scintillation spectro-photometry was used to determine 
disintegrations per minute from [3H]-PC in TLC bands.  
5.1.3 Determining 17β-estradiol concentrations  
ELISA kits were ordered from Cayman Chemical (Ann Arbor, MI) (Estradiol EIA 
Kit, Cayman Chemical Item Number 582251) for the determination of plasma 17β-
estradiol concentrations of the baseline non-pregnant as well as the pregnant animals. 
17β-estradiol was extracted from 500 µl of plasma with methylene chloride, and 
reconstituted in 200 µl of EIA buffer. For each assay, 50 µl of samples and the 
appropriate volume of standards were loaded to the 96-well plate in duplicate. Two wells 
were designated each for blanks, total activity, non-specific binding and maximum 
binding. The concentration of estradiol was measured by exposing the plates to 420 nm 
wavelength, where the wavelength reading of each well was compared to the standard 
curve. 
5.2 Statistical Analysis  
Rats were divided among twelve groups based on diet and pregnancy (Three diets 
× 4 pregnancy time points). A one-way ANOVA test was used to analyze differences in 
fatty acids, mRNA, and protein at different stages of pregnancy in rat models. Data are 
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presented as mean ± standard deviation. Statistical significance was determined at α=0.5 
via a Tukey post hoc test. 
5.3 Results 
5.3.1 Food Intake and Body Weight 
Average caloric intake increased significantly in the 7 days post partum group for 
all diets (p < 0.05) and there were no other differences (Figure 5.1)  
Bodyweight increased steadily throughout pregnancy, and reached its highest at 
day 20 (p < 0.05) (Figure 5.2). There was no significant difference in bodyweight across 
diets at any time point (p >0.05). 
 5.3.2 Plasma Estradiol 
There was no significant difference between baseline, 15 days of pregnancy, and 
7 days post partum plasma estradiol levels. Hormone levels increased significantly at 20 
days of pregnancy compared to baseline, 15 days pregnancy, and 7 days post partum, in 
all diets (p < 0.05) (Figure 5.3). The high fat diet (either TWD+DHA or TWD DHA 
deficient) had no significant effect on plasma estradiol levels at any of the time points (p 
≥ 0.05).  
5.3.3 PEMT Gene mRNA Expression 
 At baseline, PEMT mRNA expression was lowest in the chow fed group. This 
was significantly different than the TWD without DHA, but not the TWD with DHA.  
Day 15 was associated with increases in mRNA expression especially in the animals fed 
diets without DHA (342-375 % increase from baseline, p < 0.05) but muted when DHA 
was in the diet (172% increase from base line, p =0.05).  PEMT mRNA expression 
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decreased significantly from day 15 at day 20 of pregnancy (74-90 % decrease), and 7 
days post partum (88-91% decrease) in all diet groups, (Figure 5.4-A). 
  
5.3.4 PEMT Protein Levels  
 PEMT protein expression tended to gradually increase throughout pregnancy 
peaking at day 20 and then decreasing with postpartum (Figure 5.4-B). In the chow-fed 
rat the difference between baseline and day 20 was significant, while day 15 levels were 
intermediate, and PEMT returned to baseline levels at 7d postpartum.  In TWD without 
DHA, the increase in PEMT over time was not significantly higher than baseline, but the 
day 15 and day 20 PEMT levels were significantly higher than 7d postpartum. In the 
TWD with DHA, PEMT levels tended to be higher than the other diets with significantly 
higher levels at baseline and 7 d postpartum.  The PEMT increase at d20 in the TWD 
+DHA was significantly higher than at d15, but was not significantly different than 
baseline or 7d postpartum.  Additionally, the PEMT at d20 of the TWD+DHA was 
significantly higher than the d20 PEMT in the TWD – DHA group. 
 
5.3.5 PEMT Enz Activity 
PEMT enzymatic activity increased significantly during pregnancy in all dams 
(Figure 5.4-C). However, the time point of pregnancy where PEMT activity reached its 
peak was different between diet groups.  Liver PEMT activity increased significantly at 
day 15 of pregnancy in both Chow and DHA deficient diet fed dams. PEMT activity 
decreased significantly at day 20 of pregnancy in chow fed dams, but not in DHA 
deficient diet fed dams. High DHA diet fed dams had significantly lower liver PEMT 
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activity at day 15 of pregnancy compared to chow and DHA deficient diet fed dams, but 
the enzyme activity increased significantly at day 20 of pregnancy. Animals from all diet 
groups had significantly lower PEMT activity at 7 days post partum. 
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Table 5.1 Relative Percent fatty acid composition analysis of TWD and chow diets 
Name TWD-DHA+ TWD-DHA- Chow 
C 16:0 19.52 ± 0.03 20.24 ± 0.04 13.63 ± 0.06 
C 18:0 9.03 ± 0.01 9.70 ± 0.02 2.18 ± 0.33 
SFAs 33.32 ± 0.04 34.31 ± 0.10 17.35 ± 0.26 
    C 16:1 1.20 ± 0.01 1.17 ± 0.01 0.88 ± 0.01 
C 18:1n-9 37.12 ± 0.05 36.94 ± 0.02 21.03 ± 0.05 
MUFA 40.79 ± 0.03 40.69 ± 0.04 23.73 ± 0.01 
    C 18:2n-6 20.85 ± 0.01 20.73 ± 0.01 49.69 ± 0.22 
C 22:5n-6 1.58 ± 0.01 1.89 ± 0.01 0.02 ± 0.01 
N-6 22.79 ± 0.02 23.04 ± 0.07 50.01 ± 0.18 
    C 18:3n-3 1.87 ± 0.01 1.88 ± 0.01 5.72 ± 0.09 
C 22:6n-3 1.14 ± 0.02 n.d. 0.22 ± 0.01 
N-3 3.11 ± 0.04 1.96 ± 0.01 6.19 ± 0.07 
    HUFA 2.96 ± 0.04 2.08 ± 0.08 0.69 ± 0.05 
PUFA 25.90 ± 0.06 25.00± 0.06 56.20 ± 0.25 




Table 5.2 Nutrient composition of TWD and Chow diets 
Ingredient (g/kg) TWD DHA+ TWD DHA- Chow 
L-Cystine 3 3 3 
Cellulose 50 50 39 
Choline bitartrate 2.5 2.5 2.38 
TBHQ, antioxidant 0.014 0.014 0 
Kcal/g 3.7 3.7 3.0 
TWD Diet Formulation 
Corn starch 378.186 378.186  
Maltodextrin 132 132  
Sucrose 100 100  
Casein 200 200  
Corn oil 70 70  
Mineral mix, AIN-93G-
MX (94046) 48 48  
DHASCO oil 
(40% DHA) 17 0  
Macronutrients Breakdown (% Weight) 
Protein 17.7 17.7 22 
Carbohydrate 59.2 59.2 40.6 
Fat 7.2 7.2 5.5 
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Figure 5.1 Daily average Food intake pattern of dams fed with a 1.3% DHA Total 
Western Diet (DHA+), DHA deficient Total Western Diet (DHA-) or a chow diet (Chow) 
during pregnancy. Time points labeled with * are significantly different from baseline, 15 
days pregnancy and 7 days postpartum by Tukey’s post hoc test (p<0.05) following 




Figure 5.2 Average body weight of dams fed a 1.3% DHA Total Western Diet (DHA+), 
DHA deficient Total Western Diet (DHA-) or a chow diet (Chow) during pregnancy. 
Time points labeled with * are significantly different from baseline, 15 days pregnancy, 
and 7 days postpartum by Tukey’s post hoc test (p<0.05) following significant F-value by 
one-way ANOVA. 
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Figure 5.3 Plasma Estradiol concentrations of  rats on a 1.3% DHA Total Western Diet 
(DHA+), DHA deficient Total Western Diet (DHA-) and chow diet (Chow) throughout 
pregnancy and post-partum. *Significantly different than other time points within a diet 
by Tukey’s post hoc test (p<0.05) following significant F-value by one-way ANOVA. 
  





Figure 5.4 Pregnancy Effect on phosphatidylethanolamine methyl transferase 
(PEMT) expression in maternal liver: (A) Fold difference in mRNA gene expression of 
PEMT in non-pregnant female rats and dams placed on a 1.3% DHA Total Western Diet 
(DHA+), DHA deficient Total Western Diet (DHA-) and chow diet (Chow) as identified 
by qPCR.(B)  Fold difference in protein expression of PEMT in non-pregnant female rats 
and dams placed on a 1.3% DHA Total Western Diet (DHA+), DHA deficient Total 
Western Diet (DHA-) and chow diet (Chow) as identified by densitometric analysis of 
representative immunoblots (Shown below the figure). (C) Fold difference in the enzyme 
activity of PEMT in non-pregnant female rats and dams placed on a 1.3% DHA Total 
Western Diet (DHA+), DHA deficient Total Western Diet (DHA-) and chow diet (Chow) 
as indicated by the radio-enzymatic activity assay. Values with different superscripts are 
significantly different within the same diet, while values with different numbers are 
different within the same time point. Significance is determined by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA. 
 
  








6.1.1 Extraction of plasma and liver total lipids 
Tissue samples, including pups’ whole bodies, were pulverized under liquid 
nitrogen, and stored at -80°C until analyzed. Fatty acids were extracted from pulverized 
tissues according to Folch’s procedure (Folch, 1957), using 2:1 (v/v) 
chloroform:methanol. The chloroform:methanol solution contained an internal standard 
(22:3n-3 ethyl ester, Nu-Chek Prep Inc, Elysian, MN) for quantitation of fatty acid 
concentrations by GC/FID analysis. Sodium phosphate buffer (0.5 ml) was added before 
centrifuging to separate the mixture into two layers, so the chloroform bottom layer 
(containing lipids) could be collected. The collected chloroform was dried under 
nitrogen, and 1ml of BF3 in methanol and 0.3 ml of hexane were added in preparation for 
the trans-esterification reaction. The samples were heated for one hour at 90 °C, and then 
allowed to cool to room temperature. One ml of hexane and 1ml of ultrapure water were 
added to each sample, briefly vortexed and centrifuged to separated the mixture into two 
layers. The top organic layer was collected, dried under nitrogen, and reconstituted in an 
appropriate volume of hexane for final analysis on GC/FID. 
6.1.2 Thin layer chromatography of plasma and liver phospholipids 
Maternal plasma and liver phospholipids were separated into PC, PE, PI, PS, lyso-
phosphatidylcholine, and sphingomyelin fractions. Internal standards, such as 1,2-
diheptadecanoyl-sn-glyercol-3-phosphocholine (850360P, Avanti Polar Lipids Inc, 
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Alabaster, AL) and diheptadecanoyl-sn-glyercol-3-phosphoethanolamine were used to 
allow for quantification (see Ch4, Section 1 for details)  
 
6.1.3 Fatty acid determination by GC 
Fatty acid methyl esters dissolved in hexane were separated by fast gas 
chromatography (Stark and Salem, Jr., 2005). Sampled were analyzed using a Varian 
3900 gas chromatograph coupled with a DB-FFAP 15 m × 0.10 mm injected dose × 0.10 
µm film thickness, nitroterephthalic acid modified, polyethylene glycol, capillary column 
(J&W Scientific from Agilent Technologies, Mississauga, ON, Canada), and used 
hydrogen as the carrier gas. A volume of 2 µL of each sample was introduced by a Varian 
CP-8400 auto-sampler into the injector, with a split ratio of 200:1. Initial temperature was 
maintained at 150°C for 0.25-minute, followed by a 35°C/min ramp to 200°C. This was 
followed by an 8°C/min ramp to 225°C with a 3.2-minute hold, and then an 80°C/min 
ramp up to 245°C with a 15-minute hold at the end. The flame ionization detector (FID) 
temperature was maintained at 300°C with air and nitrogen make-up gas flow rates of 
300 and 25 ml/min, respectively. Sampling frequency was set to 50 Hz. Individual fatty 
acid peaks were identified using Galaxie software (version 1.9.3.2) by comparison to a 
reference mixture of fatty acids (GLC-462, Nu-Chek Prep Inc), and peaks areas were 
quantified relative to the internal standard (17:0 in PC or PE, Avanti Polar Lipids, Inc). 
Fatty acid results are presented qualitatively as relative weight % of total fatty acids. 
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6.2 Results 
6.2.1 Fatty Acid Composition of plasma lipids (Appendices A-C)  
 The concentration of the sum of fatty acids in plasma total lipids, PC, and PE 
increased significantly at day 20 of pregnancy, followed by a significant decrease at 7 
days post partum. Within the general increase in the concentration of fatty acids, the 
relative percent (rel%) of  HUFA decreased significantly at day 20 in plasma TLE, as 
well as in plasma PE in rats fed TWD-DHA+. The rel% of HUFA with 22 carbons, 
especially DHA, increased significantly at day 20 of pregnancy in plasma total lipids in 
animals fed chow and TWD-DHA+, as well as the PC and PE fractions of animals in all 
diet groups (figures 6.1, 6.3). The rel% of 22 carbon HUFA, including DHA, decreased 
significantly at 7 days post partum in all diet groups, in plasma total lipids, plasma PC, 
and plasma PE of chow fed animals and animals fed TWD-DHA-.  To the contrary of 
DHA, arachidonic acid (20:4n-6) rel% decreased significantly at day 20 pregnancy in 
plasma total lipids and plasma PC, but not plasma PE. However, arachidonic acid rel% 
did decrease in plasma PE but only at 7 days post partum.  
In both TWD groups, the rel% of PUFA decreased throughout pregnancy and up 
to 7 days post partum in plasma total lipids and in plasma PC, and at 7 days post partum 
in plasma PE the TWD-DHA- fed animals. However, this decrease in the PUFA 
percentage was a result of decreases in n-6 PUFA, and not n-3 PUFA. The percentage of 
n-3 PUFA in plasma PC increased up to day 20 of pregnancy in plasma total lipids in 
chow and TWD-DHA+ fed animals, and in plasma PC. N-3 PUFA rel % in plasma total 
lipids and plasma PC and plasma PE at 7 days post partum decreased compared with day 
20 of pregnancy in all diet groups (p<0.05). 
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The percentage of palmitic acid (16:0) increased in relative concentration at day 
20 of pregnancy in plasma total lipids and plasma PC in all diet groups (p < 0.05). While 
stearic acid (18:0) increased significantly in absolute concentration in plasma total lipids 
and plasma PC at day 2, it decreased in percentage in all diet groups (p < 0.05).  Contrary 
to plasma total lipids and plasma PC, stearic acid relative percent in plasma PE increased 
significantly at day 20 pregnancy in chow and TWD-DHA+ fed animals.  
6.2.2 Fatty acid composition in liver lipids (Appendices D&E) 
 Unlike in maternal plasma, maternal liver PC and PE total fatty acids did not 
change during pregnancy or at 7 days postpartum. PC PUFA relative percent decreased 
significantly at 7 days post partum in TWD-DHA- fed rats (p < 0.05), but did not change 
in liver PE. HUFA relative percent did not change from baseline and during pregnancy in 
either liver PC or liver PE, but decreased significantly at 7 days postpartum in liver PC, 
only in TWD fed animals. Within the HUFA pool, PC and PE 22:5n-3, 22:4n-6, and 
22:5n-6 relative percent increased significantly at 20 days of pregnancy in all diet groups. 
However DHA relative percent in liver PC and PE increased in TWD-DHA+ and chow 
fed animals (p < 0.05) (figures 6.2,6.4), but not in TWD-DHA- fed animals (p > 0.05). 
All 22 carbons HUFA relative percent decreased significantly at 7 days post partum in 
both TWD fed animals (p < 0.05). N-3 fatty acids relative percent increased significantly 
at 20 days of pregnancy in liver PC, as well as liver PE in TWD-DHA+ and chow fed 
animals, before returning to baseline levels at 7 days post partum. Contrary to that trend, 
n-6 fatty acids relative percent decreased significantly at day 20 of pregnancy in liver PC, 
and liver PE in TWD-DHA+ and chow fed animals, before they increased back to 
baseline values at 7 days post partum.  
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Palmitic acid (16:0) relative concentration increased significantly in relative 
concentration at day 20 of pregnancy in liver PC in all diet groups, and in liver PE in 
chow fed animals, before returning to baseline levels at 7 days post partum. On the other 
hand, stearic acid relative concentration decreased significantly at day 20 of pregnancy in 
liver PC in all diet groups and liver PE in chow and TWD-DHA- fed animals; liver PC 
18:0 relative percent returned to normal levels in both TWD-DHA- and chow fed 
animals, but not in TWD-DHA+ fed animals.  
6.2.3 Fatty acid composition in whole-body fetuses (Appendix F) 
Total fatty acids in whole body fetuses at day 15 and day 20 gestations were 
significantly lower than in 7-day-old pups.  There was no significant difference in the 
absolute concentrations of total fatty acids between diets at 15 days and 20 days 
gestation, but at 7 days post partum, the pups from mothers fed TWD diets had 
significantly higher total fatty acid concentrations as compared with pups from chow-fed 
mothers (figure 6.5).  Within this increased fatty acid content of the pups from the TWD 
mothers, MUFA percentages were significantly higher in the 7-day-old pups as compared 
with 15-d and 20-d fetuses.  The 7 day-old pups from TWD fed mothers had a 
significantly larger body mass than those from chow fed mothers (Figure 6.6).   
The percentage of n-3 PUFAin the fetuses increased significantly at day 20 
gestation from dams fed both TWD-DHA+ and chow fed groups, but not TWD-DHA- 
which was largely a reflection of changes in fetal/pup DHA percentages.   
  




Figure 6.1 Percentage of individual fatty acids in rat plasma PC. Each point represents 
the mean for plasma samples (n =18 for baseline and 20 days pregnancy; n=17 for 15 
days pregnancy and 7 days post partum) at each time point from non-pregnant female rats 
and dams placed on a chow diet. Values with different superscripts are significantly 
different by Tukey’s post hoc test (p<0.05) following significant F-value by one-way 
ANOVA. 
  
	  	   41 
 
Figure 6.2 Percentage of individual fatty acids in rat liver PC. Each point represents the 
mean for liver samples (n =18 for baseline and 20 days pregnancy; n=17 for 15 days 
pregnancy and 7 days post partum) at each time point from non-pregnant female rats and 
dams placed on a chow diet. Values with different superscripts are significantly different 
by Tukey’s post hoc test (p<0.05) following significant F-value by one-way ANOVA. 
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Figure 6.3 Percentage of individual fatty acids in rat plasma PE. Each point represents 
the mean for plasma samples (n =18 for baseline and 20 days pregnancy; n=17 for 15 
days pregnancy and 7 days post partum) at each time point from non-pregnant female rats 
and dams placed on a chow diet. Values with different superscripts are significantly 
different by Tukey’s post hoc test (p<0.05) following significant F-value by one-way 
ANOVA. 
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Figure 6.4 Percentage of individual fatty acids in rat liver PE. Each point represents the 
mean for liver samples (n =18 for baseline and 20 days pregnancy; n=17 for 15 days 
pregnancy and 7 days post partum) at each time point from non-pregnant female rats and 
dams placed on a chow diet. Values with different superscripts are significantly different 
by Tukey’s post hoc test (p<0.05) following significant F-value by one-way ANOVA. 
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Figure 6.5 Absolute concentrations of fetuses’ whole body fatty acids. Each column 
represents the mean for whole body fetus samples (n =18 for 20 days pregnancy; n=17 
for 15 days pregnancy and 7 days post partum) at each time point from dams placed on a 
high DHA TWD (TWD-DHA+), DHA Deficient TWD (TWD-DHA-) or chow diet. 
Values with “*” are significantly different by Tukey’s post hoc test (p<0.05) following 
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Figure 6.6 Average pups body weight at 7 days post partum. Each column represents the 
mean for pup body weight from dams placed on a a high DHA TWD (TWD-DHA+), 
DHA Deficient TWD (TWD-DHA-) or chow diet (n = 60 for TWD-DHA+ ; n=56 for 
TWD-DHA-, and n=80 for chow). Values with “*” are significantly different by Tukey’s 
post hoc test (p<0.05) following significant F-value by one-way ANOVA. 
 
  






As hypothesized, PEMT mRNA expression, protein levels, and enzyme activity 
were increased with pregnancy.  The expression of PEMT mRNA increased significantly 
at day 15 of pregnancy in all diet groups, before decreasing dramatically at day 20 and 7 
days post partum, while protein PEMT levels tended to be increased at day 20.  A dietary 
effect was observed, with dietary DHA resulting in decreased PEMT mRNA expression 
at day 15. Despite this decrease in mRNA expression, PEMT protein levels increased at 
day 20 of pregnancy in both high DHA diet and chow fed animals, and PEMT activity 
increased significantly at day 20 of pregnancy in high DHA diet fed animals. This trend 
suggests a time delay between PEMT mRNA expression and actual protein production in 
maternal liver during pregnancy. The higher protein expression and activity of PEMT in 
rats fed TWD-DHA+ as compared with rats fed TWD-DHA- at day 20 of pregnancy 
suggests a positive effect of high DHA intake on PEMT protein expression that was not 
expected.  It is possible that PEMT has a preference for PE high in unsaturated fatty acids 
(Le Kim et al., 1971); therefore, DHA intake could alter the fatty acid composition of 
liver PE, which could affect the rate of PE methylation to PC. 
Concentrations of DHA in liver and plasma PC increased at 20 days of pregnancy 
relative to baseline and post partum as hypothesized, but 18:0 levels decreased 
significantly in relative percentage at that time point. Higher DHA intake of pregnant rats 
increased the protein expression of PEMT at day 20 of pregnancy and increased DHA 
incorporation into PC in plasma and liver, which fits our hypothesis.  The levels of 16:0 
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in plasma PC were similar to the increases observed in DHA with pregnancy, but dietary 
DHA did not appear to have an effect.  Dietary DHA increased DHA in PC as expected. 
The effect of estrogen on PEMT expression has been reported by several studies, 
and an estrogen response element (ERE) has been identified ~ 7.5 kb from transcription 
start site B, TSS (+1) in the PEMT promoter region in both humans and mice (Resseguie 
et al. 2007; Resseguie et al. 2011). The significant increase in estrogen levels that were 
observed at day 20 of pregnancy may explain the significant increase in PEMT protein 
expression and enzymatic activity at that time point. However, the highest level of PEMT 
mRNA occurred at day 15 in all diet groups, and its activity peaked at day 15 in chow 
and DHA deficient diet fed animals, while plasma estrogen levels peaked at day 20. Our 
data suggest that estrogen could be preventing the degradation of PEMT mRNA 
transcripts, but no evidence of such interaction has been documented in previous studies.  
Estrogen has been previously shown to affect general protein synthesis and degradation 
rates in bovine satellite cells (Sollo et al. 2010) and there have been reports of a 
functional interaction between estradiol stimulated estrogen receptor α (ERα) expression 
and protein degeneration via proteasomes (Tsai et al. 2004). There were no differences in 
estrogen levels between rats on different diets (TWD vs. chow); therefore, the effect of 
TWD (high fat diet) on PEMT protein expression was not caused by a change in serum 
estrogen levels. 
Increased protein expression of PEMT at day 20 of pregnancy in maternal liver 
was accompanied by a general increase in DHA relative percent in plasma PC. However, 
there is strong evidence of general lipogenesis occurring at day 20 of pregnancy, an 
expected adaptation during pregnancy to supply the fetus with sufficient energy (Smith et 
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al. 1998). Total fatty acid concentrations increased significantly in all plasma pools at day 
20 of pregnancy, while liver PC and PE showed no significant changes in total fatty 
acids. The occurrence of hyperlipidemia in maternal plasma at 20 days of pregnancy 
meant that the majority of fatty acids that were examined, and not only DHA, showed 
significantly higher concentrations at that time point compared to baseline, 15 days of 
pregnancy, and 7 days post partum. However, looking at the relative concentrations of 
fatty acids reveals differential response of specific fatty acids. DHA percentages 
increased significantly in plasma PC and plasma PE, in all diet groups at day 20 of 
pregnancy. Despite the significant increase of DHA percentages in plasma phospholipids 
in DHA deficient diet fed animals at day 20 of pregnancy, the difference was not 
significant when looking at the total plasma lipids pool. This suggests either a potential 
decrease of DHA levels in other plasma lipid fractions such as triacylglycerols (TAG), or 
a dilution of this increase in DHA content by other fatty acids in the remaining plasma 
lipid fractions. Other fatty acids, including palmitic acid (16:0) and HUFA with 22 
carbons, showed similar trends as DHA. DPA n-6 (22:5n-6) was increased 10-times in 
plasma PC at 20 days pregnancy as compared with baseline and 15 days of pregnancy in 
all diet groups, which is in agreement with a recent report (Childs, 2010). The increase of 
DPA n-6 was particularly large in the DHA deficient diet fed animals suggesting a 
potential increase in maternal delta 6 desaturase activity (D6D) to meet the fetal demands 
for DHA (Nakamura and Nara, 2003), but limited available n-3 PUFA substrates. 
Contrary to DHA, ARA (20:4n-6) and stearic acid (18:0) relative percent 
decreased in plasma PC and total lipids at day 20 of pregnancy, but not in plasma PE. PC 
synthesized de novo through the Kennedy pathway, should contain high levels of 16:0 
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and 20:4n-6, while PC from the PEMT pathway should mimic fatty acid profile of PE, 
which contains high levels of 18:0 and DHA. The increase in DHA levels in plasma PC 
observed could not be fully attributed to PEMT activity despite the significant increase in 
PEMT mRNA at day 15 of pregnancy, and protein expression at day 20 of pregnancy. 
The concentration of 18:0 in plasma PC was significantly higher at day 20 of pregnancy, 
but its concentration relative to other fatty acids was decreased at that time point. It 
appears that de novo PC synthesis through the Kennedy pathway is increased at day 20 of 
pregnancy, based on the higher content of palmitic acid (16:0) relative to other fatty acids 
in plasma PC. These results are in agreement with previous reports in pregnant rats 
(Childs et al. 2012, Burdge et al. 1994) and in the developing guinea pig (Burdge et al. 
1993). Additionally, the fatty acid composition results suggest that ARA in the sn-2 
position of plasma PC molecules is being replaced by DHA. This needs to be confirmed 
with lipidomic analysis, to characterize the acyl chain composition of plasma PC at the 
sn-1 and sn-2 positions. 
Other possible mechanisms for changing maternal plasma PC fatty acid 
composition are changes to the phosphatidic acid (PA) substrate pool. Such effects have 
been previously reported in dams, where increased diacylglycerol (DAG) substrate 
availability combined with increased CDP enzymes activities were related to increased 
liver PC and PE synthesis (Burdge et al. 1994). As pregnancy carries a number of 
metabolic and regulatory changes associated with altered endocrine hormonal levels, the 
metabolism of fatty acids also changes. Evidence suggests that long chain PUFA 
synthesis is significantly increased during pregnancy (Burdge and Calder. 2006) likely 
due to increased desaturases and elongases activities associated with female sex (Kitson 
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et.al. 2012; Kitson et al. 2013). The increase of plasma and liver DPA n-6 levels suggests 
that D6D activity is increased in late pregnancy, especially when the dams are fed a diet 
deficient in DHA that has been proposed to act as a classic feedback inhibitor (Kitson 
et.al. 2010).  With increased PUFA synthesis, incorporation into PA would potentially be 
increased due to mass action effect, which would subsequently affect the fatty acid 
composition of the resulting PC and PE synthesized. The increase in PUFA synthesis 
during pregnancy cannot account for the dramatic increase in plasma DHA levels 
between day 15 and day 20 of pregnancy. It is possible that specific mechanisms 
mobilize maternal DHA into the plasma during pregnancy. Adipose tissue has been 
proposed as a source of 18:3n-3 during pregnancy (Childs et.al.2012). However, DHA is 
largely associated with protein (Stark and Patterson, 2012) and skeletal muscle appears to 
be the largest reserve of DHA (Lin and Salem, 2007). While there is little data on the 
effect of pregnancy on maternal whole body muscle mass, spinal muscular atrophy has 
been reported during pregnancy (Schonborn et al. 1992). Muscular atrophy during 
pregnancy could result in the mobilization of fatty acids stores in muscle tissue to the 
blood stream for placental transport, or for reassembly into plasma phospholipids in the 
maternal liver.  
Specific remodelling of de novo synthesized PC and PE could also be responsible 
for the shift in maternal plasma PC fatty acid composition. The synthesis of PC typically 
results in 16:0 in the sn-1 position.  The 16:0 can be replaced with 18:0 species (Tijburg 
et al. 1991), but this conversion is reduced at 21 days pregnancy, resulting in increased 
appearance of 16:0/DHA PC species (Burdge et al. 1994). The increased levels of 16:0 
and DHA, and the concurrent reduction of 18:0 and 20:4n-6 levels that we observed in 
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plasma and liver PC presently, agree with these previous findings. The detailed 
mechanism of acyl remodeling in phospholipids remains to be fully understood.  We 
hypothesize that pregnancy may also be up-regulating a phospholipase/acyltransferase 
reaction specific for 16:0 PC and DHA. 
The fatty acid composition of fetuses and pups whole body lipids helped to 
elucidate trends in selective fatty acids transport to the fetus from maternal blood stream 
via the placenta. Our results suggest a marked increase in DHA delivery to the fetus at 
day 20 of pregnancy in all diet groups, while other HUFA did not show a similar trend, 
which has been previously reported (Dutta-Roy, 2000). This trend is hypothesized to be 
an evolutionary mechanism to supply the fetus with a sufficient amount of DHA 
necessary to meet the demands of fetal brain development that occurs at this critical stage 
in pregnancy (Neuringer et.al. 1988). The fetal accretion of DHA was especially high 
when the mothers were fed a diet high in DHA (TWD-DHA+), as compared with those 
fed with a DHA deficient diet (TWD-DHA-) or chow. As expected, total fatty acids 
content increased significantly at 7 days post-partum as the pups grew in size. However, 
total fatty acids in pups of mothers on the two TWD diets were significantly higher than 
those whose mothers consumed chow diet despite similar caloric intake at that time point, 
This trend could be either related to the higher fat content of the TWD diet, or due to a 
potential effect of the maternal diet on the nutrient density of their breast milk. Breast 
milk samples were not collected presently, but should be examined in the future. 
One limitation to this study is the difference between human and rat brains in 
terms of fetal development and neurogenesis. Rat pups are born underdeveloped 
neurologically, particularly the olfactory bulbs, hippocampus, and cerebellum (Altman 
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and Bayer, 1979) relative to humans.  Contrary to rat brains, human brains develop at a 
higher rate prenatally, and human infants are born with well developed granular neurons 
(Bayer et.al. 1993).  Therefore, since DHA demand is at its highest during brain growth 
spurt (Innis, 2007; Neuringer et al. 1988), the spike in maternal plasma DHA occurs 
during the third trimester of pregnancy in women, whereas the brain growth spurt 
continues postpartum in rats (Bayer et.al. 1993).  This could explain the slight decrease in 
plasma DHA reported in humans (Wijendran, et al. 1999), which does not occur in rats, 
presently. 
The TWD diet used contained significantly higher levels of fat as compared to 
standard rodent chow that appear to have affected the outcomes of this study, and is 
considered a limitation in interpreting the effect of dietary DHA.  PEMT is regulated by 
fat intake (Clandinin et al. 1994; Bremer et al. 1961), and increased dietary fat intake is 
associated with higher blood cholesterol levels that also affect PEMT expression and 
activity (Keelan et al. 1994).  This rodent diet was chosen because it contains types of 
fatty acids in similar proportions as the diet of Western societies and, therefore, the 
addition of DHA to the diet would resemble a DHA supplementation regime.  Another 
limitation that was not accounted for with the diets was the effect of insulin on maternal 
metabolism during pregnancy. Maternal high fat intake not only influences maternal 
insulin response, but it was also recently associated with insulin resistance in the 
offspring (Murabayashi et.al. 2013) .Gestational phase insulin resistance is also common 
during the last phase of pregnancy, and insulin is hypothesized to affect PEMT activity, 
although this effect is not entirely clear (Hoffman et al.1981; Cabrero et al., 1986; 
Tashiro et al., 1983; Pangia et al., 1990).  
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7.2 Conclusion 
Pregnancy triggers various maternal adaptations through multiple mechanisms to 
facilitate the transport and accumulation of fatty acids to and by the fetus. DHA levels in 
plasma PC rat dams increase during pregnancy compared to baseline and post partum 
levels. Higher DHA intake of pregnant rats increases the protein expression and activity 
of PEMT at the end of gestation, and increases DHA incorporation into PC in plasma and 
liver. While PEMT appears to be involved in influencing the fatty acid composition of 
plasma PC, the particularly large increase in DHA content in plasma PC during the late 
stages of pregnancy indicates other mechanisms such as selective acyl remodeling of PC, 
and PC de novo synthesis could also be involved.  PEMT seems to have a supporting role 
in mobilizing maternal DHA into plasma. 
Future studies should focus on elucidating the mechanism of DHA incorporation 
into phospholipids in the Kennedy pathway for phospholipid synthesis, as well as Lands’ 
cycle for phospholipid acyl remodeling. Microarrays could be used to relate the 
differences in gene expression to different stages in pregnancy, especially to compare day 
15 and day 20. Microarrays provide an analytical advantage in that the gene expression of 
many genes can be examined at once, thereby providing a highly efficient method for 
studying gene expression. Based on the results obtained from the microarray, the specific 
genes would be targeted for subsequent analysis with RT-PCR and western blotting. 
MS/MS based lipidomics analyses could also be pursued to confirm specific 
phospholipid acyl species, such as 16:0/DHA PC or 18:0/DHA PC. This information 
could provide definitive answers to confirm whether phospholipid remodeling is indeed a 
major contributor to the change in maternal phospholipid composition during pregnancy.  
	  	   54 
  The essential nature of omega-3 fatty acids during the late stages in pregnancy has 
long been demonstrated, and DHA levels have been shown to increase during critical 
stages of fetal development. Through this research, we elucidated specific mechanisms of 
DHA mobilization to maternal plasma during pregnancy. PEMT was found to be up-
regulated in late pregnancy, but its up-regulation does not appear to be the only 
pregnancy adaptation contributing to maternal plasma DHA levels. Higher DHA intake 
during pregnancy was also found to increase PEMT expression, which a novel 
observation. According to our knowledge this is the first use of total western diet for 
rodent models in pregnant rats that could allow better insights on DHA intake during 
pregnancy in the North American population.  This research, combined with our dietary 
intervention, is a step forward in understanding the effects of pregnancy on PUFA 
metabolism and related fetal outcomes, and could be used in the future to help determine 
DHA requirements and define intake recommendations.  
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Appendix A. Plasma Total Lipids 
Table A.1.  Relative percent of fatty acids in plasma total lipids in chow fed rats at 
baseline, during pregnancy, and 7 days post partum 
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 0.32 ± 0.02 0.30 ± 0.11 0.26 ± 0.03 0.29 ± 0.01 
C 16:0 14.64 ± 0.64a 16.15 ± 0.76a 20.38 ± 1.14b 15.81 ± 1.53a 
C 18:0 15.58 ± 1.11a 13.68 ± 1.42a 8.58 ± 0.96b 13.83 ± 1.96a 
C 20:0 0.11 ± 0.02a 0.08 ± 0.01b 0.06 ± 0.02b 0.08 ± 0.01b 
C 22:0 0.24 ± 0.02a 0.17 ± 0.05ab 0.07 ± 0.02c 0.15 ± 0.04b 
C 24:0 0.59 ± 0.02a 0.39 ± 0.11b 0.18 ± 0.02c 0.42 ± 0.10b 
SFAs 32.20 ± 0.75a 31.15 ± 1.11ab 29.79 ± 1.17b 30.94 ± 1.02ab 
     
C 14:1 0.02 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 
C 16:1 0.63 ± 0.14a 0.68 ± 0.17 0.72 ± 0.14 0.69 ± 0.15 
C 18:1n-7 1.14 ± 0.06a 1.27 ± 0.06ab 1.37 ± 0.06b 1.36 ± 0.08ab 
C 18:1n-9 5.76 ± 0.43a 8.92 ± 1.67ab 11.34 ± 0.96b 10.77 ± 2.21ab 
C 20:1n-9 0.06 ± 0.01 0.09 ± 0.02 0.11 ± 0.03 0.12 ± 0.04 
C 22:1n-9 0.20 ± 0.03a 0.13 ± 0.02ab 0.04 ± 0.01c 0.06 ± 0.04bc 
C 24:1n-9 0.36 ± 0.04a 0.27 ± 0.08a 0.07 ± 0.02b 0.26 ± 0.08a 
MUFAs 8.18 ± 0.42 11.38 ± 1.74 13.67 ± 1.06 13.3 ± 2.29 
     
C 18:2n-6 18.11 ± 1.78a 21.00 ± 3.21ab 22.68 ± 1.38b 21.43 ± 2.30b 
C 18:3n-6 0.39 ± 0.03a 0.69 ± 0.18a 0.63 ± 0.05a 1.18 ± 0.20b 
C 20:2n-6 0.12 ± 0.02a 0.14 ± 0.02a 0.22 ± 0.03b 0.19 ± 0.02b 
C 20:3n-6 0.26 ± 0.02a 0.27 ± 0.06a 0.25 ± 0.04a 0.52 ± 0.07b 
C 20:4n-6 34.10 ± 1.03a 27.03 ± 3.74b 19.19 ± 1.63c 24.27 ± 3.57bc 
C 22:2n-6 0.05 ± 0.01a 0.04 ± 0.01ab 0.02 ± 0.01c 0.02 ± 0.01bc 
C 22:4n-6 0.22 ± 0.02a 0.35 ± 0.11a 1.3 ± 0.23b 0.33 ± 0.05a 
N-6 53.44 ± 1.04a 49.77 ± 0.95ab 45.88 ± 1.16b 48.55 ± 1.37ab 
     
C 18:3n-3 0.48 ± 0.03a 0.72 ± 0.33b 1.09 ± 0.1c 0.48 ± 0.2a 
C 20:3n-3 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 
C 20:5n-3 0.57 ± 0.08a 0.89 ± 0.35b 0.61 ± 0.20ab 0.83 ± 0.15ab 
C 22:5n-3 0.43 ± 0.03a 0.61 ± 0.10a 1.49 ± 0.23c 0.86 ± 0.14b 
C 22:6n-3 3.12 ± 0.13a 4.23 ± 0.75a 6.25 ± 1.01b 3.21 ± 0.49a 
N-3 4.61 ± 0.12a 6.47 ± 0.56b 9.45 ± 0.89c 5.39 ± 0.58ab 
     
HUFA 38.90 ± 1.11a 33.66 ± 4.29ab 30.71 ± 1.79b 30.65 ± 3.90b 
PUFA 58.05 ± 0.99 56.25 ± 1.05 55.33 ± 0.76 53.94 ± 1.45 
Total 208.50 ± 13.58a 288.01 ± 80.75a 502.49 ± 90.87b 319.38 ± 97.11a 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA.  
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Table A.2. Relative percent of fatty acids in plasma total lipids in high DHA diet 
(TWD DHA+) fed rats at baseline, during pregnancy, and 7 days post partum  
Name baseline 15 days 20 days 
7 days  
post partum 
C 14:0 0.45 ± 0.05a 0.61 ± 0.07b 0.58 ± 0.05ab 0.66 ± 0.10b 
C 16:0 15.96 ± 0.69a 18.10 ± 0.96ab 21.42 ± 0.92c 19.80 ± 1.73bc 
C 18:0 15.61 ± 0.46a 14.27 ± 0.57ab 10.30 ± 0.93c 12.20 ± 1.07bc 
C 20:0 0.10 ± 0.01a 0.09 ± 0.01a 0.06 ± 0.01b 0.08 ± 0.01ab 
C 22:0 0.24 ± 0.02a 0.22 ± 0.02a 0.07 ± 0.01b 0.13 ± 0.03c 
C 24:0 0.56 ± 0.04a 0.42 ± 0.06b 0.16 ± 0.02c 0.30 ± 0.07bc 
SFA 33.52 ± 0.44 34.31 ± 0.92 32.89 ± 0.78 33.64 ± 1.12 
     C 14:1 0.03 ± 0.01a 0.05 ± 0.01b 0.03 ± 0.01a 0.04 ± 0.01ab 
C 16:1 0.90 ± 0.11a 1.16 ± 0.19ab 1.12 ± 0.25ab 1.50 ± 0.28b 
C 18:1n-7 1.12 ± 0.06a 1.20 ± 0.07ab 1.41 ± 0.11bc 1.60 ± 0.13c 
C 18:1n-9 8.47 ± 0.68a 13.01 ± 1.91ab 18.36 ± 2.66bc 21.09 ± 5.18c 
C 20:1n-9 0.06 ± 0.01a 0.08 ± 0.03ab 0.14 ± 0.03b 0.10 ± 0.04ab 
C 22:1n-9 0.24 ± 0.02a 0.18 ± 0.04a 0.07 ± 0.04b 0.06 ± 0.04b 
C 24:1n-9 0.37 ± 0.07ac 0.43 ± 0.05a 0.11 ± 0.02b 0.26 ± 0.10c 
MUFA 11.20± 0.73a 15.93 ± 2.32ab 21.24 ± 2.92bc 24.67 ± 5.43c 
     C 18:2n-6 16.67 ± 0.72 15.84 ± 0.61 14.26 ± 0.48 16.20 ± 1.76 
C 18:3n-6 0.28 ± 0.04a 0.43 ± 0.09ab 0.64 ± 0.14bc 0.89 ± 0.25c 
C 20:2n-6 0.08 ± 0.01 0.08 ± 0.02 0.11 ± 0.02 0.08 ± 0.01 
C 20:3n-6 0.31 ± 0.04a 0.26 ± 0.05a 0.15 ± 0.02b 0.31 ± 0.03a 
C 20:4n-6 30.36 ± 1.55a 23.72 ± 2.09b 16.70 ± 1.89c 17.4 ± 5.41bc 
C 22:2n-6 0.04 ± 0.01a 0.05 ± 0.01b 0.02 ± 0.01c 0.03 ± 0.01ac 
C 22:4n-6 0.17 ± 0.01a 0.18 ± 0.04a 0.46 ± 0.12b 0.11 ± 0.04a 
C 22:5n-6 0.13 ± 0.02a 0.13 ± 0.04a 0.74 ± 0.25b 0.09 ± 0.03a 
N-6 48.04 ± 0.98a 40.70 ± 1.64b 33.07 ± 1.73c 35.09 ± 4.89c 
     C 18:3n-3 0.40 ± 0.05 0.47 ± 0.07 0.50 ± 0.08 0.31 ± 0.05 
C 20:3n-3 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 
C 20:5n-3 0.62 ± 0.10ab 0.77 ± 0.10a 0.39 ± 0.11b 0.59 ± 0.13ab 
C 22:5n-3 0.25 ± 0.02a 0.36 ± 0.10a 0.62 ± 0.11b 0.22 ± 0.05a 
C 22:6n-3 4.91 ± 0.41a 6.08 ± 0.69b 9.58 ± 1.12c 3.69 ± 1.28a 
N-3 6.19 ± 0.45a 7.7 ± 0.76b 11.1 ± 1.04c 4.82 ± 1.32d 
     HUFA 36.77 ± 1.27a 31.53 ± 2.72ab 28.66 ± 3.00bc 22.39 ± 6.64c 
PUFA 54.23 ± 0.83a 48.40 ± 2.13b 44.18 ± 2.66bc 39.91 ± 5.98c 
Total 221.71 ± 13.56a 196.38 ± 24.91a 508.76 ± 165.81b 238.65 ± 23.31a 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA.   
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Table A.3. Relative percent of fatty acids in plasma total lipids in DHA deficient diet 
(TWD DHA-) fed rats at baseline, during pregnancy, and 7 days post partum  
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 0.39 ± 0.06a 0.54 ± 0.04b 0.58 ± 0.06b 0.67 ± 0.11b 
C 16:0 14.52 ± 1.19a 16.85 ± 0.50b 21.27 ± 0.79c 18.41 ± 2.16b 
C 18:0 16.32 ± 0.93a 14.86 ± 0.94ab 9.58 ± 0.52c 12.95 ± 2.16b 
C 20:0 0.09 ± 0.01a 0.09 ± 0.01a 0.05 ± 0.01b 0.08 ± 0.01a 
C 22:0 0.23 ± 0.03a 0.21 ± 0.03a 0.07 ± 0.01b 0.11 ± 0.04b 
C 24:0 0.52 ± 0.06a 0.44 ± 0.04a 0.17 ± 0.03b 0.27 ± 0.13b 
SFA 32.63 ± 0.81 33.58 ± 1.01 31.96 ± 0.88 33.02 ± 0.22 
     C 14:1 0.02 ± 0.01a 0.04 ± 0.01b 0.04 ± 0.01b 0.04 ± 0.01b 
C 16:1 0.70 ± 0.17a 1.20 ± 0.14b 1.40 ± 0.18b 1.52 ± 0.42b 
C 18:1n-7 1.10 ± 0.06a 1.30 ± 0.09ab 1.43 ± 0.05b 1.73 ± 0.31c 
C 18:1n-9 7.79 ± 0.92a 13.19 ± 0.67b 21.20 ± 1.48c 22.91 ± 6.11c 
C 20:1n-9 0.05 ± 0.01a 0.11 ± 0.04ab 0.12 ± 0.03b 0.12 ± 0.04b 
C 22:1n-9 0.22 ± 0.05a 0.19 ± 0.06a 0.04 ± 0.01b 0.05 ± 0.02b 
C 24:1n-9 0.36 ± 0.05ac 0.41 ± 0.04a 0.11 ± 0.02b 0.24 ± 0.13c 
MUFA 10.27 ± 1.12a 16.46 ± 0.62b 24.32 ± 1.57c 26.62 ± 6.63c 
     C 18:2n-6 15.63 ± 0.83 15.02 ± 1.01 14.93 ± 0.89 14.07 ± 1.16 
C 18:3n-6 0.39 ± 0.02a 0.63 ± 0.09a 1.06 ± 0.17b 1.34 ± 0.26b 
C 20:2n-6 0.08 ± 0.01 0.08 ± 0.01 0.10 ± 0.02 0.09 ± 0.01 
C 20:3n-6 0.27 ± 0.03a 0.18 ± 0.02ab 0.11 ± 0.01b 0.26 ± 0.06a 
C 20:4n-6 34.46 ± 2.38a 27.24 ± 1.29b 17.31 ± 1.78c 19.6 ± 7.26c 
C 22:2n-6 0.03 ± 0.01ab 0.04 ± 0.01b 0.01 ± 0.01c 0.03 ± 0.01ac 
C 22:4n-6 0.22 ± 0.01a 0.23 ± 0.05a 0.68 ± 0.11b 0.16 ± 0.03a 
C 22:5n-6 0.29 ± 0.04a 0.32 ± 0.12a 2.23 ± 0.48b 0.35 ± 0.07a 
N-6 51.38 ± 1.60a 43.76 ± 0.72b 36.44 ± 1.30c 35.89 ± 6.15c 
     C 18:3n-3 0.36 ± 0.03 0.46 ± 0.04 0.51 ± 0.04 0.22 ± 0.07 
C 20:3n-3 Not detected 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 
C 20:5n-3 0.40 ± 0.04 0.37 ± 0.07 0.25 ± 0.07 0.23 ± 0.04 
C 22:5n-3 0.36 ± 0.03a 0.36 ± 0.07a 0.61 ± 0.06b 0.30 ± 0.04a 
C 22:6n-3 3.41 ± 0.28a 3.71 ± 0.3a 3.94 ± 0.35a 1.63 ± 0.73b 
N-3 4.54 ± 0.27a 4.90 ± 0.32a 5.32 ± 0.33a 2.39 ± 0.69b 
     HUFA 39.42 ± 2.58a 32.42 ± 1.42ab 25.13 ± 2.14bc 22.54 ± 8.09c 
PUFA 55.92 ± 1.81a 48.66 ± 0.94b 41.76 ± 1.49c 38.28 ± 6.83c 
Total 233.29 ± 26.33a 185.55 ± 19.98a 588.21 ± 64.92b 233.04 ± 50.12a 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA. 
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Table A.4. Concentration of fatty acids in plasma total lipids in chow fed rats at 
baseline, during pregnancy, and 7 days post partum (µg/100µl plasma) 
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 0.67 ± 0.06 0.86 ± 0.32 1.32 ± 0.20 0.95 ± 0.33 
C 16:0 30.99 ± 2.10a 47.50 ± 15.45a 103.58 ± 18.59b 52.45 ± 21.04a 
C 18:0 33.02 ± 3.36 39.18 ± 8.06 43.15 ± 4.86 43.41 ± 5.82 
C 20:0 0.23 ± 0.04 0.22 ± 0.05 0.31 ± 0.09 0.24 ± 0.05 
C 22:0 0.50 ± 0.04a 0.46 ± 0.07ab 0.36 ± 0.06b 0.47 ± 0.10ab 
C 24:0 1.25 ± 0.11a 1.10 ± 0.22ab 0.91 ± 0.05b 1.31 ± 0.24a 
SFA 68.21 ± 4.68a 90.38 ± 23.63a 150.86 ± 21.99b 99.95 ± 27.02a 
     
C 14:1 0.03 ± 0.01 0.04 ± 0.02 0.05 ± 0.02 0.03 ± 0.01 
C 16:1 1.36 ± 0.38 2.00 ± 0.79 3.70 ± 1.25 2.34 ± 1.27 
C 18:1n-7 2.41 ± 0.21a 3.71 ± 1.01a 7.03 ± 1.58b 4.40 ± 1.30a 
C 18:1n-9 12.17 ± 0.56a 26.81 ± 11.41ab 58.29 ± 15.57b 36.76 ± 19.58ab 
C 20:1n-9 0.14 ± 0.01a 0.26 ± 0.08a 0.59 ± 0.23b 0.38 ± 0.15ab 
C 22:1n-9 0.42 ± 0.07a 0.37 ± 0.07ab 0.19 ± 0.06b 0.20 ± 0.14b 
C 24:1n-9 0.76 ± 0.11a 0.75 ± 0.10a 0.36 ± 0.06b 0.79 ± 0.15a 
MUFA 17.31 ± 1.01a 33.97 ± 13.27ab 70.22 ± 18.45b 45.01 ± 22.25ab 
     
C 18:2n-6 38.32 ± 4.04a 62.14 ± 22.62ab 114.97 ± 18.44c 71.25 ± 28.85b 
C 18:3n-6 0.83 ± 0.09a 2.12 ± 1.13ab 3.22 ± 0.88b 3.98 ± 2.16b 
C 20:3n-6 0.55 ± 0.06a 0.75 ± 0.15a 1.29 ± 0.32b 1.65 ± 0.33b 
C 20:2n-6 0.26 ± 0.04a 0.39 ± 0.08ac 1.12 ± 0.39b 0.61 ± 0.17c 
C 20:4n-6 72.29 ± 6.14 77.51 ± 18.14 97.96 ± 22.43 76.38 ± 12.23 
C 22:2n-6 0.11 ± 0.02a 0.10 ± 0.01ab 0.09 ± 0.02ab 0.06 ± 0.01b 
C 22:4n-6 0.47 ± 0.05a 0.99 ± 0.33a 6.68 ± 1.94b 1.07 ± 0.42a 
C 22:5n-6 0.39 ± 0.06a 0.78 ± 0.33a 8.19 ± 1.98b 2.05 ± 0.84a 
N-6 113.22 ± 8.06a 144.78 ± 39.2a 233.53 ± 43.97b 157.05 ± 43.53a 
     
C 18:3n-3 1.01 ± 0.08a 2.20 ± 1.26a 5.53 ± 1.04b 1.69 ± 1.19a 
C 20:3n-3 0.02 ± 0.01a 0.03 ± 0.02a 0.07 ± 0.01b 0.02 ± 0.01a 
C 20:5n-3 1.22 ± 0.24a 2.67 ± 1.33ab 3.22 ± 1.73b 2.74 ± 1.02b 
C 22:5n-3 0.92 ± 0.09a 1.77 ± 0.45ab 7.71 ± 2.54c 2.78 ± 0.89b 
C 22:6n-3 6.60 ± 0.45a 12.22 ± 3.38a 31.36 ± 4.37b 10.15 ± 2.01a 
N-3 9.77 ± 0.76a 18.89 ± 5.31a 47.88 ± 8.26b 17.37 ± 4.86a 
     
HUFA 82.45 ± 6.91a 96.72 ± 22.92a 156.48 ± 32.27b 96.84 ± 16.67a 
PUFA 122.99 ± 8.73a 163.67 ± 44.31a 281.41 ± 50.99b 174.42 ± 48.11a 
Total 208.50 ± 13.58a 288.01 ± 80.75a 502.49 ± 90.87b 319.38 ± 97.11a 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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 Table A.5. Concentration of fatty acids in plasma total lipids in high DHA diet 
(TWD DHA+) fed rats at baseline, during pregnancy, and 7 days post partum 
(µg/100µl plasma)  
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 1.01 ± 0.14a 1.20 ± 0.12a 3.08 ± 1.26b 1.60 ± 0.36a 
C 16:0 35.74 ± 2.21a 35.95 ± 4.25a 111.38 ± 39.12b 48.41 ± 8.84a 
C 18:0 35.00 ± 2.70a 28.37 ± 3.39a 52.21 ± 12.78b 29.48 ± 2.01a 
C 20:0 0.21 ± 0.02a 0.18 ± 0.01a 0.30 ± 0.09b 0.19 ± 0.02a 
C 22:0 0.53 ± 0.06a 0.43 ± 0.05ab 0.35 ± 0.07b 0.32 ± 0.06b 
C 24:0 1.26 ± 0.13a 0.83 ± 0.09b 0.82 ± 0.16b 0.72 ± 0.15b 
SFA 75.09 ± 4.50a 68.14 ± 7.08a 169.61 ± 53.3b 81.87 ± 9.97a 
     
C 14:1 0.07 ± 0.02a 0.09 ± 0.02a 0.17 ± 0.09b 0.09 ± 0.02a 
C 16:1 2.01 ± 0.29a 2.37 ± 0.49a 6.07 ± 3.13b 3.67 ± 0.99ab 
C 18:1n-7 2.52 ± 0.24a 2.38 ± 0.35a 7.39 ± 2.78b 3.89 ± 0.57a 
C 18:1n-9 18.92 ± 1.14a 26.04 ± 5.86a 98.63 ± 46.51b 51.93 ± 16.39a 
C 20:1n-9 0.13 ± 0.01a 0.17 ± 0.06a 0.73 ± 0.37b 0.25 ± 0.09a 
C 22:1n-9 0.54 ± 0.03a 0.35 ± 0.07b 0.32 ± 0.17bc 0.15 ± 0.09c 
C 24:1n-9 0.84 ± 0.17a 0.86 ± 0.10a 0.54 ± 0.10b 0.63 ± 0.18ab 
MUFA 25.05 ± 1.43a 31.90 ± 7.16a 113.87 ± 52.83b 60.64 ± 17.67a 
     
C 18:2n-6 37.29 ± 1.46a 31.51 ± 3.88a 74.06 ± 25.52b 39.55 ± 6.88a 
C 18:3n-6 0.62 ± 0.09a 0.87 ± 0.26a 3.34 ± 1.32b 2.17 ± 0.69ab 
C 20:2n-6 0.18 ± 0.03a 0.17 ± 0.05a 0.59 ± 0.31b 0.20 ± 0.03a 
C 20:3n-6 0.68 ± 0.07 0.53 ± 0.14 0.77 ± 0.28 0.75 ± 0.11 
C 20:4n-6 68.17 ± 7.24ac 47.25 ± 7.40ab 84.10 ± 18.26c 41.42 ± 10.5b 
C 22:2n-6 0.09 ± 0.01 0.09 ± 0.02 0.09 ± 0.02 0.06 ± 0.01 
C 22:4n-6 0.38 ± 0.02a 0.36 ± 0.11a 2.46 ± 1.22b 0.26 ± 0.09a 
C 22:5n-6 0.30 ± 0.04a 0.25 ± 0.08a 3.64 ± 0.98b 0.20 ± 0.07a 
N-6 107.72 ± 8.22a 81.02 ± 10.69a 169.03 ± 46.44b 84.62 ± 9.4a 
     
C 18:3n-3 0.88 ± 0.09a 0.93 ± 0.20a 2.68 ± 1.32b 0.76 ± 0.13a 
C 20:3n-3 0.02 ± 0.01a 0.02 ± 0.01a 0.05 ± 0.02b 0.02 ± 0.01a 
C 20:5n-3 1.38 ± 0.22 1.53 ± 0.23 2.13 ± 1.02 1.42 ± 0.32 
C 22:5n-3 0.57 ± 0.03a 0.73 ± 0.25a 3.19 ± 1.10b 0.53 ± 0.11a 
C 22:6n-3 11.00 ± 1.03a 12.11 ± 2.06a 48.19 ± 10.36b 8.80 ± 2.47a 
N-3 13.86 ± 1.11a 15.32 ± 2.47a 56.25 ± 13.62b 11.53 ± 2.37a 
     
HUFA 82.50 ± 7.65a 62.78 ± 9.80a 144.53 ± 32.19b 53.35 ± 12.52a 
PUFA 121.58 ± 8.76a 96.34 ± 12.87a 225.28 ± 59.96b 96.15 ± 10.92a 
Total 221.71 ± 13.56a 196.38 ± 24.91a 508.76 ± 165.81b 238.65 ± 23.31a 
Values with different superscripts are significantly different by Tukey’s post hoc test 
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Table A.6. Concentration of fatty acids in plasma total lipids in DHA deficient diet 
(TWD DHA-) fed rats at baseline, during pregnancy, and 7 days post partum 
(µg/100µl plasma) 
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 0.92 ± 0.11a 1.02 ± 0.08a 3.47 ± 0.50b 1.61 ± 0.51a 
C 16:0 34.18 ± 3.93a 31.73 ± 3.99a 127.54 ± 14.19b 44.57 ± 14.3a 
C 18:0 38.50 ± 4.82a 27.98 ± 3.81a 57.24 ± 4.20b 30.17 ± 3.77a 
C 20:0 0.20 ± 0.02a 0.18 ± 0.03a 0.31 ± 0.03b 0.19 ± 0.01a 
C 22:0 0.53 ± 0.10a 0.39 ± 0.06bc 0.40 ± 0.03c 0.26 ± 0.04b 
C 24:0 1.24 ± 0.23a 0.82 ± 0.12bc 1.01 ± 0.11c 0.61 ± 0.19b 
SFA 76.89 ± 7.53a 63.21 ± 7.79a 191.46 ± 17.99b 78.63 ± 17.19a 
     
C 14:1 0.06 ± 0.01a 0.08 ± 0.01a 0.24 ± 0.05b 0.10 ± 0.04a 
C 16:1 1.64 ± 0.36a 2.25 ± 0.29a 8.39 ± 1.58b 3.74 ± 1.62a 
C 18:1n-7 2.60 ± 0.30a 2.44 ± 0.25a 8.57 ± 1.01b 4.15 ± 1.32a 
C 18:1n-9 18.25 ± 1.84a 24.82 ± 3.18a 127.75 ± 21.85b 56.22 ± 23.57b 
C 20:1n-9 0.13 ± 0.02a 0.20 ± 0.06a 0.69 ± 0.20b 0.28 ± 0.12a 
C 22:1n-9 0.52 ± 0.08a 0.35 ± 0.08ab 0.21 ± 0.08bc 0.13 ± 0.06c 
C 24:1n-9 0.86 ± 0.17a 0.76 ± 0.08ab 0.62 ± 0.1ab 0.53 ± 0.21b 
MUFA 24.07 ± 2.34a 30.93 ± 3.44a 146.50 ± 24.17b 65.19 ± 26.43a 
     
C 18:2n-6 36.81 ± 3.72a 28.33 ± 4.28a 89.72 ± 12.82b 33.76 ± 9.10a 
C 18:3n-6 0.93 ± 0.13a 1.19 ± 0.21ab 6.41 ± 1.46c 3.28 ± 1.3b 
C 20:2n-6 0.19 ± 0.02a 0.15 ± 0.02a 0.62 ± 0.20b 0.20 ± 0.04a 
C 20:3n-6 0.63 ± 0.04 0.34 ± 0.05 0.63 ± 0.08 0.62 ± 0.19 
C 20:4n-6 81.72 ± 13.19a 51.09 ± 4.63b 103.35 ± 10.7a 44.59 ± 10.49b 
C 22:2n-6 0.08 ± 0.02 0.08 ± 0.02 0.09 ± 0.01 0.07 ± 0.02 
C 22:4n-6 0.52 ± 0.06a 0.44 ± 0.09a 4.09 ± 0.98b 0.38 ± 0.10a 
C 22:5n-6 0.68 ± 0.12a 0.59 ± 0.19a 13.50 ± 3.53b 0.82 ± 0.22a 
N-6 121.56 ± 16.28a 82.21 ± 8.38a 218.41 ± 23.13b 83.71 ± 11.97a 
     
C 18:3n-3 0.84 ± 0.09a 0.87 ± 0.14a 3.10 ± 0.53b 0.53 ± 0.22a 
C 20:3n-3 0.01 ± 0.01a 0.02 ± 0.01a 0.04 ± 0.01b 0.02 ± 0.01a 
C 20:5n-3 0.95 ± 0.17 0.69 ± 0.15 1.51 ± 0.49 0.55 ± 0.19 
C 22:5n-3 0.85 ± 0.12a 0.67 ± 0.14a 3.67 ± 0.47b 0.74 ± 0.25a 
C 22:6n-3 8.12 ± 1.48a 6.94 ± 0.68a 23.52 ± 2.26b 3.69 ± 1.10a 
N-3 10.77 ± 1.76a 9.20 ± 0.95a 31.84 ± 2.98b 5.52 ± 1.08a 
     
HUFA 93.48 ± 14.97a 60.79 ± 5.20ab 150.31 ± 16.2c 51.40 ± 11.80b 
PUFA 132.33 ± 18.01a 91.41 ± 9.21a 250.25 ± 25.69b 89.22 ± 12.89a 
Total 233.29 ± 26.33a 185.55 ± 19.98a 588.21 ± 64.92b 233.04 ± 50.12a 
Values with different superscripts are significantly different by Tukey’s post hoc test (p<0.05) following 
significant F-value by one-way ANOVA 
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Appendix B. Plasma PC  
Table B.1. Relative percent of fatty acids in plasma PC in chow fed rats at baseline, 
during pregnancy, and 7 days post partum  
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 0.41 ± 0.22 0.56 ± 0.13 0.69 ± 0.09 0.74 ± 0.18 
C 16:0 16.86 ± 0.99a 18.35 ± 1.46a 26.76 ± 1.73b 18.32 ± 0.66a 
C 18:0 25.46 ± 2.33a 28.88 ± 2.18ab 21.55 ± 1.02c 29.64 ± 1.65b 
C 20:0 0.18 ± 0.04 0.15 ± 0.07 0.13 ± 0.01 0.20 ± 0.06 
C 22:0 0.25 ± 0.08a 0.14 ± 0.05b 0.10 ± 0.02b 0.10 ± 0.02b 
C 24:0 0.22 ± 0.04 0.20 ± 0.08 0.24 ± 0.04 0.17 ± 0.05 
SFA 43.92 ± 1.26a 49.27 ± 2.34b 51.06 ± 1.73b 50.47 ± 2.18b 
     C 14:1 0.05 ± 0.01a 0.04 ± 0.01a Not detected b 0.03 ± 0.01ab 
C 16:1 0.58 ± 0.17 0.74 ± 0.17 0.78 ± 0.12 0.64 ± 0.09 
C 18:1n-7 1.49 ± 0.12a 1.25 ± 0.11ab 1.12 ± 0.1b 1.42 ± 0.17a 
C 18:1n-9 9.54 ± 6.09a 4.30 ± 0.92b 4.43 ± 0.31ab 6.54 ± 1.02ab 
C 20:1n-9 0.36 ± 0.25 0.13 ± 0.05 0.10 ± 0.02 0.12 ± 0.01 
C 22:1n-9 0.20 ± 0.04ab 0.27 ± 0.07a 0.10 ± 0.03b 0.23 ± 0.03ab 
C 24:1n-9 0.24 ± 0.04 0.26 ± 0.17 0.05 ± 0.03 0.10 ± 0.03 
MUFA 12.49 ± 6.38a 7.02 ± 0.99ab 6.59 ± 0.25b 9.09 ± 1.14ab 
     C 18:2n-6 15.78 ± 2.34a 12.56 ± 1.53b 11.46 ± 1.85b 14.42 ± 1.93ab 
C 18:3n-6 0.74 ± 0.81 0.23 ± 0.07 0.10 ± 0.02 0.15 ± 0.02 
C 20:2n-6 0.26 ± 0.08a 0.18 ± 0.02b 0.16 ± 0.02b 0.24 ± 0.03a 
C 20:3n-6 0.41 ± 0.11a 0.37 ± 0.0ab 0.22 ± 0.03b 0.78 ± 0.08c 
C 20:4n-6 18.04 ± 3.56a 19.54 ± 1.23a 11.61 ± 2.05b 15.22 ± 1.78ab 
C 22:2n-6 0.13 ± 0.09 0.12 ± 0.07 0.07 ± 0.05 0.07 ± 0.02 
C 22:4n-6 0.32 ± 0.08a 0.23 ± 0.06a 0.61 ± 0.06b 0.33 ± 0.07a 
C 22:5n-6 0.30 ± 0.04a 0.33 ± 0.12a 3.36 ± 0.43b 0.99 ± 0.32a 
N-6 35.98 ± 4.91a 33.57 ± 1.72a 27.60 ± 2.68b 32.20 ± 3.06ab 
     C 18:3n-3 0.18 ± 0.10 0.10 ± 0.02 0.12 ± 0.02 0.08 ± 0.01 
C 20:3n-3 0.05 ± 0.01 0.08 ± 0.05 0.04 ± 0.01 0.02 ± 0.01 
C 20:5n-3 0.21 ± 0.08a 0.16 ± 0.07ab 0.08 ± 0.01b 0.11 ± 0.02ab 
C 22:5n-3 0.84 ± 0.15a 0.80 ± 0.11a 1.17 ± 0.12b 1.36 ± 0.27b 
C 22:6n-3 5.69 ± 0.86a 6.89 ± 1.45a 12.67 ± 1.13b 5.69 ± 0.95a 
N-3 6.98 ± 1.03a 8.03 ± 1.45a 14.09 ± 1.09b 7.26 ± 1.17a 
     HUFA 25.86 ± 4.62 28.41 ± 2.48 29.77 ± 1.5 24.50 ± 2.46 
PUFA 42.96 ± 5.84 41.60 ± 2.44 41.69 ± 1.71 39.46 ± 2.98 
Total 106.81 ± 34.92a 106.13 ± 27.14a 184.00 ± 35.52b 179.90 ± 20.84b 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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Table B.2. Relative percent of fatty acids in plasma PC in high DHA diet (TWD 
DHA+) fed rats at baseline, during pregnancy, and 7 days post partum 
Name baseline 15 days 20 days 
7 days 
post partum 
C 16:0 17.40 ± 0.68a 18.05 ± 1.46a 24.54 ± 2.14c 21.09 ± 1.10b 
C 18:0 27.99 ± 0.59a 29.93 ± 1.49a 23.77 ± 1.66b 28.06 ± 1.68a 
C 20:0 0.18 ± 0.02a 0.19 ± 0.06ab 0.12 ± 0.02a 0.28 ± 0.07b 
C 22:0 0.20 ± 0.05a 0.15 ± 0.06ab 0.09 ± 0.02b 0.15 ± 0.06ab 
C 24:0 0.31 ± 0.08 0.24 ± 0.07 0.22 ± 0.03 0.26 ± 0.14 
SFA 47.09 ± 1.14a 51.24 ± 1.24b 50.73 ± 0.88ab 53.23 ± 1.65b 
     
C 16:1 0.72 ± 0.14 1.24 ± 0.20 0.88 ± 0.46 1.11 ± 0.32 
C 18:1n-7 1.33 ± 0.10a 1.03 ± 0.06b 1.04 ± 0.11b 1.30 ± 0.19a 
C 18:1n-9 6.69 ± 1.02 6.06 ± 1.59 5.62 ± 1.06 10.07 ± 2.70 
C 20:1n-9 0.21 ± 0.09 0.14 ± 0.07 0.10 ± 0.03 0.09 ± 0.03 
C 22:1n-9 0.26 ± 0.08a 0.43 ± 0.18b 0.09 ± 0.02c 0.32 ± 0.07ab 
C 24:1n-9 0.21 ± 0.07 0.22 ± 0.18 0.05 ± 0.03 0.17 ± 0.11 
MUFA 9.50 ± 0.97 9.19 ± 2.14 7.78 ± 1.11 13.15 ± 2.51 
     
C 18:2n-6 14.75 ± 0.68a 10.79 ± 0.77bc 8.34 ± 0.69c 12.58 ± 1.87ab 
C 18:3n-6 0.15 ± 0.02 0.20 ± 0.12 0.08 ± 0.04 0.17 ± 0.07 
C 20:2n-6 0.21 ± 0.01a 0.13 ± 0.04b 0.08 ± 0.01b 0.11 ± 0.02b 
C 20:3n-6 0.51 ± 0.08a 0.47 ± 0.08a 0.22 ± 0.03b 0.52 ± 0.12a 
C 20:4n-6 17.69 ± 0.6a 15.67 ± 2.79ac 10.30 ± 1.09b 11.87 ± 2.38bc 
C 22:2n-6 0.09 ± 0.01 0.13 ± 0.12 0.06 ± 0.02 0.08 ± 0.05 
C 22:4n-6 0.35 ± 0.04a 0.16 ± 0.05b 0.34 ± 0.10a 0.12 ± 0.03b 
C 22:5n-6 0.20 ± 0.06a 0.16 ± 0.06a 1.62 ± 0.43b 0.14 ± 0.05a 
N-6 33.94 ± 0.70a 27.71 ± 2.53b 21.05 ± 0.28c 25.58 ± 2.18bc 
     
C 18:3n-3 0.13 ± 0.02 0.09 ± 0.06 0.09 ± 0.04 0.16 ± 0.21 
C 20:3n-3 0.07 ± 0.05 0.07 ± 0.08 0.03 ± 0.01 0.04 ± 0.04 
C 20:5n-3 0.19 ± 0.03a 0.17 ± 0.04ab 0.06 ± 0.02b 0.19 ± 0.10a 
C 22:5n-3 0.49 ± 0.02ab 0.50 ± 0.13ab 0.72 ± 0.10a 0.30 ± 0.04b 
C 22:6n-3 8.25 ± 0.89ac 10.39 ± 0.98a 18.75 ± 1.31b 5.86 ± 1.84c 
N-3 9.14 ± 0.90a 11.23 ± 0.91a 19.65 ± 1.31b 6.55 ± 1.62c 
     
HUFA 27.75 ± 1.08ab 27.60 ± 3.2a 32.04 ± 1.18a 19.03 ± 3.74b 
PUFA 43.09 ± 0.81a 38.94 ± 2.84a 40.70 ± 1.13a 32.12 ± 3.09b 
Total 107.63 ± 20.35a 93.06 ± 23.54a 197.99 ± 25.67b 129.25 ± 32.39a 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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Table B.3. Relative percent of fatty acids in plasma PC in DHA deficient diet (TWD 
DHA-) fed rats at baseline, during pregnancy, and 7 days post partum 
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 0.35 ± 0.08a 0.69 ± 0.18ab 0.87 ± 0.19b 1.11 ± 0.20b 
C 16:0 15.73 ± 0.83a 17.06 ± 0.95a 23.64 ± 0.85c 19.82 ± 0.78b 
C 18:0 27.36 ± 3.57a 31.15 ± 0.88b 23.27 ± 1.06c 29.26 ± 1.98ab 
C 20:0 0.16 ± 0.02ab 0.13 ± 0.04a 0.12 ± 0.04a 0.25 ± 0.05b 
C 22:0 0.19 ± 0.07 0.11 ± 0.05 0.10 ± 0.05 0.12 ± 0.03 
C 24:0 0.21 ± 0.05 0.19 ± 0.05 0.21 ± 0.04 0.2 ± 0.06 
SFA 44.38 ± 2.71a 50.41 ± 0.99b 49.56 ± 1.85b 52.38 ± 2.30b 
     
C 14:1 0.03 ± 0.02ab 0.05 ± 0.03a Not detected b 0.07 ± 0.02a 
C 16:1 0.69 ± 0.25 1.07 ± 0.37 0.68 ± 0.20 0.82 ± 0.29 
C 18:1n-7 1.30 ± 0.10ab 1.11 ± 0.09a 1.15 ± 0.09a 1.44 ± 0.18b 
C 18:1n-9 8.09 ± 4.01 5.33 ± 1.09 7.53 ± 1.20 9.95 ± 1.04 
C 20:1n-9 0.41 ± 0.31a 0.08 ± 0.03b 0.08 ± 0.03b 0.09 ± 0.01b 
C 22:1n-9 0.19 ± 0.06ab 0.32 ± 0.10a 0.10 ± 0.04b 0.31 ± 0.04a 
C 24:1n-9 0.31 ± 0.26 0.16 ± 0.07 0.08 ± 0.07 0.12 ± 0.03 
MUFA 11.04 ± 4.21 8.14 ± 1.68 9.64 ± 1.32 12.8 ± 1.27 
     C 18:2n-6 13.16 ± 1.39a 10.59 ± 1.31ab 8.69 ± 0.57b 12.1 ± 2.14a 
C 18:3n-6 2.09 ± 3.02a 0.16 ± 0.02b 0.15 ± 0.08b 0.24 ± 0.07ab 
C 20:2n-6 0.17 ± 0.03a 0.09 ± 0.01b 0.09 ± 0.02b 0.11 ± 0.01ab 
C 20:3n-6 0.43 ± 0.11a 0.33 ± 0.03ab 0.19 ± 0.03b 0.45 ± 0.06a 
C 20:4n-6 19.76 ± 3.22a 20.41 ± 4.18a 13.37 ± 1.31b 15.95 ± 1.78ab 
C 22:2n-6 0.08 ± 0.06 0.08 ± 0.02 0.05 ± 0.04 0.06 ± 0.02 
C 22:4n-6 0.35 ± 0.05a 0.25 ± 0.08ac 0.68 ± 0.11b 0.17 ± 0.03c 
C 22:5n-6 0.45 ± 0.09a 0.53 ± 0.25a 5.7 ± 1.45b 0.64 ± 0.09a 
N-6 36.48 ± 1.66a 32.43 ± 3.36ab 28.93 ± 1.13b 29.72 ± 2.63b 
     C 18:3n-3 0.22 ± 0.21 0.08 ± 0.03 0.09 ± 0.07 0.07 ± 0.03 
C 20:3n-3 0.04 ± 0.01 0.04 ± 0.03 0.03 ± 0.02 0.02 ± 0.01 
C 20:5n-3 0.22 ± 0.11a 0.10 ± 0.03b 0.05 ± 0.01b 0.09 ± 0.03b 
C 22:5n-3 0.62 ± 0.09a 0.59 ± 0.14a 0.89 ± 0.09b 0.46 ± 0.06a 
C 22:6n-3 6.20 ± 0.82ac 7.61 ± 0.93ab 9.99 ± 1.82b 3.01 ± 0.83c 
N-3 7.30 ± 0.90a 8.41 ± 1.04a 11.05 ± 1.83b 3.65 ± 0.81c 
     HUFA 28.06 ± 4.32a 29.85 ± 3.23a 30.91 ± 2.86a 20.80 ± 1.96b 
PUFA 43.78 ± 2.41a 40.84 ± 2.57a 39.98 ± 2.76a 33.37 ± 2.04b 
Total 124.17 ± 23.53a 96.30 ± 29.76a 215.91 ± 24.9b 135.38 ± 15.97a 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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Table B.4. Concentration of fatty acids in plasma PC in chow fed rats at baseline, 
during pregnancy, and 7 days post partum (µg/100µl plasma) 
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 0.51 ± 0.49 0.62 ± 0.29 1.25 ± 0.13 1.32 ± 0.28 
C 16:0 18.35 ± 7.08a 19.79 ± 4.88a 49.11 ± 6.9b 33.17 ± 2.68c 
C 18:0 26.89 ± 6.71a 31.28 ± 7.88a 40.02 ± 8.7ab 53.93 ± 7.64b 
C 20:0 0.20 ± 0.12a 0.16 ± 0.04a 0.24 ± 0.03ab 0.36 ± 0.1b 
C 22:0 0.28 ± 0.18 0.15 ± 0.05 0.18 ± 0.04 0.18 ± 0.03 
C 24:0 0.23 ± 0.05a 0.20 ± 0.03a 0.44 ± 0.07b 0.31 ± 0.06ab 
SFA 47.06 ± 14.70a 53.32 ± 13.14a 94.09 ± 15.21b 91.62 ± 10.4b 
     
C 14:1 0.06 ± 0.03a 0.05 ± 0.02ab Not Detected 0.06 ± 0.02a 
C 16:1 0.59 ± 0.15 0.77 ± 0.06 1.42 ± 0.23 1.15 ± 0.09 
C 18:1n-7 1.63 ± 0.65a 1.35 ± 0.31a 2.07 ± 0.46ab 2.57 ± 0.32b 
C 18:1n-9 11.94 ± 12.56 4.83 ± 2.45 8.25 ± 2.03 11.76 ± 1.29 
C 20:1n-9 0.45 ± 0.51 0.14 ± 0.03 0.18 ± 0.04 0.21 ± 0.01 
C 22:1n-9 0.22 ± 0.08a 0.27 ± 0.02a 0.17 ± 0.03a 0.42 ± 0.05b 
C 24:1n-9 0.25 ± 0.08 0.25 ± 0.11 0.09 ± 0.04 0.18 ± 0.05 
MUFA 15.17 ± 13.93 7.68 ± 2.77 12.22 ± 2.53 16.36 ± 1.27 
     
C 18:2n-6 16.4 ± 2.83ab 13.41 ± 2.62a 21.55 ± 7.15bc 26.15 ± 4.22c 
C 18:3n-6 0.75 ± 0.8 0.27 ± 0.16 0.18 ± 0.05 0.27 ± 0.05 
C 20:2n-6 0.27 ± 0.05ab 0.19 ± 0.04a 0.31 ± 0.08b 0.43 ± 0.06c 
C 20:3n-6 0.42 ± 0.07a 0.40 ± 0.1a 0.41 ± 0.08a 1.41 ± 0.20b 
C 20:4n-6 18.74 ± 4.01 21.43 ± 6.61 22.01 ± 7.30 27.82 ± 5.76 
C 22:2n-6 0.13 ± 0.08 0.12 ± 0.07 0.12 ± 0.07 0.13 ± 0.03 
C 22:4n-6 0.33 ± 0.04ac 0.25 ± 0.06a 1.13 ± 0.24b 0.60 ± 0.18c 
C 22:5n-6 0.31 ± 0.08a 0.35 ± 0.12a 6.19 ± 1.26b 1.82 ± 0.77a 
N-6 37.35 ± 6.03a 36.42 ± 9.47a 51.88 ± 14.65ab 58.63 ± 9.77b 
     
C 18:3n-3 0.19 ± 0.09 0.11 ± 0.02 0.22 ± 0.09 0.15 ± 0.04 
C 20:3n-3 0.05 ± 0.02 0.08 ± 0.05 0.08 ± 0.03 0.04 ± 0.01 
C 20:5n-3 0.22 ± 0.05 0.16 ± 0.04 0.16 ± 0.05 0.21 ± 0.04 
C 22:5n-3 0.86 ± 0.09a 0.85 ± 0.16a 2.19 ± 0.51b 2.48 ± 0.69b 
C 22:6n-3 5.91 ± 1.01a 7.52 ± 2.39a 23.17 ± 2.73b 10.43 ± 2.63a 
N-3 7.23 ± 1.10a 8.72 ± 2.54a 25.81 ± 3.35b 13.3 ± 3.31a 
     
HUFA 26.85 ± 5.15a 31.05 ± 9.06a 55.32 ± 11.69b 44.8 ± 9.21ab 
PUFA 44.58 ± 7.04a 45.14 ± 11.65a 77.69 ± 17.86b 71.92 ± 11.86b 
Total 106.81 ± 34.92a 106.13 ± 27.14a 184.00 ± 35.52b 179.90 ± 20.84b 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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Table B.5. Concentration of fatty acids in plasma PC in high DHA diet (TWD 
DHA+) fed rats at baseline, during pregnancy, and 7 days post partum (µg/100µl 
plasma) 
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 0.46 ± 0.09a 0.82 ± 0.03a 1.42 ± 0.45ab 1.96 ± 1.21b 
C 16:0 18.71 ± 3.06ac 16.70 ± 3.49a 48.91 ± 6.83b 27.78 ± 7.67c 
C 18:0 30.20 ± 5.55a 28.20 ± 7.93a 47.60 ± 8.24b 36.54 ± 8.16ab 
C 20:0 0.20 ± 0.04a 0.17 ± 0.02a 0.24 ± 0.05ab 0.37 ± 0.14b 
C 22:0 0.21 ± 0.03 0.13 ± 0.02 0.18 ± 0.04 0.19 ± 0.05 
C 24:0 0.33 ± 0.06ab 0.21 ± 0.03a 0.43 ± 0.1b 0.32 ± 0.14ab 
SFA 50.69 ± 8.49a 47.79 ± 11.15a 101.33 ± 14.23b 69.61 ± 16.72a 
     
C 14:1 0.05 ± 0.01ab 0.05 ± 0.01ab 0.01 ± 0.01a 0.08 ± 0.05b 
C 16:1 0.76 ± 0.10a 1.13 ± 0.17ab 1.83 ± 1.24b 1.42 ± 0.47ab 
C 18:1n-7 1.44 ± 0.27ab 0.96 ± 0.22a 2.07 ± 0.34b 1.72 ± 0.53b 
C 18:1n-9 7.32 ± 2.16 5.41 ± 0.71 11.18 ± 2.17 13.38 ± 5.88 
C 20:1n-9 0.24 ± 0.11 0.12 ± 0.03 0.19 ± 0.06 0.11 ± 0.02 
C 22:1n-9 0.27 ± 0.06ab 0.37 ± 0.09bc 0.17 ± 0.03a 0.41 ± 0.07c 
C 24:1n-9 0.23 ± 0.10 0.17 ± 0.11 0.09 ± 0.05 0.20 ± 0.09 
MUFA 10.34 ± 2.57ab 8.22 ± 0.80a 15.56 ± 3.23b 17.35 ± 6.30ab 
     
C 18:2n-6 15.89 ± 2.81 10.1 ± 2.55 16.60 ± 1.97 16.44 ± 4.55 
C 18:3n-6 0.16 ± 0.05 0.16 ± 0.06 0.16 ± 0.08 0.21 ± 0.05 
C 20:2n-6 0.23 ± 0.03a 0.12 ± 0.03b 0.17 ± 0.02ab 0.14 ± 0.02ab 
C 20:3n-6 0.54 ± 0.06ab 0.44 ± 0.13a 0.43 ± 0.03ab 0.66 ± 0.14b 
C 20:4n-6 19.19 ± 4.29 15.23 ± 6.32 20.70 ± 4.44 15.64 ± 4.59 
C 22:2n-6 0.10 ± 0.03 0.11 ± 0.09 0.11 ± 0.04 0.09 ± 0.03 
C 22:4n-6 0.37 ± 0.05ab 0.15 ± 0.03a 0.69 ± 0.22b 0.15 ± 0.06a 
C 22:5n-6 0.21 ± 0.05a 0.14 ± 0.04a 3.20 ± 0.79b 0.17 ± 0.05a 
N-6 36.69 ± 7.23 26.44 ± 8.78 42.06 ± 5.95 33.49 ± 8.03 
     
C 18:3n-3 0.14 ± 0.03 0.08 ± 0.03 0.17 ± 0.07 0.16 ± 0.15 
C 20:3n-3 0.07 ± 0.04 0.06 ± 0.05 0.06 ± 0.01 0.05 ± 0.03 
C 20:5n-3 0.21 ± 0.03 0.15 ± 0.03 0.12 ± 0.04 0.23 ± 0.12 
C 22:5n-3 0.53 ± 0.10a 0.46 ± 0.12a 1.43 ± 0.29b 0.40 ± 0.13a 
C 22:6n-3 8.96 ± 2.35a 9.85 ± 3.24a 37.25 ± 3.55b 7.96 ± 3.67a 
N-3 9.92 ± 2.46a 10.60 ± 3.29a 39.04 ± 3.75b 8.80 ± 3.60a 
     
HUFA 30.09 ± 6.69a 26.48 ± 9.72a 63.88 ± 7.72b 25.25 ± 8.09a 
PUFA 46.61 ± 9.51a 37.05 ± 11.98a 81.10 ± 9.22b 42.29 ± 11.24a 
Total 107.63 ± 20.35a 93.06 ± 23.54a 197.99 ± 25.67b 129.25 ± 32.39a 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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Table B.6. Concentration of fatty acids in plasma PC in DHA deficient diet (TWD 
DHA-) fed rats at baseline, during pregnancy, and 7 days post partum (µg/100µl 
plasma) 
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 0.45 ± 0.16a 0.63 ± 0.06ab 1.89 ± 0.41c 1.54 ± 0.37bc 
C 16:0 19.70 ± 3.83ac 16.31 ± 4.21a 51.34 ± 4.82b 27.17 ± 2.77c 
C 18:0 33.96 ± 6.72a 30.27 ± 9.72a 50.51 ± 4.59b 40.16 ± 5.03ab 
C 20:0 0.20 ± 0.05ab 0.12 ± 0.01a 0.26 ± 0.07ab 0.35 ± 0.09b 
C 22:0 0.25 ± 0.12a 0.10 ± 0.01b 0.21 ± 0.08ab 0.16 ± 0.02ab 
C 24:0 0.27 ± 0.08a 0.17 ± 0.02a 0.46 ± 0.07b 0.27 ± 0.05a 
SFA 55.3 ± 9.77a 48.61 ± 14.13a 107.54 ± 8.59b 71.88 ± 8.18ab 
     
C 14:1 0.04 ± 0.03ab 0.04 ± 0.01ab Not Detected 0.09 ± 0.03b 
C 16:1 0.89 ± 0.45a 0.97 ± 0.15ab 1.44 ± 0.31b 1.10 ± 0.35ab 
C 18:1n-7 1.62 ± 0.27ac 1.07 ± 0.31a 2.51 ± 0.42b 1.98 ± 0.27bc 
C 18:1n-9 10.38 ± 6.06ab 4.96 ± 0.97a 16.41 ± 3.35b 13.73 ± 2.5ab 
C 20:1n-9 0.54 ± 0.47a 0.07 ± 0.01b 0.16 ± 0.05ab 0.13 ± 0.02ab 
C 22:1n-9 0.24 ± 0.09a 0.29 ± 0.02a 0.21 ± 0.08a 0.42 ± 0.04b 
C 24:1n-9 0.41 ± 0.41 0.14 ± 0.04 0.17 ± 0.13 0.16 ± 0.03 
MUFA 14.16 ± 6.8 7.56 ± 1.37 20.94 ± 3.53 17.61 ± 2.77 
     
C 18:2n-6 16.29 ± 2.61ab 10.23 ± 3.33a 18.91 ± 2.4b 16.5 ± 2.74ab 
C 18:3n-6 2.88 ± 4.27a 0.15 ± 0.03b 0.32 ± 0.14ab 0.34 ± 0.12ab 
C 20:2n-6 0.21 ± 0.04a 0.08 ± 0.02b 0.20 ± 0.03a 0.14 ± 0.01ab 
C 20:3n-6 0.51 ± 0.07ab 0.31 ± 0.10a 0.42 ± 0.04ab 0.62 ± 0.14b 
C 20:4n-6 24.58 ± 5.71 20.65 ± 9.54 29.15 ± 4.72 22.02 ± 4.47 
C 22:2n-6 0.11 ± 0.09 0.07 ± 0.02 0.11 ± 0.07 0.08 ± 0.03 
C 22:4n-6 0.43 ± 0.08a 0.22 ± 0.02a 1.49 ± 0.35b 0.24 ± 0.06a 
C 22:5n-6 0.55 ± 0.13a 0.47 ± 0.14a 12.53 ± 3.85b 0.89 ± 0.22a 
N-6 45.56 ± 8.35ab 32.20 ± 12.8a 63.13 ± 9.03b 40.83 ± 6.37a 
     
C 18:3n-3 0.30 ± 0.30 0.07 ± 0.02 0.18 ± 0.13 0.09 ± 0.05 
C 20:3n-3 0.05 ± 0.02 0.04 ± 0.02 0.07 ± 0.04 0.02 ± 0.01 
C 20:5n-3 0.27 ± 0.15a 0.09 ± 0.03b 0.12 ± 0.03b 0.12 ± 0.04b 
C 22:5n-3 0.77 ± 0.11a 0.55 ± 0.14a 1.93 ± 0.29b 0.64 ± 0.14a 
C 22:6n-3 7.76 ± 1.89a 7.19 ± 1.62a 21.99 ± 6.00b 4.18 ± 1.38a 
N-3 9.15 ± 2.22a 7.94 ± 1.74a 24.29 ± 6.17b 5.06 ± 1.44a 
     
HUFA 34.93 ± 8.01a 29.53 ± 11.20a 67.71 ± 13.04b 28.74 ± 5.57a 
PUFA 54.71 ± 10.41a 40.13 ± 14.4a 87.43 ± 14.91b 45.89 ± 6.74a 
Total 124.17 ± 23.53a 96.30 ± 29.76a 215.91 ± 24.9b 135.38 ± 15.97a 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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Appendix C. Plasma PE 
Table C.1. Relative percent of fatty acids in plasma PE in chow fed rats at baseline, 
during pregnancy, and 7 days post partum 
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 2.47 ± 2.48 2.14 ± 0.34 2.29 ± 0.16 2.87 ± 0.53 
C 16:0 15.18 ± 5.29 15.11 ± 1.45 17.38 ± 1.50 18.79 ± 1.02 
C 18:0 23.86 ± 5.51a 33.44 ± 2.74b 34.60 ± 2.80b 38.38 ± 2.37ab 
C 20:0 0.42 ± 0.09 0.40 ± 0.11 0.44 ± 0.05 0.53 ± 0.04 
C 22:0 0.48 ± 0.15 0.38 ± 0.14 0.50 ± 0.06 0.30 ± 0.03b 
C 24:0 0.90 ± 0.46 0.66 ± 0.23 0.60 ± 0.08 0.40 ± 0.04 
SFA 45.54 ± 7.37a 55.48 ± 1.14b 60.62 ± 3.26b 65.69 ± 1.47 
     C 14:1 0.09 ± 0.05 0.16 ± 0.06 0.01 ± 0.01 0.10 ± 0.04 
C 16:1 2.92 ± 1.67 3.50 ± 0.40 1.94 ± 0.11 2.23 ± 0.47b 
C 18:1n-7 1.13 ± 1.08 0.57 ± 0.11 0.59 ± 0.22 0.50 ± 0.05ab 
C 18:1n-9 18.46 ± 8.23a 7.86 ± 1.15ab 9.86 ± 2.64ab 5.91 ± 1.23 
C 20:1n-9 0.36 ± 0.31ab 0.65 ± 0.18a 0.27 ± 0.08b 0.25 ± 0.07ab 
C 22:1n-9 0.59 ± 0.21ab 1.33 ± 0.28a 0.40 ± 0.14b 0.92 ± 0.14ab 
C 24:1n-9 0.71 ± 0.20 0.59 ± 0.26 0.35 ± 0.07 0.35 ± 0.12b 
MUFA 24.33 ± 7.13a 14.75 ± 1.28ab 13.48 ± 2.65b 10.27 ± 1.34b 
     C 18:2n-6 4.37 ± 1.36 3.58 ± 0.87 2.71 ± 0.40 2.86 ± 0.57 
C 18:3n-6 2.81 ± 4.07 0.48 ± 0.14 0.22 ± 0.02 0.44 ± 0.07a 
C 20:2n-6 0.28 ± 0.13 0.24 ± 0.14 0.09 ± 0.01 0.11 ± 0.02 
C 20:3n-6 0.40 ± 0.22a 0.50 ± 0.08a 0.23 ± 0.05a 0.92 ± 0.08 
C 20:4n-6 14.27 ± 4.8 18.26 ± 2.40 15.63 ± 1.47 13.83 ± 1.88b 
C 22:2n-6 0.34 ± 0.20 0.38 ± 0.15 0.16 ± 0.06 0.20 ± 0.04 
C 22:4n-6 0.50 ± 0.23 0.45 ± 0.13 0.36 ± 0.08 0.44 ± 0.12a 
C 22:5n-6 0.76 ± 0.43 0.56 ± 0.30 0.82 ± 0.20 0.36 ± 0.07 
N-6 23.73 ± 5.69 24.45 ± 1.73 20.22 ± 1.81 19.16 ± 1.90ab 
     C 18:3n-3 0.69 ± 0.67 0.35 ± 0.13 0.26 ± 0.06 0.29 ± 0.07b 
C 20:3n-3 0.28 ± 0.17 0.29 ± 0.17 0.24 ± 0.05 0.11 ± 0.03 
C 20:5n-3 0.70 ± 0.34a 0.29 ± 0.08ab 0.08 ± 0.02b 0.14 ± 0.05 
C 22:5n-3 0.75 ± 0.35 0.66 ± 0.22 0.53 ± 0.11 0.73 ± 0.16b 
C 22:6n-3 1.26 ± 0.22a 1.84 ± 0.33ab 3.16 ± 0.67b 1.53 ± 0.15 
N-3 3.68 ± 0.84 3.44 ± 0.65 4.27 ± 0.65 2.81 ± 0.25b 
     HUFA 18.91 ± 6.22 22.86 ± 2.38 21.05 ± 1.36 18.07 ± 2.3 
PUFA 27.41 ± 6.43 27.89 ± 1.80 24.49 ± 1.73 21.97 ± 2.14 
Total 17.68 ± 10.20 12.18 ± 1.87 21.43 ± 1.17 18.97 ± 3.36 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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Table C.2. Relative percent of fatty acids in plasma PE in high DHA diet (TWD 
DHA+) fed rats at baseline, during pregnancy, and 7 days post partum 
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 1.66 ± 0.63 2.49 ± 0.34 3.06 ± 0.52 2.88 ± 0.40 
C 16:0 15.58 ± 2.98a 17.30 ± 0.81ab 17.07 ± 1.56a 24.56 ± 6.55b 
C 18:0 20.97 ± 4.78a 32.49 ± 1.75b 30.13 ± 3.49b 34.20 ± 6.78b 
C 20:0 0.61 ± 0.22 0.47 ± 0.04 0.44 ± 0.03 0.58 ± 0.11 
C 22:0 0.78 ± 0.33 0.46 ± 0.11 0.41 ± 0.14 0.38 ± 0.08 
C 24:0 1.26 ± 0.76a 0.72 ± 0.15ab 0.38 ± 0.10b 0.52 ± 0.27ab 
SFA 43.22 ± 5.44a 57.61 ± 1.13b 57.63 ± 3.48b 66.85 ± 0.65b 
     C 14:1 0.26 ± 0.13a 0.22 ± 0.02a 0.01 ± 0.01b 0.12 ± 0.02ab 
C 16:1 3.35 ± 1.79 4.50 ± 0.36 2.70 ± 0.82 2.66 ± 0.82 
C 18:1n-7 0.93 ± 0.32 0.55 ± 0.03 0.74 ± 0.20 0.65 ± 0.28 
C 18:1n-9 21.57 ± 10.07a 9.26 ± 0.91b 13.17 ± 3.77ab 7.93 ± 2.81b 
C 20:1n-9 0.46 ± 0.18 0.63 ± 0.15 0.26 ± 0.06 0.37 ± 0.23 
C 22:1n-9 0.94 ± 0.51ab 1.50 ± 0.10a 0.43 ± 0.14b 1.09 ± 0.22ab 
C 24:1n-9 0.92 ± 0.62a 0.60 ± 0.12ab 0.27 ± 0.12b 0.33 ± 0.14ab 
MUFA 28.64 ± 8.71a 17.34 ± 1.13b 17.61 ± 4.25b 13.21 ± 2.08b 
     C 18:2n-6 4.68 ± 1.46a 2.30 ± 0.19b 2.79 ± 0.68ab 1.69 ± 0.19b 
C 18:3n-6 0.47 ± 0.23 0.45 ± 0.09 0.29 ± 0.12 0.35 ± 0.07 
C 20:2n-6 0.50 ± 0.25a 0.23 ± 0.09ab 0.07 ± 0.03b 0.09 ± 0.04b 
C 20:3n-6 0.48 ± 0.28 0.53 ± 0.09 0.25 ± 0.05 0.49 ± 0.14 
C 20:4n-6 9.24 ± 4.43 15.22 ± 1.87 14.36 ± 2.00 9.62 ± 2.59 
C 22:2n-6 0.59 ± 0.36 0.37 ± 0.08 0.15 ± 0.12 0.22 ± 0.05 
C 22:4n-6 1.14 ± 0.79a 0.38 ± 0.07b 0.20 ± 0.04b 0.27 ± 0.13b 
C 22:5n-6 1.13 ± 0.68a 0.47 ± 0.17ab 0.37 ± 0.10b 0.34 ± 0.10ab 
N-6 18.23 ± 3.36 19.94 ± 1.68 18.47 ± 1.72 13.07 ± 3.20 
     C 18:3n-3 0.56 ± 0.27 0.32 ± 0.06 0.30 ± 0.22 0.24 ± 0.10 
C 20:3n-3 0.41 ± 0.24 0.29 ± 0.20 0.17 ± 0.10 0.10 ± 0.04 
C 20:5n-3 0.95 ± 0.54a 0.26 ± 0.07b 0.13 ± 0.08b 0.13 ± 0.01b 
C 22:5n-3 1.27 ± 0.64a 0.46 ± 0.13b 0.36 ± 0.14b 0.50 ± 0.10ab 
C 22:6n-3 2.48 ± 1.32ab 2.07 ± 0.39a 3.64 ± 1.07b 2.21 ± 0.56ab 
N-3 5.67 ± 2.83 3.40 ± 0.34 4.60 ± 1.42 3.18 ± 0.75 
     HUFA 17.11 ± 5.3 19.68 ± 1.96 19.47 ± 2.80 13.66 ± 3.54 
PUFA 23.90 ± 4.65 23.34 ± 1.84 23.07 ± 2.31 16.25 ± 3.93 
Total 13.65 ± 11.06ab 11.06 ± 1.09a 23.40 ± 2.72b 19.03 ± 2.78ab 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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Table C.3. Relative percent of fatty acids in plasma PE in DHA deficient diet (TWD 
DHA-) fed rats at baseline, during pregnancy, and 7 days post partum 
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 1.84 ± 0.47 2.81 ± 0.33 2.33 ± 0.28 3.40 ± 0.53 
C 16:0 16.21 ± 3.34a 17.22 ± 1.40ab 16.65 ± 1.11ab 23.05 ± 3.5b 
C 18:0 25.69 ± 3.34a 30.86 ± 2.48ab 34.49 ± 1.32b 32.59 ± 3.14ab 
C 20:0 0.55 ± 0.20 0.54 ± 0.10 0.43 ± 0.07 0.62 ± 0.16 
C 22:0 0.79 ± 0.51 0.61 ± 0.09 0.44 ± 0.11 0.43 ± 0.12 
C 24:0 1.07 ± 0.66 0.87 ± 0.23 0.49 ± 0.13 0.56 ± 0.16 
SFA 48.10 ± 3.99a 57.11 ± 1.74b 59.70 ± 2.30b 64.62 ± 5.64b 
     C 14:1 0.23 ± 0.14a 0.24 ± 0.05a 0.02 ± 0.03b 0.16 ± 0.05ab 
C 16:1 3.11 ± 0.60ab 4.66 ± 0.76a 2.03 ± 0.80b 2.59 ± 0.53ab 
C 18:1n-7 1.04 ± 0.50 0.63 ± 0.08 0.61 ± 0.11 0.82 ± 0.36 
C 18:1n-9 18.30 ± 7.04 10.26 ± 2.17 10.11 ± 1.70 11.57 ± 4.40 
C 20:1n-9 0.37 ± 0.20ab 0.70 ± 0.22a 0.19 ± 0.03b 0.19 ± 0.03b 
C 22:1n-9 0.84 ± 0.41a 1.73 ± 0.79b 0.44 ± 0.08a 0.92 ± 0.21a 
C 24:1n-9 0.71 ± 0.43 0.55 ± 0.12 0.29 ± 0.17 0.43 ± 0.15 
MUFA 24.73 ± 6.37a 18.85 ± 2.59ab 13.74 ± 1.79b 16.72 ± 4.66ab 
     C 18:2n-6 4.18 ± 1.83 2.32 ± 0.33 2.19 ± 0.18 2.89 ± 1.36 
C 18:3n-6 1.40 ± 2.63 0.49 ± 0.08 0.27 ± 0.08 0.35 ± 0.10 
C 20:2n-6 0.56 ± 0.36a 0.16 ± 0.05b 0.08 ± 0.02b 0.07 ± 0.05b 
C 20:3n-6 0.37 ± 0.18 0.50 ± 0.12 0.24 ± 0.07 0.44 ± 0.11 
C 20:4n-6 13.17 ± 3.78ab 14.64 ± 2.42ab 16.20 ± 1.43a 8.74 ± 1.68b 
C 22:2n-6 0.63 ± 0.54a 0.32 ± 0.07ab 0.14 ± 0.04b 0.15 ± 0.07ab 
C 22:4n-6 0.89 ± 0.49 0.50 ± 0.11 0.44 ± 0.07 0.24 ± 0.04 
C 22:5n-6 0.91 ± 0.47ab 0.62 ± 0.2a 1.43 ± 0.41b 0.28 ± 0.12a 
N-6 22.11 ± 4.26a 19.55 ± 2.46ab 21.00 ± 1.83a 13.15 ± 2.41b 
     C 18:3n-3 0.43 ± 0.15 0.28 ± 0.06 0.22 ± 0.04 0.23 ± 0.05 
C 20:3n-3 0.36 ± 0.21 0.29 ± 0.11 0.16 ± 0.05 0.12 ± 0.03 
C 20:5n-3 0.72 ± 0.41a 0.30 ± 0.11ab 0.07 ± 0.05b 0.15 ± 0.06b 
C 22:5n-3 1.17 ± 0.78a 0.54 ± 0.16ab 0.45 ± 0.10ab 0.36 ± 0.10b 
C 22:6n-3 1.49 ± 0.33a 1.31 ± 0.16a 2.81 ± 0.56b 1.14 ± 0.23a 
N-3 4.17 ± 1.62 2.72 ± 0.43 3.72 ± 0.56 2.00 ± 0.4 
     
HUFA 19.08 ± 5.16ab 18.69 ± 2.29ab 21.82 ± 2.14a 11.46 ± 2.16b 
PUFA 26.28 ± 4.97a 22.27 ± 2.46ab 24.72 ± 2.19a 15.15 ± 2.73b 
Total 13.18 ± 5.37ab 11.18 ± 1.19a 22.07 ± 1.95b 19.71 ± 1.95ab 
Values with different superscripts are significantly different by Tukey’s post hoc test (p<0.05) 
following significant F-value by one-way ANOVA  
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Table C.4. Concentration of fatty acids in plasma PE in chow fed rats at baseline, 
during pregnancy, and 7 days post partum (µg/100µl plasma) 
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 0.5 ± 0.71 0.27 ± 0.06 0.50 ± 0.02 0.55 ± 0.11 
C 16:0 2.91 ± 2.22 1.87 ± 0.34 3.78 ± 0.38 3.62 ± 0.56 
C 18:0 4.00 ± 1.57a 4.16 ± 0.83a 7.54 ± 0.92b 7.47 ± 1.59b 
C 20:0 0.07 ± 0.03 0.05 ± 0.01 0.09 ± 0.01 0.10 ± 0.02 
C 22:0 0.08 ± 0.02ab 0.05 ± 0.01a 0.11 ± 0.02b 0.06 ± 0.01ab 
C 24:0 0.13 ± 0.03 0.08 ± 0.02 0.13 ± 0.02 0.08 ± 0.01 
SFA 8.03 ± 4.1a 6.87 ± 0.99ab 13.19 ± 1.23c 12.70 ± 2.1ac 
     
C 14:1 0.01 ± 0.01ab 0.02 ± 0.01a Not Detected 0.02 ± 0.01a 
C 16:1 0.43 ± 0.15 0.43 ± 0.07 0.42 ± 0.04 0.42 ± 0.07 
C 18:1n-7 0.25 ± 0.32 0.07 ± 0.02 0.13 ± 0.04 0.09 ± 0.01 
C 18:1n-9 3.86 ± 3.94 0.99 ± 0.26 2.12 ± 0.45 1.13 ± 0.24 
C 20:1n-9 0.08 ± 0.09 0.08 ± 0.01 0.06 ± 0.02 0.05 ± 0.02 
C 22:1n-9 0.09 ± 0.02a 0.16 ± 0.01ab 0.09 ± 0.03a 0.18 ± 0.05b 
C 24:1n-9 0.12 ± 0.05 0.07 ± 0.02 0.08 ± 0.02 0.07 ± 0.03 
MUFA 4.85 ± 4.13 1.83 ± 0.33 2.91 ± 0.42 1.97 ± 0.30 
     
C 18:2n-6 0.75 ± 0.46 0.45 ± 0.15 0.59 ± 0.09 0.55 ± 0.14 
C 18:3n-6 0.79 ± 1.54 0.06 ± 0.01 0.05 ± 0.01 0.09 ± 0.02 
C 20:2n-6 0.04 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 
C 20:3n-6 0.06 ± 0.01a 0.06 ± 0.01a 0.05 ± 0.01a 0.18 ± 0.04b 
C 20:4n-6 2.29 ± 0.68 2.28 ± 0.56 3.4 ± 0.43 2.72 ± 0.77 
C 22:2n-6 0.05 ± 0.01 0.05 ± 0.02 0.04 ± 0.01 0.04 ± 0.01 
C 22:4n-6 0.07 ± 0.01 0.05 ± 0.01 0.08 ± 0.02 0.09 ± 0.04 
C 22:5n-6 0.11 ± 0.04ab 0.07 ± 0.03a 0.18 ± 0.05b 0.07 ± 0.02a 
N-6 4.16 ± 2.55 3.05 ± 0.62 4.40 ± 0.54 3.76 ± 0.96 
     
C 18:3n-3 0.17 ± 0.28 0.04 ± 0.01 0.06 ± 0.01 0.06 ± 0.02 
C 20:3n-3 0.04 ± 0.01 0.03 ± 0.02 0.05 ± 0.01 0.02 ± 0.01 
C 20:5n-3 0.10 ± 0.03a 0.04 ± 0.01b 0.02 ± 0.01b 0.03 ± 0.01b 
C 22:5n-3 0.11 ± 0.02 0.08 ± 0.02 0.11 ± 0.03 0.14 ± 0.05 
C 22:6n-3 0.22 ± 0.12a 0.23 ± 0.06a 0.69 ± 0.14b 0.30 ± 0.07a 
N-3 0.64 ± 0.38ab 0.42 ± 0.06a 0.93 ± 0.15b 0.55 ± 0.13ab 
     
HUFA 3.00 ± 0.77a 2.84 ± 0.59a 4.58 ± 0.46b 3.55 ± 0.98ab 
PUFA 4.80 ± 2.93 3.47 ± 0.65 5.33 ± 0.55 4.31 ± 1.09 
Total 17.68 ± 10.2 12.18 ± 1.87 21.43 ± 1.17 18.97 ± 3.36 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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Table C.5. Concentration of fatty acids in plasma PE in high DHA diet (TWD 
DHA+) fed rats at baseline, during pregnancy, and 7 days post partum (µg/100µl 
plasma) 
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 0.20 ± 0.11a 0.28 ± 0.07ab 0.73 ± 0.16b 0.58 ± 0.15ab 
C 16:0 2.27 ± 2.14 1.95 ± 0.28 4.07 ± 0.62 4.99 ± 2.10 
C 18:0 2.8 ± 1.81a 3.64 ± 0.21a 7.17 ± 1.22b 6.64 ± 0.68b 
C 20:0 0.07 ± 0.03 0.05 ± 0.01 0.10 ± 0.01 0.11 ± 0.01 
C 22:0 0.08 ± 0.02 0.05 ± 0.02 0.10 ± 0.03 0.07 ± 0.01 
C 24:0 0.12 ± 0.01 0.08 ± 0.02 0.09 ± 0.03 0.10 ± 0.04 
SFA 5.87 ± 4.17a 6.48 ± 0.71a 13.7 ± 1.64b 13.24 ± 2.12b 
     
C 14:1 0.03 ± 0.01a 0.02 ± 0a Not Detected 0.02 ± 0.01a 
C 16:1 0.35 ± 0.11a 0.51 ± 0.09ab 0.63 ± 0.15b 0.53 ± 0.18ab 
C 18:1n-7 0.16 ± 0.20 0.06 ± 0.01 0.18 ± 0.06 0.13 ± 0.08 
C 18:1n-9 3.92 ± 5.06 1.04 ± 0.15 3.16 ± 1.05 1.62 ± 0.82 
C 20:1n-9 0.06 ± 0.03 0.07 ± 0.02 0.06 ± 0.02 0.07 ± 0.04 
C 22:1n-9 0.09 ± 0.02a 0.17 ± 0.02bc 0.10 ± 0.03ab 0.21 ± 0.01c 
C 24:1n-9 0.08 ± 0.03 0.07 ± 0.02 0.06 ± 0.03 0.06 ± 0.02 
MUFA 4.72 ± 5.37 1.96 ± 0.28 4.20 ± 1.17 2.66 ± 0.83 
     
C 18:2n-6 0.77 ± 0.90 0.26 ± 0.04 0.67 ± 0.20 0.33 ± 0.02 
C 18:3n-6 0.05 ± 0.03 0.05 ± 0.01 0.07 ± 0.03 0.07 ± 0.01 
C 20:2n-6 0.05 ± 0.01a 0.03 ± 0.01b 0.02 ± 0.01b 0.02 ± 0.01b 
C 20:3n-6 0.05 ± 0.02a 0.06 ± 0.01ab 0.06 ± 0.01ab 0.09 ± 0.020b 
C 20:4n-6 1.29 ± 0.99a 1.70 ± 0.17a 3.4 ± 0.52b 1.85 ± 0.19a 
C 22:2n-6 0.05 ± 0.02 0.04 ± 0.01 0.04 ± 0.02 0.04 ± 0.01 
C 22:4n-6 0.10 ± 0.03a 0.04 ± 0.01b 0.05 ± 0.01b 0.05 ± 0.02b 
C 22:5n-6 0.11 ± 0.03 0.05 ± 0.02 0.09 ± 0.03 0.07 ± 0.01 
N-6 2.49 ± 1.65 2.24 ± 0.2 4.39 ± 0.56 2.52 ± 0.21 
     
C 18:3n-3 0.06 ± 0.02 0.04 ± 0.01 0.07 ± 0.06 0.05 ± 0.01 
C 20:3n-3 0.04 ± 0.01 0.03 ± 0.03 0.04 ± 0.02 0.02 ± 0.01 
C 20:5n-3 0.1 ± 0.03a 0.03 ± 0.01b 0.03 ± 0.02b 0.03 ± 0.01b 
C 22:5n-3 0.13 ± 0.05a 0.05 ± 0.02b 0.09 ± 0.04ab 0.10 ± 0.01ab 
C 22:6n-3 0.25 ± 0.03a 0.23 ± 0.03a 0.88 ± 0.33b 0.43 ± 0.07a 
N-3 0.57 ± 0.07a 0.38 ± 0.04a 1.11 ± 0.43b 0.62 ± 0.07a 
     
HUFA 2.07 ± 1.00a 2.20 ± 0.18a 4.63 ± 0.87b 2.63 ± 0.27a 
PUFA 3.06 ± 1.67ab 2.62 ± 0.23a 5.50 ± 0.89b 3.14 ± 0.27ab 
Total 13.65 ± 11.06ab 11.06 ± 1.09a 23.40 ± 2.72b 19.03 ± 2.78ab 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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Table C.6. Concentration of fatty acids in plasma PE in DHA deficient diet (TWD 
DHA-) fed rats at baseline, during pregnancy, and 7 days post partum (µg/100µl 
plasma) 
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 0.25 ± 0.14 0.32 ± 0.06 0.52 ± 0.08 0.70 ± 0.18 
C 16:0 2.25 ± 1.21ab 1.96 ± 0.21a 3.74 ± 0.39ab 4.76 ± 1.15b 
C 18:0 3.41 ± 1.43a 3.50 ± 0.33a 7.75 ± 0.67b 6.63 ± 0.70b 
C 20:0 0.07 ± 0.04a 0.06 ± 0.01a 0.10 ± 0.02ab 0.13 ± 0.04b 
C 22:0 0.09 ± 0.03 0.07 ± 0.01 0.10 ± 0.03 0.09 ± 0.03 
C 24:0 0.12 ± 0.03 0.10 ± 0.02 0.11 ± 0.04 0.11 ± 0.04 
SFA 6.43 ± 2.77a 6.48 ± 0.51a 13.42 ± 1.21b 13.24 ± 2.13b 
     
C 14:1 0.02 ± 0.01a 0.03 ± 0.01a Not Detected 0.03 ± 0.01a 
C 16:1 0.40 ± 0.13 0.53 ± 0.11 0.47 ± 0.21 0.53 ± 0.15 
C 18:1n-7 0.15 ± 0.12 0.07 ± 0.01 0.14 ± 0.02 0.17 ± 0.09 
C 18:1n-9 2.53 ± 1.45 1.19 ± 0.34 2.27 ± 0.39 2.35 ± 0.96 
C 20:1n-9 0.04 ± 0.02 0.08 ± 0.02 0.04 ± 0.01 0.04 ± 0.01 
C 24:1n-9 0.08 ± 0.02 0.06 ± 0.01 0.07 ± 0.04 0.09 ± 0.03 
MUFA 3.34 ± 1.61 2.16 ± 0.44 3.09 ± 0.51 3.41 ± 1.05 
     
C 18:2n-6 0.56 ± 0.29 0.27 ± 0.05 0.49 ± 0.07 0.59 ± 0.30 
C 18:3n-6 0.25 ± 0.51 0.06 ± 0.01 0.06 ± 0.02 0.07 ± 0.01 
C 20:2n-6 0.06 ± 0.03a 0.02 ± 0.01b 0.02 ± 0.01b 0.01 ± 0.01b 
C 20:3n-6 0.04 ± 0.01a 0.06 ± 0.01ab 0.05 ± 0.02ab 0.09 ± 0.02b 
C 20:4n-6 1.75 ± 0.92a 1.67 ± 0.39a 3.64 ± 0.44b 1.77 ± 0.22a 
C 22:2n-6 0.06 ± 0.03 0.04 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 
C 22:4n-6 0.10 ± 0.02a 0.06 ± 0.01b 0.10 ± 0.02a 0.05 ± 0.01b 
C 22:5n-6 0.10 ± 0.02a 0.07 ± 0.02a 0.32 ± 0.10b 0.05 ± 0.02a 
N-6 2.92 ± 1.38ab 2.23 ± 0.42a 4.73 ± 0.60b 2.66 ± 0.31ab 
     
C 18:3n-3 0.06 ± 0.04 0.03 ± 0.01 0.05 ± 0.01 0.05 ± 0.01 
C 20:3n-3 0.04 ± 0.01 0.03 ± 0.01 0.04 ± 0.01 0.02 ± 0.01 
C 20:5n-3 0.08 ± 0.02a 0.03 ± 0.01b 0.02 ± 0.01b 0.03 ± 0.01b 
C 22:1n-9 0.09 ± 0.01a 0.19 ± 0.08b 0.10 ± 0.02a 0.18 ± 0.02b 
C 22:5n-3 0.13 ± 0.04a 0.06 ± 0.01b 0.10 ± 0.03ab 0.07 ± 0.02ab 
C 22:6n-3 0.18 ± 0.05a 0.15 ± 0.02a 0.63 ± 0.13b 0.23 ± 0.02a 
N-3 0.49 ± 0.08ab 0.31 ± 0.02a 0.84 ± 0.15b 0.40 ± 0.04a 
     
HUFA 2.42 ± 0.92a 2.13 ± 0.37a 4.91 ± 0.65b 2.31 ± 0.23z 
PUFA 3.41 ± 1.42a 2.54 ± 0.41b 5.56 ± 0.72a 3.06 ± 0.33ab 
Total 13.18 ± 5.37ab 11.18 ± 1.19a 22.07 ± 1.95b 19.71 ± 1.95ab 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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Appendix D. Liver PC  
Table D.1.  Relative percent of fatty acids in liver PC in chow fed rats at baseline, 
during pregnancy, and 7 days post partum 
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 0.45 ± 0.17 0.49 ± 0.26 0.49 ± 0.13 0.4 ± 0.09 
C 16:0 17.59 ± 0.58a 17.40 ± 0.99a 26.3 ± 1.22b 17.19 ± 1.00a 
C 18:0 28.95 ± 1.17a 28.71 ± 1.26a 19.67 ± 1.42b 28.06 ± 0.77a 
C 20:0 0.08 ± 0.02 0.08 ± 0.02 0.07 ± 0.02 0.06 ± 0.01 
C 22:0 0.09 ± 0.05 0.07 ± 0.04 0.08 ± 0.04 0.05 ± 0.02 
C 24:0 0.08 ± 0.05 0.09 ± 0.07 0.11 ± 0.02 0.10 ± 0.03 
SFAs 48.98 ± 2.39 47.37 ± 1.24 47.47 ± 0.76 46.95 ± 1.36 
     C 14:1 0.01 ± 0.01 0.02 ± 0.02 0.02 ± 0.01 0.01 ± 0.01 
C 16:1 0.27 ± 0.03 0.43 ± 0.13 0.36 ± 0.11 0.32 ± 0.07 
C 18:1n-7 1.35 ± 0.08ab 1.27 ± 0.12ab 1.14 ± 0.09a 1.49 ± 0.17b 
C 18:1n-9 4.86 ± 1.24 5.05 ± 0.87 6.14 ± 1.05 6.72 ± 1.16 
C 20:1n-9 0.10 ± 0.03ab 0.08 ± 0.03a 0.07 ± 0.01a 0.14 ± 0.03b 
C 22:1n-9 0.22 ± 0.10a 0.17 ± 0.10ab 0.14 ± 0.08ab 0.09 ± 0.03b 
C 24:1n-9 0.13 ± 0.08 0.13 ± 0.11 0.08 ± 0.03 0.06 ± 0.02 
MUFA 10.78 ± 0.86a 10.37 ± 0.89ab 8.39 ± 0.60b 11.06 ± 1.18ab 
     C 18:2n-6 0.25 ± 0.03a 0.35 ± 0.08a 0.31 ± 0.04a 0.61 ± 0.12b 
C 18:3n-6 0.17 ± 0.04 0.17 ± 0.02 0.19 ± 0.02 0.21 ± 0.02 
C 20:2n-6 0.33 ± 0.05a 0.29 ± 0.05ab 0.16 ± 0.01b 0.61 ± 0.08c 
C 20:3n-6 25.34 ± 1.59a 24.39 ± 1.42a 16.61 ± 1.06b 22.24 ± 1.08a 
C 20:4n-6 0.05 ± 0.02 0.08 ± 0.08 0.05 ± 0.01 0.04 ± 0.01 
C 22:2n-6 0.20 ± 0.05a 0.20 ± 0.07a 0.55 ± 0.04b 0.23 ± 0.05a 
C 22:4n-6 0.17 ± 0.03a 0.27 ± 0.15a 3.00 ± 0.40b 0.89 ± 0.23a 
C 22:5n-6 37.30 ± 1.97a 36.13 ± 1.69a 29.26 ± 1.60b 35.88 ± 1.53a 
N-6 0.10 ± 0.01 0.12 ± 0.04 0.14 ± 0.01 0.10 ± 0.02 
     C 18:3n-3 0.03 ± 0.02 0.02 ± 0.02 0.05 ± 0.02 0.01 ± 0.01 
C 20:3n-3 0.17 ± 0.04 0.19 ± 0.04 0.15 ± 0.03 0.23 ± 0.03 
C 20:5n-3 0.53 ± 0.11a 0.67 ± 0.11a 1.06 ± 0.11b 1.10 ± 0.11b 
C 22:5n-3 5.98 ± 10.01a 7.51 ± 1.23a 13.31 ± 1.4ob 6.07 ± 0.23a 
C 22:6n-3 5.82 ± 2.58a 8.52 ± 1.28b 14.71 ± 1.33c 7.52 ± 0.23ab 
N-3 31.76 ± 1.69 33.55 ± 2.36 34.89 ± 1.48 30.25 ± 2.28 
     HUFA 6.99 ± 1.28 7.18 ± 1.15 7.96 ± 1.18 8.87 ± 1.19 
PUFA 43.11 ± 1.67 44.65 ± 2.28 43.98 ± 1.54 43.39 ± 1.64 
Total 31.82 ± 5.26 35.60 ± 5.20 33.36 ± 14.22 42.05 ± 15.84 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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Table D.2. Relative percent of fatty acids in liver PC in high DHA diet (TWD 
DHA+) fed rats at baseline, during pregnancy, and 7 days post partum 
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 0.62 ± 0.13 0.55 ± 0.13 0.61 ± 0.15 0.55 ± 0.13 
C 16:0 18.19 ± 1.68a 17.61 ± 1.7a 24.14 ± 2.17b 19.96 ± 1.88a 
C 18:0 26.09 ± 6.12ab 29.36 ± 1.19a 22.59 ± 1.69b 24.08 ± 2.01b 
C 20:0 0.08 ± 0.02 0.08 ± 0.01 0.08 ± 0.03 0.06 ± 0.01 
C 22:0 0.10 ± 0.04 0.08 ± 0.05 0.09 ± 0.02 0.05 ± 0.02 
C 24:0 0.12 ± 0.04 0.10 ± 0.06 0.08 ± 0.03 0.09 ± 0.02 
SFA 48.38 ± 1.14 48.37 ± 1.41 48.21 ± 1.82 46.10 ± 0.69 
     C 14:1 0.03 ± 0.02 0.03 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 
C 16:1 0.27 ± 0.06a 0.51 ± 0.06b 0.41 ± 0.2ab 0.43 ± 0.13ab 
C 18:1n-7 1.22 ± 0.08a 1.13 ± 0.1a 1.06 ± 0.11a 1.54 ± 0.24b 
C 18:1n-9 5.58 ± 1.39a 6.26 ± 1.25a 6.84 ± 1.4a 9.8 ± 2.05b 
C 22:1n-9 0.24 ± 0.05a 0.18 ± 0.06ab 0.13 ± 0.03ab 0.11 ± 0.02b 
C 20:1n-9 0.09 ± 0.02 0.07 ± 0.03 0.07 ± 0.01 0.10 ± 0.02 
C 24:1n-9 0.18 ± 0.07a 0.14 ± 0.08ab 0.07 ± 0.02ab 0.06 ± 0.01b 
MUFA 7.65 ± 1.48a 8.34 ± 1.37a 8.6 ± 1.41a 12.03 ± 2.22b 
     C 18:2n-6 9.83 ± 0.33a 8.98 ± 0.73a 5.93 ± 0.91b 10.39 ± 2.00a 
C 18:3n-6 0.20 ± 0.06a 0.21 ± 0.04a 0.23 ± 0.05a 0.61 ± 0.28b 
C 20:2n-6 0.11 ± 0.04 0.09 ± 0.03 0.1 ± 0.01 0.09 ± 0.02 
C 20:3n-6 0.36 ± 0.09ac 0.33 ± 0.05a 0.15 ± 0.03b 0.47 ± 0.12c 
C 20:4n-6 23.89 ± 1.40a 22.38 ± 1.83ab 16 .00± 1.21c 20.47 ± 2.44b 
C 22:2n-6 0.05 ± 0.02 0.08 ± 0.08 0.04 ± 0.01 0.02 ± 0.01 
C 22:4n-6 0.18 ± 0.03ab 0.13 ± 0.09a 0.29 ± 0.08b 0.06 ± 0.02ac 
C 22:5n-6 0.16 ± 0.10a 0.11 ± 0.05a 1.30 ± 0.36b 0.10 ± 0.03a 
N-6 34.78 ± 1.44a 32.32 ± 1.75a 24.03 ± 1.37b 32.22 ± 1.44a 
     C 18:3n-3 0.09 ± 0.04 0.07 ± 0.01 0.07 ± 0.01 0.06 ± 0.01 
C 20:3n-3 0.03 ± 0.01 0.05 ± 0.07 0.04 ± 0.02 0.01 ± 0.01 
C 20:5n-3 0.15 ± 0.04a 0.26 ± 0.04ab 0.12 ± 0.02a 0.41 ± 0.24b 
C 22:5n-3 0.35 ± 0.12a 0.31 ± 0.06a 0.58 ± 0.09b 0.27 ± 0.05a 
C 22:6n-3 7.40 ± 1.19a 9.63 ± 0.55b 17.41 ± 1.29c 7.41 ± 2.31a 
N-3 8.03 ± 1.08a 10.33 ± 0.53a 18.22 ± 1.28b 8.16 ± 2.17a 
     HUFA 32.53 ± 0.99ab 33.21 ± 1.98a 35.89 ± 1.79a 27.78 ± 5.61b 
PUFA 42.81 ± 1.11 42.64 ± 1.91 42.25 ± 1.54 40.38 ± 2.37 
Total 28.92 ± 6.52 32.61 ± 6.23 38.49 ± 4.06 29.37 ± 6.40 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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Table D.3.  Relative percent of fatty acids in liver PC in DHA deficient diet (TWD 
DHA-) fed rats at baseline, during pregnancy, and 7 days post partum 
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 0.60 ± 0.09 0.46 ± 0.12 0.69 ± 0.09 0.61 ± 0.09 
C 16:0 17.42 ± 1.15a 16.02 ± 0.87a 23.87 ± 0.73b 18.04 ± 0.75a 
C 18:0 28.69 ± 1.58a 30.66 ± 0.75a 21.44 ± 1.57b 25.20 ± 1.15a 
C 20:0 0.09 ± 0.03 0.06 ± 0.01 0.07 ± 0.02 0.06 ± 0.02 
C 22:0 0.09 ± 0.03 0.07 ± 0.01 0.11 ± 0.04 0.07 ± 0.02 
C 24:0 0.10 ± 0.02 0.09 ± 0.01 0.13 ± 0.03 0.11 ± 0.02 
SFA 47.82 ± 1.60 47.57 ± 1.07 46.89 ± 0.98 45.55 ± 0.56 
     C 14:1 0.03 ± 0.02 0.02 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 
C 16:1 0.27 ± 0.05 0.40 ± 0.12 0.44 ± 0.12 0.48 ± 0.11 
C 18:1n-7 1.31 ± 0.04a 1.16 ± 0.08a 1.21 ± 0.06a 1.61 ± 0.18b 
C 18:1n-9 6.81 ± 1.48ab 5.78 ± 1.52a 9.23 ± 1.13bc 11.02 ± 1.86c 
C 20:1n-9 0.09 ± 0.01ab 0.06 ± 0.01a 0.08 ± 0.02ab 0.12 ± 0.02b 
C 22:1n-9 0.21 ± 0.05 0.18 ± 0.05 0.16 ± 0.06 0.13 ± 0.04 
C 24:1n-9 0.12 ± 0.02 0.11 ± 0.02 0.08 ± 0.02 0.07 ± 0.02 
MUFA 8.87 ± 1.50a 7.73 ± 1.56a 11.24 ± 1.26ab 13.49 ± 2.07b 
     C 18:2n-6 9.17 ± 0.74a 8.37 ± 1.35ab 7.01 ± 0.53b 8.79 ± 0.88ab 
C 18:3n-6 0.23 ± 0.02a 0.29 ± 0.05a 0.43 ± 0.08a 0.95 ± 0.16b 
C 20:2n-6 0.10 ± 0.01 0.07 ± 0.01 0.09 ± 0.02 0.09 ± 0.02 
C 20:3n-6 0.35 ± 0.06a 0.22 ± 0.04b 0.13 ± 0.01b 0.43 ± 0.08a 
C 20:4n-6 24.99 ± 1.68a 26.26 ± 0.93a 18.95 ± 1.99b 23.41 ± 2.08a 
C 22:2n-6 0.05 ± 0.01 0.06 ± 0.03 0.06 ± 0.03 0.03 ± 0.01 
C 22:4n-6 0.19 ± 0.04a 0.15 ± 0.01a 0.54 ± 0.07b 0.13 ± 0.03a 
C 22:5n-6 0.27 ± 0.10a 0.42 ± 0.18a 4.07 ± 1.08b 0.68 ± 0.07a 
N-6 35.35 ± 1.38a 35.84 ± 1.04a 31.28 ± 1.27b 34.51 ± 1.79a 
     C 18:3n-3 0.09 ± 0.02 0.07 ± 0.03 0.07 ± 0.01 0.05 ± 0.02 
C 20:3n-3 0.02 ± 0.01 0.02 ± 0.01 0.06 ± 0.03 0.02 ± 0.01 
C 20:5n-3 0.12 ± 0.06 0.10 ± 0.03 0.11 ± 0.01 0.17 ± 0.04 
C 22:5n-3 0.39 ± 0.08a 0.42 ± 0.06a 0.72 ± 0.06b 0.48 ± 0.09a 
C 22:6n-3 5.79 ± 0.49ac 7.27 ± 0.43a 8.39 ± 0.84ab 3.90 ± 1.07c 
N-3 6.41 ± 0.46ab 7.87 ± 0.4a 9.34 ± 0.89ac 4.62 ± 1.00b 
     HUFA 32.13 ± 1.78ab 34.85 ± 1.28a 32.95 ± 1.06ab 29.21 ± 2.98b 
PUFA 41.76 ± 1.54ab 43.71 ± 0.98a 40.61 ± 0.99ab 39.12 ± 2.54b 
Total 32.87 ± 4.00 37.07 ± 5.81 37.50 ± 5.34 32.10 ± 3.61 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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Table D.4. Concentration of fatty acids in liver PC in chow fed rats at baseline, 
during pregnancy, and 7 days post partum (µg/mg) 
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 0.14 ± 0.04 0.17 ± 0.06 0.15 ± 0.04 0.17 ± 0.06 
C 16:0 5.62 ± 0.70 6.24 ± 0.98 8.78 ± 3.73 7.27 ± 2.73 
C 18:0 9.33 ± 1.84ab 10.29 ± 1.45ab 6.63 ± 2.83a 11.92 ± 4.57b 
C 20:0 0.03 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 0.03 ± 0.01 
C 22:0 0.03 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 
C 24:0 0.03 ± 0.02 0.03 ± 0.02 0.04 ± 0.01 0.04 ± 0.01 
SFA 15.81 ± 3.38 16.95 ± 2.11 15.87 ± 6.61 19.88 ± 7.43 
     
C 14:1 Not Detected 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 
C 16:1 0.09 ± 0.02 0.15 ± 0.04 0.12 ± 0.08 0.14 ± 0.06 
C 18:1n-7 0.44 ± 0.09ab 0.46 ± 0.10ab 0.38 ± 0.16a 0.62 ± 0.19b 
C 18:1n-9 1.53 ± 0.31a 1.80 ± 0.38ab 2.00 ± 0.70ab 2.84 ± 1.13b 
C 20:1n-9 0.03 ± 0.01a 0.03 ± 0.01a 0.02 ± 0.01a 0.06 ± 0.01b 
C 22:1n-9 0.07 ± 0.03 0.06 ± 0.02 0.04 ± 0.01 0.04 ± 0.01 
C 24:1n-9 0.04 ± 0.02 0.04 ± 0.03 0.02 ± 0.01 0.03 ± 0.01 
MUFA 2.21 ± 0.32a 2.56 ± 0.46ab 2.6 ± 0.94ab 3.73 ± 1.37b 
     
C 18:2n-6 3.46 ± 0.62a 3.75 ± 0.78a 2.82 ± 1.23b 4.78 ± 2.27a 
C 18:3n-6 0.08 ± 0.01a 0.12 ± 0.02a 0.1 ± 0.05a 0.26 ± 0.12b 
C 20:2n-6 0.05 ± 0.01a 0.06 ± 0.01ab 0.06 ± 0.03ab 0.08 ± 0.02b 
C 20:3n-6 0.10 ± 0.02a 0.11 ± 0.03a 0.05 ± 0.02a 0.27 ± 0.15b 
C 20:4n-6 8.18 ± 1.79 8.79 ± 1.57 5.59 ± 2.47 9.41 ± 3.46 
C 22:2n-6 0.02 ± 0.01 0.03 ± 0.02 0.02 ± 0.01 0.02 ± 0.01 
C 22:4n-6 0.06 ± 0.02a 0.07 ± 0.02a 0.19 ± 0.09b 0.09 ± 0.03a 
C 22:5n-6 0.06 ± 0.02a 0.10 ± 0.05a 1.04 ± 0.55b 0.36 ± 0.08a 
N-6 12.02 ± 2.44 13.02 ± 2.31 9.88 ± 4.42 15.27 ± 6.04 
     
C 18:3n-3 0.03 ± 0.01 0.04 ± 0.01 0.05 ± 0.02 0.04 ± 0.02 
C 20:3n-3 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 
C 20:5n-3 0.05 ± 0.02 0.07 ± 0.02 0.05 ± 0.03 0.10 ± 0.05 
C 22:5n-3 0.17 ± 0.05a 0.24 ± 0.06ab 0.36 ± 0.18b 0.46 ± 0.16cb 
C 22:6n-3 1.92 ± 0.45a 2.71 ± 0.65ab 4.54 ± 2.19b 2.55 ± 0.87a 
N-3 1.78 ± 0.76a 3.07 ± 0.70ab 5.01 ± 2.40b 3.17 ± 1.10ab 
     
HUFA 10.15 ± 1.35 12.09 ± 2.21 11.84 ± 5.44 12.82 ± 4.95 
PUFA 13.80 ± 1.91 16.09 ± 2.88 14.89 ± 6.75 18.44 ± 7.14 
Total 31.82 ± 5.26 35.60 ± 5.20 33.36 ± 14.22 42.05 ± 15.84 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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Table D.5. Concentration of fatty acids in liver PC in high DHA diet (TWD DHA+) 
fed rats at baseline, during pregnancy, and 7 days post partum (µg/mg) 
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 0.19 ± 0.08 0.18 ± 0.02 0.24 ± 0.06 0.16 ± 0.03 
C 16:0 5.49 ± 1.30a 5.71 ± 0.87a 9.40 ± 1.42b 5.88 ± 0.90a 
C 18:0 8.57 ± 1.59 9.69 ± 2.12 8.78 ± 1.21 7.27 ± 2.21 
C 20:0 0.02 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 
C 22:0 0.03 ± 0.02 0.02 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 
C 24:0 0.04 ± 0.02 0.03 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 
SFA 14.56 ± 2.83 15.83 ± 2.84 18.76 ± 2.38 13.75 ± 3.04 
     
C 14:1 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 Not Detected 
C 16:1 0.08 ± 0.03 0.17 ± 0.04 0.15 ± 0.07 0.13 ± 0.03 
C 18:1n-7 0.37 ± 0.06 0.37 ± 0.06 0.41 ± 0.05 0.45 ± 0.07 
C 18:1n-9 1.65 ± 0.36 2.02 ± 0.40 2.68 ± 0.72 2.84 ± 0.41 
C 20:1n-9 0.03 ± 0.01 0.02 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 
C 22:1n-9 0.07 ± 0.02a 0.06 ± 0.02ab 0.05 ± 0.02ab 0.03 ± 0.01b 
C 24:1n-9 0.05 ± 0.02a 0.04 ± 0.02ab 0.03 ± 0.01ab 0.02 ± 0.01b 
MUFA 2.27 ± 0.42 2.69 ± 0.45 3.37 ± 0.76 3.49 ± 0.43 
     
C 18:2n-6 2.95 ± 0.52 2.97 ± 0.69 2.30 ± 0.43 3.01 ± 0.36 
C 18:3n-6 0.06 ± 0.01a 0.07 ± 0.02a 0.09 ± 0.02ab 0.18 ± 0.07b 
C 20:2n-6 0.03 ± 0.01 0.03 ± 0.01 0.04 ± 0.01 0.02 ± 0.01 
C 20:3n-6 0.11 ± 0.02 0.11 ± 0.03 0.06 ± 0.01 0.14 ± 0.03 
C 20:4n-6 7.16 ± 1.19 7.43 ± 1.82 6.19 ± 0.57 6.20 ± 2.09 
C 22:2n-6 0.02 ± 0.01 0.02 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 
C 22:4n-6 0.05 ± 0.01ab 0.04 ± 0.01a 0.11 ± 0.04b 0.02 ± 0.01a 
C 22:5n-6 0.05 ± 0.03a 0.03 ± 0.01a 0.50 ± 0.16b 0.03 ± 0.01a 
N-6 10.43 ± 1.7 10.70 ± 2.46 9.31 ± 0.87 9.61 ± 2.13 
     
C 18:3n-3 0.03 ± 0.01 0.02 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 
C 20:3n-3 0.01 ± 0.01ab 0.01 ± 0.01ab 0.02 ± 0.01b Not Detected 
C 20:5n-3 0.05 ± 0.02a 0.09 ± 0.02ab 0.05 ± 0.01a 0.12 ± 0.07b 
C 22:5n-3 0.11 ± 0.04 0.10 ± 0.02 0.23 ± 0.05 0.08 ± 0.02 
C 22:6n-3 2.24 ± 0.62a 3.17 ± 0.64a 6.74 ± 0.58b 2.30 ± 1.27a 
N-3 2.43 ± 0.64a 3.39 ± 0.66a 7.05 ± 0.62b 2.52 ± 1.28a 
     
HUFA 9.77 ± 1.71 10.98 ± 2.46 13.90 ± 1.01 8.54 ± 3.68 
PUFA 12.85 ± 2.24 14.09 ± 3.09 16.37 ± 1.21 12.13 ± 3.33 
Total 28.92 ± 6.52 32.61 ± 6.23 38.49 ± 4.06 29.37 ± 6.40 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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Table D.6. Concentration of fatty acids in liver PC in DHA deficient diet (TWD 
DHA-) fed rats at baseline, during pregnancy, and 7 days post partum (µg/mg) 
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 0.20 ± 0.04 0.18 ± 0.07 0.26 ± 0.05 0.20 ± 0.03 
C 16:0 5.82 ± 0.83a 5.96 ± 0.66a 9.08 ± 1.45b 5.88 ± 0.45a 
C 18:0 9.57 ± 1.23 11.49 ± 1.88 8.13 ± 1.31 8.25 ± 1.13 
C 20:0 0.03 ± 0.01 0.02 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 
C 22:0 0.03 ± 0.01 0.03 ± 0.01 0.04 ± 0.01 0.02 ± 0.01 
C 24:0 0.03 ± 0.01 0.03 ± 0.01 0.05 ± 0.01 0.04 ± 0.01 
SFA 15.96 ± 1.98 17.79 ± 2.6 17.81 ± 2.61 14.89 ± 1.58 
     
C 14:1 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 001 
C 16:1 0.09 ± 0.02 0.16 ± 0.07 0.17 ± 0.05 0.16 ± 0.04 
C 18:1n-7 0.44 ± 0.05 0.43 ± 0.04 0.46 ± 0.07 0.53 ± 0.09 
C 18:1n-9 2.28 ± 0.56a 2.20 ± 0.84a 3.50 ± 0.61b 3.59 ± 0.66b 
C 20:1n-9 0.03 ± 0.01a 0.02 ± 0.01a 0.03 ± 0.01ab 0.04 ± 0.01b 
C 22:1n-9 0.07 ± 0.02 0.07 ± 0.02 0.06 ± 0.02 0.04 ± 0.02 
C 24:1n-9 0.04 ± 0.01 0.04 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 
MUFA 2.96 ± 0.61 2.93 ± 0.95 4.26 ± 0.71 4.4 ± 0.77 
     
C 18:2n-6 3.05 ± 0.33 3.07 ± 0.20 2.67 ± 0.48 2.87 ± 0.41 
C 18:3n-6 0.08 ± 0.01a 0.11 ± 0.02a 0.16 ± 0.04a 0.31 ± 0.04b 
C 20:2n-6 0.03 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 
C 20:3n-6 0.12 ± 0.02 0.08 ± 0.01 0.05 ± 0.01 0.14 ± 0.02 
C 20:4n-6 8.36 ± 1.31 9.86 ± 1.81 7.22 ± 1.46 7.68 ± 1.27 
C 22:2n-6 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.01 ± 0.01 
C 22:4n-6 0.06 ± 0.01a 0.06 ± 0.01a 0.20 ± 0.02b 0.04 ± 0.01a 
C 22:5n-6 0.09 ± 0.03a 0.16 ± 0.10a 1.52 ± 0.38b 0.22 ± 0.03a 
N-6 11.80 ± 1.54 13.39 ± 1.86 11.89 ± 1.82 11.3 ± 1.52 
     
C 18:3n-3 0.03 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 
C 20:3n-3 0.01 ± 0.01a 0.01 ± 0.01a 0.02 ± 0.01b 0.01 ± 0.01a 
C 20:5n-3 0.04 ± 0.02 0.04 ± 0.01 0.04 ± 0.01 0.06 ± 0.01 
C 22:5n-3 0.13 ± 0.03 0.15 ± 0.01 0.27 ± 0.05 0.16 ± 0.03 
C 22:6n-3 1.94 ± 0.32ab 2.73 ± 0.57ab 3.18 ± 0.56a 1.28 ± 0.41b 
N-3 2.14 ± 0.33ab 2.96 ± 0.58ab 3.55 ± 0.61a 1.52 ± 0.41b 
     
HUFA 10.74 ± 1.61 13.09 ± 2.48 12.52 ± 1.81 9.58 ± 1.65 
PUFA 13.95 ± 1.83 16.35 ± 2.43 15.43 ± 2.28 12.82 ± 1.85 
Total 32.87 ± 4.00 37.07 ± 5.81 37.50 ± 5.34 32.10 ± 3.61 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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Appendix E. Liver PE 
Table E.1. Relative percent of fatty acids in liver PE in chow fed rats at baseline, 
during pregnancy, and 7 days post partum 
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 0.75 ± 0.32ab 0.63 ± 0.20ab 0.92 ± 0.28a 0.43 ± 0.13b 
C 16:0 15.56 ± 1.62a 15.67 ± 2.02a 20.27 ± 0.81b 15.45 ± 0.41a 
C 18:0 29.70 ± 2.31a 31.22 ± 3.54a 23.20 ± 1.13b 27.75 ± 0.77a 
C 20:0 0.14 ± 0.04a 0.10 ± 0.02ab 0.14 ± 0.03a 0.05 ± 0.01b 
C 22:0 0.12 ± 0.03ab 0.13 ± 0.08ab 0.17 ± 0.07a 0.06 ± 0.02b 
C 24:0 0.13 ± 0.05 0.13 ± 0.07 0.19 ± 0.06 0.14 ± 0.03 
SFA 47.68 ± 0.89a 48.47 ± 1.31a 46.77 ± 1.53ab 45.11 ± 0.45b 
     C 14:1 0.03 ± 0.01 0.03 ± 0.02 0.06 ± 0.03 0.02 ± 0.01 
C 16:1 0.13 ± 0.02a 0.46 ± 0.35ab 0.86 ± 0.49b 0.29 ± 0.09a 
C 18:1n-7 1.02 ± 0.11ab 0.84 ± 0.11ab 0.73 ± 0.15a 1.05 ± 0.14b 
C 18:1n-9 6.65 ± 2.58 3.94 ± 1.02 9.26 ± 3.64 6.83 ± 1.55 
C 20:1n-9 0.12 ± 0.05 0.07 ± 0.03 0.09 ± 0.02 0.12 ± 0.02 
C 22:1n-9 0.40 ± 0.10a 0.34 ± 0.12a 0.40 ± 0.11a 0.15 ± 0.05b 
C 24:1n-9 0.20 ± 0.09 0.17 ± 0.13 0.16 ± 0.06 0.10 ± 0.02 
MUFA 8.53 ± 2.69 5.89 ± 1.57 11.58 ± 3.85 8.58 ± 1.68 
     C 18:2n-6 5.98 ± 1.07a 4.48 ± 0.24ab 2.86 ± 0.42b 5.64 ± 0.97a 
C 18:3n-6 0.16 ± 0.04a 0.14 ± 0.06a 0.09 ± 0.03a 0.28 ± 0.03b 
C 20:2n-6 0.12 ± 0.04 0.13 ± 0.03 0.13 ± 0.03 0.16 ± 0.02 
C 20:3n-6 0.29 ± 0.03a 0.29 ± 0.06a 0.12 ± 0.03b 0.58 ± 0.10c 
C 20:4n-6 21.57 ± 3.21a 23.31 ± 3.07a 13.24 ± 1.20b 21.27 ± 1.58a 
C 22:2n-6 0.10 ± 0.05ab 0.13 ± 0.07a 0.09 ± 0.04ab 0.04 ± 0.01b 
C 22:4n-6 0.54 ± 0.09a 0.56 ± 0.12a 1.07 ± 0.11b 0.68 ± 0.08a 
C 22:5n-6 0.25 ± 0.06a 0.44 ± 0.25ac 3.95 ± 0.71b 1.42 ± 0.39c 
N-6 29.01 ± 3.29a 29.48 ± 2.81a 21.54 ± 1.66b 30.09 ± 2.18a 
     C 18:3n-3 0.21 ± 0.10 0.13 ± 0.03 0.16 ± 0.05 0.09 ± 0.03 
C 20:3n-3 0.05 ± 0.02ab 0.07 ± 0.05ab 0.11 ± 0.04a 0.02 ± 0.01b 
C 20:5n-3 0.24 ± 0.07ab 0.25 ± 0.05ab 0.11 ± 0.02a 0.37 ± 0.09b 
C 22:5n-3 1.09 ± 0.26a 1.27 ± 0.19a 1.27 ± 0.19a 2.20 ± 0.23b 
C 22:6n-3 11.22 ± 2.16a 13.77 ± 2.35ab 17.46 ± 1.82b 12.47 ± 1.07a 
N-3 12.81 ± 1.92a 15.49 ± 2.44ab 19.11 ± 1.88b 15.14 ± 1.33a 
     HUFA 35.25 ± 3.82 39.96 ± 1.58 37.32 ± 3.61 38.83 ± 1.81 
PUFA 41.82 ± 3.33 44.97 ± 1.31 40.65 ± 3.40 45.22 ± 1.99 
Total 10.05 ± 1.49 14.33 ± 2.59 10.69 ± 5.01 16.64 ± 9.68 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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Table E.2. Relative percent of fatty acids in liver PE in high DHA diet (TWD 
DHA+) fed rats at baseline, during pregnancy, and 7 days post partum 
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 0.92 ± 0.37 0.77 ± 0.19 0.68 ± 0.20 0.68 ± 0.13 
C 16:0 15.22 ± 1.03ab 14.96 ± 0.54ab 17.32 ± 1.32a 14.51 ± 0.94b 
C 18:0 28.97 ± 2.66 30.16 ± 0.87 26.79 ± 1.74 27.75 ± 1.95 
C 20:0 0.12 ± 0.05 0.10 ± 0.02 0.10 ± 0.04 0.07 ± 0.02 
C 22:0 0.13 ± 0.05 0.12 ± 0.02 0.13 ± 0.01 0.10 ± 0.03 
C 24:0 0.14 ± 0.03 0.13 ± 0.03 0.13 ± 0.03 0.16 ± 0.03 
SFA 46.81 ± 2.25 46.99 ± 1.07 47.00 ± 0.31 44.99 ± 1.12 
     C 14:1 0.05 ± 0.06 0.04 ± 0.01 0.04 ± 0.01 0.03 ± 0 
C 16:1 0.12 ± 0.04a 0.66 ± 0.12b 0.45 ± 0.23ab 0.49 ± 0.16ab 
C 18:1n-7 0.85 ± 0.26ab 0.60± 0.07a 0.60 ± 0.05a 1.04 ± 0.21b 
C 18:1n-9 7.09 ± 3.42 5.99 ± 2.35 7.85 ± 2.81 8.39 ± 2.38 
C 20:1n-9 0.11 ± 0.06 0.07 ± 0.01 0.08 ± 0.02 0.12 ± 0.02 
C 22:1n-9 0.38 ± 0.11a 0.29 ± 0.06ab 0.39 ± 0.16a 0.18 ± 0.05b 
C 24:1n-9 0.23 ± 0.07 0.20 ± 0.07 0.11 ± 0.03 0.42 ± 0.67 
MUFA 8.93 ± 3.75 7.89 ± 2.49 9.54 ± 3.09 10.73 ± 2.34 
     C 18:2n-6 4.75 ± 2.06a 2.87 ± 0.76b 1.84 ± 0.34b 3.57 ± 0.80ab 
C 18:3n-6 0.12 ± 0.04a 0.09 ± 0.03a 0.05 ± 0.01ab 0.25 ± 0.04b 
C 20:2n-6 0.08 ± 0.03 0.07 ± 0.01 0.09 ± 0.01 0.06 ± 0.02 
C 20:3n-6 0.25 ± 0.03ac 0.21 ± 0.02a 0.10 ± 0.02b 0.33 ± 0.08c 
C 20:4n-6 19.72 ± 2.72a 18.19 ± 1.50a 13.41 ± 0.73b 18.56 ± 1.60a 
C 22:2n-6 0.08 ± 0.03 0.09 ± 0.02 0.05 ± 0.02 0.05 ± 0.01 
C 22:4n-6 0.45 ± 0.06ac 0.30 ± 0.05ab 0.59 ± 0.10c 0.26 ± 0.06b 
C 22:5n-6 0.27 ± 0.23a 0.19 ± 0.06a 1.83 ± 0.30b 0.21 ± 0.04a 
N-6 25.73 ± 2.73a 22.01 ± 1.51ab 17.96 ± 0.50b 23.29 ± 2.29a 
     C 18:3n-3 0.33 ± 0.44a 0.10 ± 0.03ab 0.11 ± 0.02ab 0.06 ± 0.02b 
C 20:3n-3 0.05 ± 0.03 0.09 ± 0.02 0.07 ± 0.01 0.05 ± 0.02 
C 20:5n-3 0.19 ± 0.03ab 0.34 ± 0.07ac 0.10 ± 0.01b 0.49 ± 0.27c 
C 22:5n-3 0.68 ± 0.23 0.58 ± 0.08 0.69 ± 0.12 0.53 ± 0.05 
C 22:6n-3 15.16 ± 3.51a 21.17 ± 1.72b 23.87 ± 2.04b 17.91 ± 1.67a 
N-3 16.41 ± 2.98a 22.29 ± 1.72bc 24.84 ± 2.08c 19.03 ± 1.54ab 
     HUFA 36.78 ± 5.43 41.07 ± 2.54 40.66 ± 2.62 38.34 ± 1.21 
PUFA 42.14 ± 3.53 44.29 ± 2.25 42.80 ± 2.51 42.32 ± 1.71 
Total 10.89 ± 0.77 17.37 ± 3.78 13.92 ± 2.39 11.71 ± 1.73 
Values with different superscripts are significantly different by Tukey’s post hoc test (p<0.05) 
following significant F-value by one-way ANOVA  
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Table E.3.  Relative percent of fatty acids in liver PE in DHA deficient diet (TWD 
DHA-) fed rats at baseline, during pregnancy, and 7 days post partum 
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 0.93 ± 0.14 0.68 ± 0.17 0.91 ± 0.28 0.52 ± 0.09 
C 16:0 15.73 ± 0.65a 13.37 ± 0.63b 16.26 ± 1.98a 13.75 ± 0.26a 
C 18:0 28.42 ± 0.91ab 32.34 ± 2.86a 27.39 ± 3.03b 28.15 ± 0.66ab 
C 20:0 0.12 ± 0.03 0.10 ± 0.01 0.11 ± 0.03 0.06 ± 0.01 
C 22:0 0.13 ± 0.02 0.13 ± 0.08 0.16 ± 0.07 0.07 ± 0.03 
C 24:0 0.16 ± 0.02 0.16 ± 0.05 0.19 ± 0.06 0.19 ± 0.03 
SFA 47.04 ± 0.71a 47.36 ± 2.19a 46.26 ± 0.54ab 44.13 ± 0.97b 
     C 14:1 0.04 ± 0.01 0.03 ± 0.02 0.05 ± 0.02 0.02 ± 0.01 
C 16:1 0.21 ± 0.12a 0.53 ± 0.24ab 0.67 ± 0.34b 0.38 ± 0.08ab 
C 18:1n-7 0.93 ± 0.07ab 0.67 ± 0.05a 0.72 ± 0.04a 1.20 ± 0.22b 
C 18:1n-9 8.28 ± 2.89 6.34 ± 3.34 8.80 ± 1.56 7.98 ± 0.70 
C 20:1n-9 0.14 ± 0.01a 0.07 ± 0.03b 0.09 ± 0.02ab 0.12 ± 0.01ab 
C 22:1n-9 0.43 ± 0.07a 0.31 ± 0.08ab 0.34 ± 0.07a 0.16 ± 0.03b 
C 24:1n-9 0.35 ± 0.33 0.22 ± 0.13 0.11 ± 0.03 0.14 ± 0.09 
MUFA 10.43 ± 2.81 8.24 ± 3.62 10.82 ± 1.81 10.04 ± 0.6 
     C 18:2n-6 4.44 ± 0.38a 3.05 ± 0.5ab 2.35 ± 0.49b 3.91 ± 0.45ab 
C 18:3n-6 0.15 ± 0.02a 0.12 ± 0.04a 0.09 ± 0.04a 0.34 ± 0.05b 
C 20:2n-6 0.08 ± 0.01 0.07 ± 0.03 0.09 ± 0.03 0.07 ± 0.01 
C 20:3n-6 0.25 ± 0.03ac 0.17 ± 0.01ab 0.10 ± 0.02b 0.32 ± 0.08c 
C 20:4n-6 20.31 ± 2.03a 22.00 ± 2.63a 15.91 ± 2.79b 24.14 ± 1.13a 
C 22:2n-6 0.08 ± 0.01ab 0.12 ± 0.03a 0.08 ± 0.02ab 0.05 ± 0.01b 
C 22:4n-6 0.52 ± 0.09a 0.5 ± 0.06a 1.14 ± 0.15b 0.56 ± 0.09a 
C 22:5n-6 0.46 ± 0.17a 0.79 ± 0.35ac 7.07 ± 1.51b 1.72 ± 0.36c 
N-6 26.29 ± 2.18a 26.82 ± 2.12ab 26.82 ± 1.86ab 31.11 ± 1.78b 
     C 18:3n-3 0.22 ± 0.08 0.10 ± 0.03 0.13 ± 0.05 0.06 ± 0.02 
C 20:3n-3 0.07 ± 0.02ab 0.09 ± 0.06a 0.10 ± 0.05a 0.02 ± 0.01b 
C 20:5n-3 0.16 ± 0.04 0.14 ± 0.02 0.10 ± 0.01 0.27 ± 0.07 
C 22:5n-3 0.83 ± 0.23a 0.86 ± 0.13ab 1.00 ± 0.11ab 1.23 ± 0.28b 
C 22:6n-3 12.70 ± 1.54 15.64 ± 1.47 13.59 ± 0.80 11.79 ± 1.53 
N-3 13.96 ± 1.36 16.84 ± 1.51 14.91 ± 0.81 13.37 ± 1.27 
     HUFA 35.29 ± 2.67 40.20 ± 2.72 36.37 ± 7.37 40.05 ± 1.14 
PUFA 40.26 ± 2.41 43.66 ± 2.23 41.73 ± 1.88 44.48 ± 1.21 
Total 11.18 ± 2.93 19.23 ± 8.60 14.67 ± 2.58 11.90 ± 1.84 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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Table E.4. Concentration of fatty acids in liver PE in chow fed rats at baseline, 
during pregnancy, and 7 days post partum (µg/mg) 
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 0.10 ± 0.03 0.09 ± 0.03 0.09 ± 0.03 0.07 ± 0.03 
C 16:0 1.68 ± 0.28 2.24 ± 0.37 2.19 ± 1.04 2.59 ± 1.47 
C 18:0 2.91 ± 0.55 4.52 ± 1.10 2.49 ± 1.13 4.68 ± 2.8 
C 20:0 0.02 ± 0.01ab 0.01 ± 0.01ab 0.01 ± 0.01ab 0.01 ± 0.01b 
C 22:0 0.01 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.01 ± 0.01 
C 24:0 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 
SFA 4.87 ± 0.87 6.99 ± 1.25 5.00 ± 2.23 7.58 ± 4.36 
     
C 14:1 0.01 ± 0.01 Not Detected 0.01 ± 0.01 Not Detected 
C 16:1 0.02 ± 0.01a 0.07 ± 0.05ab 0.08 ± 0.03b 0.05 ± 0.02ab 
C 18:1n-7 0.11 ± 0.01 0.12 ± 0.02 0.08 ± 0.03 0.17 ± 0.09 
C 18:1n-9 0.83 ± 0.23 0.55 ± 0.12 1.01 ± 0.5 1.09 ± 0.50 
C 20:1n-9 0.02 ± 0.01ab 0.01 ± 0.01a 0.01 ± 0.01a 0.02 ± 0.01b 
C 22:1n-9 0.04 ± 0.01 0.05 ± 0.01 0.04 ± 0.02 0.02 ± 0.01 
C 24:1n-9 0.02 ± 0.01 0.02 ± 0.02 0.02 ± 0.01 0.02 ± 0.01 
MUFA 1.04 ± 0.24 0.83 ± 0.19 1.24 ± 0.56 1.37 ± 0.62 
     
C 18:2n-6 0.69 ± 0.06 0.65 ± 0.12 0.32 ± 0.16 0.96 ± 0.66 
C 18:3n-6 0.02 ± 0.01ab 0.02 ± 0.01ab 0.01 ± 0.01a 0.05 ± 0.03b 
C 20:2n-6 0.01 ± 0.01a 0.02 ± 0.01ab 0.01 ± 0.01a 0.03 ± 0.01b 
C 20:3n-6 0.03 ± 0.01a 0.04 ± 0.01a 0.01 ± 0.01a 0.10 ± 0.06b 
C 20:4n-6 2.05 ± 0.4 3.39 ± 0.93 1.43 ± 0.71 3.61 ± 2.27 
C 22:2n-6 0.01 ± 0.01a 0.02 ± 0.01b 0.01 ± 0.01ab 0.01 ± 0.01a 
C 22:4n-6 0.06 ± 0.01 0.08 ± 0.02 0.12 ± 0.06 0.11 ± 0.06 
C 22:5n-6 0.03 ± 0.01a 0.06 ± 0.04a 0.44 ± 0.27b 0.23 ± 0.12ab 
N-6 2.89 ± 0.44 4.28 ± 1.03 2.36 ± 1.20 5.09 ± 3.16 
     
C 18:3n-3 0.04 ± 0.03a 0.02 ± 0.01ab 0.02 ± 0.01b 0.02 ± 0.01b 
C 20:3n-3 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 Not Detected 
C 20:5n-3 0.02 ± 0.01a 0.04 ± 0.01ab 0.01 ± 0.01a 0.07 ± 0.06b 
C 22:5n-3 0.12 ± 0.03a 0.18 ± 0.05a 0.14 ± 0.07a 0.38 ± 0.23b 
C 22:6n-3 1.05 ± 0.23 1.99 ± 0.46 1.92 ± 1.04 2.14 ± 1.32 
N-3 1.24 ± 0.24 2.24 ± 0.5 2.10 ± 1.12 2.60 ± 1.61 
     
HUFA 3.36 ± 0.68 5.79 ± 1.23 4.09 ± 2.15 6.62 ± 4.09 
PUFA 4.13 ± 0.67 6.51 ± 1.34 4.45 ± 2.31 7.69 ± 4.76 
Total 10.05 ± 1.49 14.33 ± 2.59 10.69 ± 5.01 16.64 ± 9.68 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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Table E.5. Concentration of fatty acids in liver PE in high DHA diet (TWD DHA+) 
fed rats at baseline, during pregnancy, and 7 days post partum (µg/mg) 
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 0.10 ± 0.02 0.13 ± 0.04 0.09 ± 0.03 0.08 ± 0.02 
C 16:0 1.72 ± 0.05 2.62 ± 0.56 2.41 ± 0.32 1.72 ± 0.33 
C 18:0 3.15 ± 0.26 5.29 ± 1.21 3.77 ± 0.80 3.28 ± 0.64 
C 20:0 0.01 ± 0ab 0.02 ± 0.01a 0.01 ± 0.01ab 0.01 ± 0.01b 
C 22:0 0.01 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.01 ± 0.01 
C 24:0 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 
SFA 5.19 ± 0.31 8.24 ± 1.86 6.59 ± 1.15 5.32 ± 0.99 
     
C 14:1 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 001 Not Detected 
C 16:1 0.01 ± 0.01a 0.12 ± 0.03b 0.06 ± 0.03ab 0.06 ± 0.01a 
C 18:1n-7 0.09 ± 0.02 0.10 ± 0.02 0.08 ± 0.02 0.12 ± 0.03 
C 18:1n-9 0.76 ± 0.15 1.04 ± 0.43 1.08 ± 0.35 0.99 ± 0.29 
C 20:1n-9 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 001 0.01 ± 0.01 
C 22:1n-9 0.04 ± 0.01ab 0.05 ± 0.01a 0.06 ± 0.03a 0.02 ± 0.01b 
C 24:1n-9 0.03 ± 0.01 0.04 ± 0.02 0.02 ± 0.01 0.05 ± 0.09 
MUFA 0.96 ± 0.16 1.38 ± 0.48 1.31 ± 0.40 1.27 ± 0.32 
     
C 18:2n-6 0.43 ± 0.04 0.50 ± 0.15 0.26 ± 0.08 0.41 ± 0.03 
C 18:3n-6 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 0.03 ± 0.01 
C 20:2n-6 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 
C 20:3n-6 0.03 ± 0,01 0.04 ± 0.01 0.01 ± 0.01 0.04 ± 0.01 
C 20:4n-6 2.07 ± 0.26 3.17 ± 0.66 1.89 ± 0.38 2.17 ± 0.32 
C 22:2n-6 0.01 ± 0.01a 0.02 ± 0.01b 0.01 ± 0.01a 0.01 ± 0.01a 
C 22:4n-6 0.05 ± 0.01 0.05 ± 0.02 0.08 ± 0.02 0.03 ± 0.01 
C 22:5n-6 0.02 ± 0.01a 0.03 ± 0.02ab 0.25 ± 0.03b 0.03 ± 0.01a 
N-6 2.63 ± 0.31 3.83 ± 0.75 2.52 ± 0.48 2.72 ± 0.33 
     
C 18:3n-3 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.01 ± 0.01 
C 20:3n-3 0.01 ± 0.01a 0.02 ± 0.01b 0.01 ± 0.01ab 0.01 ± 0.01a 
C 20:5n-3 0.03 ± 0.01a 0.06 ± 0.01a 0.01 ± 0.01b 0.05 ± 0.03ab 
C 22:5n-3 0.06 ± 0.01 0.10 ± 0.02 0.10 ± 0.03 0.06 ± 0.01 
C 22:6n-3 1.78 ± 0.11a 3.73 ± 1.03b 3.36 ± 0.72bc 2.13 ± 0.51ac 
N-3 1.89 ± 0.12a 3.92 ± 1.06b 3.49 ± 0.75ab 2.26 ± 0.51a 
     
HUFA 4.03 ± 0.37 7.20 ± 1.72 5.71 ± 1.16 4.52 ± 0.78 
PUFA 4.52 ± 0.4 7.75 ± 1.77 6.02 ± 1.21 4.98 ± 0.78 
Total 10.89 ± 0.77 17.37 ± 3.78 13.92 ± 2.39 11.71 ± 1.73 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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Table E.6. Concentration of fatty acids in liver PE in DHA deficient diet (TWD 
DHA-) fed rats at baseline, during pregnancy, and 7 days post partum (µg/mg) 
Name baseline 15 days 20 days 
7 days 
post partum 
C 14:0 0.10 ± 0.04ab 0.13 ± 0.03a 0.14 ± 0.04a 0.06 ± 0.02b 
C 16:0 1.79 ± 0.51 2.85 ± 1.49 2.46 ± 0.41 1.66 ± 0.27 
C 18:0 3.26 ± 0.75a 6.21 ± 2.57b 3.98 ± 0.87ab 3.40 ± 0.53a 
C 20:0 0.01 ± 0.01ab 0.02 ± 0.01a 0.02 ± 0.01a 0.01 ± 0.01b 
C 22:0 0.01 ± 0.01ab 0.02 ± 0.01a 0.02 ± 0.01a 0.01 ± 0.01b 
C 24:0 0.02 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 
SFA 5.37 ± 1.38 9.37 ± 4.06 6.87 ± 1.26 5.33 ± 0.86 
     
C 14:1 Not Detected 0.01 ± 0.01ab 0.01 ± 0.01b Not Detected 
C 16:1 0.03 ± 0.02a 0.11 ± 0.03b 0.12 ± 0.04b 0.05 ± 0.01a 
C 18:1n-7 0.11 ± 0.03 0.17 ± 0.13 0.11 ± 0.02 0.14 ± 0.04 
C 18:1n-9 0.94 ± 0.66 1.29 ± 0.52 1.32 ± 0.31 0.96 ± 0.16 
C 20:1n-9 0.02 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 
C 22:1n-9 0.05 ± 0.02a 0.05 ± 0.02a 0.05 ± 0.01a 0.02 ± 0.01b 
C 24:1n-9 0.04 ± 0.03 0.04 ± 0.02 0.02 ± 0.01 0.02 ± 0.01 
MUFA 1.18 ± 0.73 1.70 ± 0.64 1.63 ± 0.35 1.21 ± 0.20 
     
C 18:2n-6 0.52 ± 0.17 0.96 ± 1.11 0.35 ± 0.09 0.47 ± 0.05 
C 18:3n-6 0.02 ± 0.01 0.04 ± 0.04 0.01 ± 0.01 0.04 ± 0.01 
C 20:2n-6 0.01 ± 0.01 0.02 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 
C 20:3n-6 0.03 ± 0.01 0.04 ± 0.02 0.01 ± 0.01 0.04 ± 0.01 
C 20:4n-6 2.33 ± 0.37a 4.57 ± 2.61b 2.23 ± 0.38a 2.90 ± 0.39ab 
C 22:2n-6 0.01 ± 0.02a 0.02 ± 0.01b 0.01 ± 0.01a 0.01 ± 0.01a 
C 22:4n-6 0.06 ± 0.01a 0.08 ± 0.02a 0.17 ± 0.04b 0.07 ± 0.02a 
C 22:5n-6 0.06 ± 0.01a 0.14 ± 0.06a 1.06 ± 0.23b 0.20 ± 0.03a 
N-6 3.04 ± 0.57 5.86 ± 3.76 3.86 ± 0.60 3.73 ± 0.45 
     
C 18:3n-3 0.03 ± 0.02 0.02 ± 0.01 0.02 ± 0.01 0.01 ± 0.01 
C 20:3n-3 0.01 ± 0.02ac 0.02 ± 0.01b 0.02 ± 0.01ab Not Detected 
C 20:5n-3 0.02 ± 0.01 0.03 ± 0.01 0.01 ± 0.01 0.03 ± 0.01 
C 22:5n-3 0.10 ± 0.02 0.15 ± 0.01 0.15 ± 0.03 0.14 ± 0.02 
C 22:6n-3 1.42 ± 0.25 2.64 ± 0.27 2.10 ± 0.48 1.44 ± 0.39 
N-3 1.58 ± 0.29 2.85 ± 0.27 2.30 ± 0.52 1.63 ± 0.39 
     
HUFA 4.04 ± 0.65a 7.65 ± 2.64b 5.45 ± 1.62ab 4.83 ± 0.78ab 
PUFA 4.62 ± 0.84 8.72 ± 3.79 6.16 ± 1.08 5.36 ± 0.81 
Total 11.18 ± 2.93 19.23 ± 8.60 14.67 ± 2.58 11.90 ± 1.84 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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Appendix F. Pups whole body Total Lipids 
Table F.1.  Relative percent of fatty acids in whole body pups of chow fed rats 
during pregnancy, and 7 days post partum  
Name 15 days 20 days 
7 days 
post partum 
C 14:0 2.04 ± 0.24a 2.26 ± 0.18a 4.59 ± 1.19b 
C 16:0 26.74 ± 0.73a 26.27 ± 0.73a 22.08 ± 0.82b 
C 18:0 14.53 ± 0.65a 13.05 ± 0.16a 9.14 ± 1.89b 
C 20:0 0.28 ± 0.08 0.26 ± 0.01 0.19 ± 0.05 
C 22:0 0.16 ± 0.03a 0.38 ± 0.04b 0.23 ± 0.07ab 
C 24:0 0.20 ± 0.06a 1.05 ± 0.05b 0.65 ± 0.22b 
SFA 45.47 ± 0.74a 43.99 ± 0.70ab 42.03 ± 1.30b 
    C 14:1 0.03 ± 0.02 Not detected 0.03 ± 0.01 
C 16:1 2.61 ± 0.14a 2.72 ± 0.26a 0.99 ± 0.11b 
C 18:1n-7 3.54 ± 0.16a 3.42 ± 0.15a 2.03 ± 0.21b 
C 18:1n-9 15.90 ± 0.88 15.14 ± 0.42 15.81 ± 1.26 
C 20:1n-9 0.32 ± 0.07 0.22 ± 0.01 0.28 ± 0.03 
C 22:1n-9 0.40 ± 0.24 0.23 ± 0.05 0.09 ± 0.03 
C 24:1n-9 0.26 ± 0.08 0.33 ± 0.03 0.17 ± 0.07 
MUFA 23.44 ± 0.87a 22.19 ± 0.79ab 19.66 ± 1.13b 
    C 18:2n-6 3.49 ± 0.29a 7.46 ± 0.70b 18.06 ± 2.25c 
C 18:3n-6 0.25 ± 0.05a 0.18 ± 0.02a 0.38 ± 0.08b 
C 20:2n-6 0.36 ± 0.13a 0.34 ± 0.09a 0.76 ± 0.06b 
C 20:3n-6 0.52 ± 0.09a 0.71 ± 0.09b 1.08 ± 0.07c 
C 20:4n-6 13.88 ± 0.78a 11.49 ± 0.10a 8.61 ± 2.00b 
C 22:2n-6 0.10 ± 0.03 0.14 ± 0.09 0.05 ± 0.02 
C 22:4n-6 2.96 ± 0.30a 1.93 ± 0.08b 1.44 ± 0.29b 
C 22:5n-6 1.57 ± 0.23a 1.14 ± 0.12a 0.44 ± 0.15b 
N-6 23.13 ± 0.81a 23.39 ± 0.81a 30.84 ± 0.89b 
    C 18:3n-3 0.09 ± 0.06 0.21 ± 0.09 0.76 ± 0.24 
C 20:3n-3 0.06 ± 0.02 0.03 ± 0.02 0.06 ± 0.01 
C 20:5n-3 0.12 ± 0.08a 0.16 ± 0.04ab 0.25 ± 0.04b 
C 22:5n-3 0.26 ± 0.12a 0.46 ± 0.07a 1.03 ± 0.11b 
C 22:6n-3 2.61 ± 0.23a 4.34 ± 0.56b 2.57 ± 0.68a 
N-3 3.15 ± 0.29a 5.21 ± 0.72b 4.67 ± 0.53b 
    HUFA 21.98 ± 1.10a 20.26 ± 0.71a 15.48 ± 3.23b 
PUFA 26.28 ± 0.82a 28.59 ± 1.42a 35.50 ± 1.22b 
Total 8.24 ± 1.29 11.30 ± 2.27 33.44 ± 11.97 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA  
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Table F.2. Relative percent of fatty acids in whole body pups of high DHA diet 
(TWD DHA+) fed rats during pregnancy, and 7 days post partum  
Name 15 days 20 days 
7 days 
post partum 
C 14:0 2.23 ± 0.26a 2.48 ± 0.09a 4.56 ± 0.72b 
C 16:0 26.55 ± 0.3a 25.06 ± 0.51a 20.96 ± 0.66b 
C 18:0 13.94 ± 0.44a 13.22 ± 0.37a 6.89 ± 0.88b 
C 20:0 0.25 ± 0.09a 0.30 ± 0.08a 0.10 ± 0.04b 
C 22:0 0.14 ± 0.07a 0.35 ± 0.10b 0.09 ± 0.04a 
C 24:0 0.15 ± 0.05a 0.79 ± 0.11b 0.20 ± 0.13a 
SFA 45.44 ± 0.66a 43.60 ± 0.77a 38.23 ± 0.64b 
    C 14:1 0.03 ± 0.01a 0.03 ± 0.01a 0.12 ± 0.02b 
C 16:1 2.65 ± 0.15a 2.60 ± 0.12a 1.54 ± 0.19b 
C 18:1n-7 3.59 ± 0.10a 3.38 ± 0.15a 2.29 ± 0.14b 
C 18:1n-9 17.12 ± 1.03a 16.81 ± 1.14a 30.33 ± 1.83b 
C 20:1n-9 0.38 ± 0.05a 0.25 ± 0.04a 0.51 ± 0.04c 
C 22:1n-9 0.24 ± 0.13 0.33 ± 0.13 0.07 ± 0.02 
C 24:1n-9 0.23 ± 0.09a 0.44 ± 0.14b 0.09 ± 0.04a 
MUFA 24.81 ± 1.09a 24.12 ± 1.34a 35.06 ± 1.79b 
    C 18:2n-6 3.19 ± 0.27a 6.35 ± 0.40b 12.69 ± 0.35c 
C 18:3n-6 0.19 ± 0.03a 0.18 ± 0.03a 0.32 ± 0.05b 
C 20:2n-6 0.31 ± 0.08a 0.31 ± 0.04a 0.65 ± 0.05b 
C 20:3n-6 0.52 ± 0.08a 0.72 ± 0.06b 0.85 ± 0.05b 
C 20:4n-6 12.62 ± 0.51a 11.00 ± 0.38a 4.16 ± 1.24b 
C 22:2n-6 0.13 ± 0.08a 0.06 ± 0.03ab 0.03 ± 0.01b 
C 22:4n-6 2.56 ± 0.16a 1.67 ± 0.12b 0.83 ± 0.21b 
C 22:5n-6 1.21 ± 0.13a 0.69 ± 0.15b 0.11 ± 0.05c 
N-6 20.73 ± 0.81 20.99 ± 0.71 19.63 ± 1.34 
    C 18:3n-3 0.07 ± 0.03 0.15 ± 0.07 0.59 ± 0.07 
C 20:3n-3 0.07 ± 0.03 0.05 ± 0.02 0.04 ± 0.01 
C 20:5n-3 0.10 ± 0.05a 0.21 ± 0.05b 0.19 ± 0.02b 
C 22:5n-3 0.27 ± 0.07a 0.29 ± 0.09ab 0.48 ± 0.13b 
C 22:6n-3 3.60 ± 0.35a 6.00 ± 0.54b 2.65 ± 0.81a 
N-3 4.11 ± 0.31a 6.70 ± 0.61b 3.95 ± 0.91a 
    HUFA 20.96 ± 0.96a 20.64 ± 0.51a 9.32 ± 2.46b 
PUFA 24.85 ± 1.08ab 27.70 ± 0.89a 23.59 ± 2.23b 
Total 8.90 ± 0.84a 9.96 ± 0.57a 94.03 ± 35.11b 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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Table F.3. Relative percent of fatty acids in whole body pups of DHA deficient diet 
(TWD DHA-) fed rats during pregnancy, and 7 days post partum 
Name 15 days 20 days 
7 days 
post partum 
C 14:0 2.40 ± 0.37a 2.33 ± 0.32a 4.86 ± 1.00b 
C 16:0 26.50 ± 0.97a 25.77 ± 0.69a 20.94 ± 1.52b 
C 18:0 13.87 ± 0.89a 12.93 ± 0.40a 6.46 ± 0.82b 
C 20:0 0.25 ± 0.07a 0.27 ± 0.05a 0.10 ± 0.02b 
C 22:0 0.20 ± 0.17a 0.44 ± 0.07b 0.07 ± 0.02a 
C 24:0 0.26 ± 0.44a 0.89 ± 0.06b 0.18 ± 0.06a 
SFA 44.98 ± 1.03a 43.31 ± 1.11a 38.13 ± 2.43b 
    C 14:1 0.04 ± 0.01a 0.02 ± 0.01a 0.12 ± 0.02b 
C 16:1 2.68 ± 0.09a 2.69 ± 0.16a 1.55 ± 0.29b 
C 18:1n-7 3.54 ± 0.17a 3.44 ± 0.18a 2.25 ± 0.16b 
C 18:1n-9 17.06 ± 0.66a 17.56 ± 1.46a 31.48 ± 1.25b 
C 20:1n-9 0.35 ± 0.04a 0.26 ± 0.05a 0.53 ± 0.10b 
C 22:1n-9 0.34 ± 0.20 0.31 ± 0.08 0.06 ± 0.01 
C 24:1n-9 0.16 ± 0.13ab 0.32 ± 0.07a 0.09 ± 0.03b 
MUFA 24.52 ± 0.67a 24.77 ± 1.67a 36.21 ± 1.30b 
    C 18:2n-6 3.75 ± 1.32a 6.19 ± 0.53b 12.76 ± 0.4c 
C 18:3n-6 0.22 ± 0.04 0.25 ± 0.09 0.31 ± 0.05 
C 20:2n-6 0.29 ± 0.05a 0.30 ± 0.08a 0.66 ± 0.10b 
C 20:3n-6 0.49 ± 0.10a 0.63 ± 0.05a 0.81 ± 0.09b 
C 20:4n-6 12.96 ± 1.06a 11.69 ± 0.93a 4.36 ± 1.02b 
C 22:2n-6 0.11 ± 0.06 0.08 ± 0.06 0.03 ± 0.01 
C 22:4n-6 2.65 ± 0.43a 2.05 ± 0.19b 0.99 ± 0.39b 
C 22:5n-6 1.63 ± 0.30a 1.85 ± 0.30a 0.30 ± 0.03b 
N-6 22.10 ± 0.92ab 23.04 ± 1.24a 20.24 ± 1.78b 
    C 18:3n-3 0.14 ± 0.07 0.15 ± 0.01 0.58 ± 0.05 
C 20:3n-3 0.09 ± 0.03a 0.03 ± 0.01b 0.04 ± 0.01b 
C 20:5n-3 0.09 ± 0.02 0.09 ± 0.05 0.16 ± 0.01 
C 22:5n-3 0.20 ± 0.10a 0.21 ± 0.12a 0.49 ± 0.10b 
C 22:6n-3 2.71 ± 0.59a 3.43 ± 0.41a 0.90 ± 0.21b 
N-3 3.22 ± 0.68 3.90 ± 0.35 2.17 ± 0.26 
    HUFA 20.82 ± 1.27a 19.98 ± 1.27a 8.06 ± 1.79b 
PUFA 25.33 ± 1.53ab 26.95 ± 1.35a 22.41 ± 2.04b 
Total 8.15 ± 1.20a 9.96 ± 0.22a 97.29 ± 19.46b 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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Table F.4. Concentration of fatty acids in whole body pups of chow fed rats during 
pregnancy, and 7 days post partum (µg/mg) 
Name 15 days 20 days 
7 days 
post partum 
C 14:0 0.17 ± 0.01 0.27 ± 0.03 1.68 ± 0.88 
C 16:0 2.32 ± 0.38 3.13 ± 0.64 7.66 ± 2.93 
C 18:0 1.26 ± 0.22a 1.55 ± 0.29ab 2.96 ± 0.54b 
C 20:0 0.02 ± 0.01a 0.03 ± 0.01a 0.06 ± 0.01b 
C 22:0 0.01 ± 0.01a 0.04 ± 0.01b 0.07 ± 0.01c 
C 24:0 0.02 ± 0.01a 0.12 ± 0.02b 0.20 ± 0.03c 
SFA 3.94 ± 0.64 5.24 ± 1.00 14.47 ± 5.21 
    
C 14:1 Not Detected Not Detected 0.01 ± 0.01 
C 16:1 0.23 ± 0.04 0.32 ± 0.07 0.35 ± 0.15 
C 18:1n-7 0.31 ± 0.05 0.41 ± 0.08 0.68 ± 0.19 
C 18:1n-9 1.37 ± 0.15a 1.80 ± 0.36a 5.55 ± 2.35b 
C 20:1n-9 0.03 ± 0.01 0.03 ± 0.01 0.10 ± 0.04 
C 22:1n-9 0.03 ± 0.02 0.03 ± 0.01 0.03 ± 0.01 
C 24:1n-9 0.02 ± 0.01a 0.04 ± 0.01ab 0.05 ± 0.01b 
MUFA 2.02 ± 0.25 2.64 ± 0.52 6.84 ± 2.73 
    
C 18:2n-6 0.30 ± 0.03a 0.89 ± 0.20a 6.42 ± 2.87b 
C 18:3n-6 0.02 ± 0.01 0.02 ± 0.01 0.14 ± 0.07 
C 20:2n-6 0.03 ± 0.01a 0.04 ± 0.01a 0.26 ± 0.10b 
C 20:3n-6 0.04 ± 0.01a 0.08 ± 0.01a 0.37 ± 0.12b 
C 20:4n-6 1.21 ± 0.23a 1.37 ± 0.28a 2.76 ± 0.44b 
C 22:2n-6 0.01 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 
C 22:4n-6 0.26 ± 0.06a 0.23 ± 0.04a 0.47 ± 0.10b 
C 22:5n-6 0.14 ± 0.04 0.14 ± 0.04 0.14 ± 0.02 
N-6 2.01 ± 0.36a 2.79 ± 0.57a 10.58 ± 3.68b 
    
C 18:3n-3 0.01 ± 0.01a 0.03 ± 0.01a 0.28 ± 0.17b 
C 20:3n-3 0.01 ± 0.01a Not Detected 0.02 ± 0.01b 
C 20:5n-3 0.01 ± 0.01a 0.02 ± 0.01a 0.09 ± 0.04b 
C 22:5n-3 0.02 ± 0.01a 0.05 ± 0.01a 0.34 ± 0.10b 
C 22:6n-3 0.23 ± 0.04a 0.52 ± 0.17a 0.82 ± 0.11b 
N-3 0.27 ± 0.04a 0.63 ± 0.20a 1.55 ± 0.41b 
    
HUFA 1.91 ± 0.36a 2.42 ± 0.56a 5.01 ± 0.91b 
PUFA 2.28 ± 0.40a 3.42 ± 0.76a 12.13 ± 4.09b 
Total 8.24 ± 1.29 11.30 ± 2.27 33.44 ± 11.97 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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Table F.5. Concentration of fatty acids in whole body pups of high DHA diet (TWD 
DHA+) fed rats during pregnancy, and 7 days post partum (µg/mg) 
Name 15 days 20 days 
7 days 
post partum 
C 14:0 0.21 ± 0.02a 0.26 ± 0.02a 4.57 ± 1.99b 
C 16:0 2.49 ± 0.24a 2.62 ± 0.18a 20.47 ± 8.00b 
C 18:0 1.30 ± 0.12a 1.38 ± 0.09a 6.46 ± 1.87b 
C 20:0 0.02 ± 0.01a 0.03 ± 0.01a 0.09 ± 0.01b 
C 22:0 0.01 ± 0.01a 0.04 ± 0.01b 0.08 ± 0.01c 
C 24:0 0.01 ± 0.01a 0.08 ± 0.01b 0.16 ± 0.03c 
SFA 4.25 ± 0.43a 4.55 ± 0.29a 37.19 ± 13.98b 
    
C 14:1 Not Detected Not Detected 0.11 ± 0.05b 
C 16:1 0.25 ± 0.03a 0.27 ± 0.01a 1.53 ± 0.69b 
C 18:1n-7 0.34 ± 0.03a 0.35 ± 0.01a 2.19 ± 0.76b 
C 18:1n-9 1.60 ± 0.15a 1.75 ± 0.08a 29.96 ± 12.6b 
C 20:1n-9 0.04 ± 0.01a 0.03 ± 0.01a 0.49 ± 0.19b 
C 22:1n-9 0.02 ± 0.01a 0.03 ± 0.01ab 0.06 ± 0.01b 
C 24:1n-9 0.02 ± 0.01a 0.05 ± 0.02b 0.08 ± 0.01c 
MUFA 2.32 ± 0.20a 2.51 ± 0.09a 34.54 ± 14.28b 
    
C 18:2n-6 0.30 ± 0.04a 0.66 ± 0.07a 12.34 ± 4.64b 
C 18:3n-6 0.02 ± 0.01a 0.02 ± 0.01a 0.32 ± 0.16b 
C 20:2n-6 0.03 ± 0.01a 0.03 ± 0.01a 0.63 ± 0.21b 
C 20:3n-6 0.05 ± 0.01a 0.08 ± 0.01a 0.82 ± 0.29b 
C 20:4n-6 1.18 ± 0.14a 1.15 ± 0.08a 3.73 ± 0.72b 
C 22:2n-6 0.01 ± 0.01a 0.01 ± 0.01a 0.02 ± 0.01b 
C 22:4n-6 0.24 ± 0.01a 0.17 ± 0.02a 0.77 ± 0.21b 
C 22:5n-6 0.11 ± 0.02a 0.07 ± 0.02a 0.10 ± 0.02b 
N-6 1.94 ± 0.20a 2.19 ± 0.18a 18.72 ± 6.16b 
    
C 18:3n-3 0.01 ± 0.01a 0.02 ± 0.01a 0.58 ± 0.22b 
C 20:3n-3 0.01 ± 0.01a 0.01 ± 0.01a 0.04 ± 0.01b 
C 20:5n-3 0.01 ± 0.01a 0.02 ± 0.01a 0.18 ± 0.06b 
C 22:5n-3 0.03 ± 0.01a 0.03 ± 0.01a 0.43 ± 0.08b 
C 22:6n-3 0.34 ± 0.05a 0.63 ± 0.08a 2.36 ± 0.37b 
N-3 0.39 ± 0.05a 0.70 ± 0.10a 3.59 ± 0.72b 
    
HUFA 1.96 ± 0.21a 2.16 ± 0.17a 8.42 ± 1.71b 
PUFA 2.33 ± 0.25a 2.90 ± 0.25a 22.31 ± 6.87b 
Total 8.9 ± 0.84a 9.96 ± 0.57a 94.03 ± 35.11b 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA 
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Table F.6. Concentration of fatty acids in whole body pups of DHA deficient diet 
(TWD DHA-) fed rats during pregnancy, and 7 days post partum (µg/mg) 
Name 15 days 20 days 
7 days 
post partum 
C 14:0 0.21 ± 0.05a 0.24 ± 0.03a 5.02 ± 1.98b 
C 16:0 2.27 ± 0.26a 2.70 ± 0.12a 21.26 ± 5.73b 
C 18:0 1.18 ± 0.11a 1.36 ± 0.06a 6.40 ± 0.75b 
C 20:0 0.02 ± 0.01a 0.03 ± 0.01a 0.10 ± 0.01b 
C 22:0 0.02 ± 0.02a 0.05 ± 0.01b 0.07 ± 0.01c 
C 24:0 0.03 ± 0.05a 0.09 ± 0.01b 0.17 ± 0.03c 
SFA 3.86 ± 0.49a 4.54 ± 0.18a 38.65 ± 10.07b 
    
C 14:1 Not Detected Not Detected 0.12 ± 0.05b 
C 16:1 0.23 ± 0.03a 0.28 ± 0.02a 1.59 ± 0.55b 
C 18:1n-7 0.30 ± 0.04a 0.36 ± 0.02a 2.24 ± 0.28b 
C 18:1n-9 1.47 ± 0.25a 1.84 ± 0.17a 31.62 ± 6.00b 
C 20:1n-9 0.03 ± 0.01a 0.03 ± 0.01a 0.52 ± 0.06b 
C 22:1n-9 0.03 ± 0.02a 0.03 ± 0.01ab 0.06 ± 0.01b 
C 24:1n-9 0.01 ± 0.01a 0.03 ± 0.01a 0.09 ± 0.01b 
MUFA 2.11 ± 0.33a 2.60 ± 0.2a 36.35 ± 6.83b 
    
C 18:2n-6 0.33 ± 0.18a 0.65 ± 0.05a 12.8 ± 2.35b 
C 18:3n-6 0.02 ± 0.01a 0.03 ± 0.01a 0.32 ± 0.11b 
C 20:2n-6 0.03 ± 0.01a 0.03 ± 0.01a 0.65 ± 0.07b 
C 20:3n-6 0.04 ± 0.01a 0.07 ± 0.01a 0.81 ± 0.10b 
C 20:4n-6 1.11 ± 0.11a 1.22 ± 0.08a 4.27 ± 0.51b 
C 22:2n-6 0.01 ± 0.01a 0.01 ± 0.01a 0.03 ± 0.01b 
C 22:4n-6 0.22 ± 0.03a 0.22 ± 0.02a 0.96 ± 0.24b 
C 22:5n-6 0.14 ± 0.04a 0.19 ± 0.03a 0.30 ± 0.04b 
N-6 1.90 ± 0.31a 2.41 ± 0.10a 20.14 ± 2.7b 
    
C 18:3n-3 0.01 ± 0.01a 0.02 ± 0.01a 0.59 ± 0.16b 
C 20:3n-3 0.01 ± 0.01a Not Detected 0.04 ± 0.01b 
C 20:5n-3 0.01 ± 0.01a 0.01 ± 0.01a 0.16 ± 0.04b 
C 22:5n-3 0.02 ± 0.01a 0.02 ± 0.01a 0.48 ± 0.05b 
C 22:6n-3 0.24 ± 0.08a 0.36 ± 0.04a 0.88 ± 0.11b 
N-3 0.28 ± 0.09a 0.41 ± 0.04a 2.15 ± 0.27b 
    
HUFA 1.78 ± 0.23a 2.09 ± 0.12a 7.89 ± 0.92b 
PUFA 2.18 ± 0.40a 2.82 ± 0.11a 22.29 ± 2.96b 
Total 8.15 ± 1.20a 9.96 ± 0.22a 97.29 ± 19.46b 
Values with different superscripts are significantly different by Tukey’s post hoc test 
(p<0.05) following significant F-value by one-way ANOVA	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